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I 
Abstract 
 
Methyl mercury (MeHg) is known to be a teratogen and neurotoxicant. Human 
contact with it is unavoidable due to its widespread prevalence in the environment. 
There is a need for model organisms and biosensors for better monitoring its presence 
in the environment and investigating the underlying mechanisms of its toxicity.  
 
In this study, zebrafish was chosen as the model organism due to its ecotoxicological, 
developmental and genetics advantages. A global view of gene expression changes in 
zebrafish embryos with acute sub-lethal MeHg exposure was generated. In response 
to MeHg, a total of 464 MeHg-up-regulated and 379 MeHg-down-regulated genes 
were obtained from the microarray analysis (p-value < 0.05 and M-value > 1.3 or < -
1-3, in which M-value refers to the log2 ratio of the fold change). The up-regulated 
genes were associated with functions of oxidative stress, cell redox homeostasis, 
apoptosis, inflammatory response, blood circulation, hormone stimulus and so forth; 
while the down-regulated ones were involved in oxidation reduction, RNA splicing, 
RNA elongation, fatty acid metabolism, DNA repair and so forth. Eighty-eight 
candidate genes were selected from the microarray for whole-mount in situ 
hybridisation analysis (ISH). The ISH result showed a 68% positive correlation with 
the microarray result. Ectopic expressions of the genes were noted in various organs 
including the brain, eyes, olfactory bulb, branchial arches, heart, liver, intestine or gut, 
pronephos, somites, lateral lines, pectoral fins, caudal fin fold, trunk and tail blood 
vessels, dermal epithelium, and yolk syncytial layer. The expression levels of 12 
genes at 30 μg/l and 60 μg/l MeHg were further quantified by real-time PCR. Eleven 
out of twelen were significantly regulated at 60 μg/l MeHg. arfl, c4-2, c6, cbx7l, 
prdx1 and zgc:101661 showed significant changes even at 30 μg/l MeHg. The 
sensitive expression changes of these 6 genes suggested that they may serve as marker 
genes for detecting the presence of MeHg in the environment. 
 
The effects of MeHg on the nervous system and the caudal fin fold were further 
investigated. Although no obvious change in some of the marker genes of CNS or the 
neurotransmitter system examined was detected, through the toxicogenomic screen, 
24 genes showing changes in the expression levels or patterns in the brain in response 
to MeHg exposure were identified. Besides, MeHg treatment caused a decrease in the 
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number of neuromast hair cells in the lateral line. The expressions of 12 genes were 
shown to be regulated by MeHg in the lateral line. 
 
MeHg could induce a loss of the gap in the melanophore stripe, disruption of caudal 
fin growth zone and disruption of caudal fin fold tissue. The disruption of 
melanophore stripe by MeHg was restricted to a time window of exposure from 12 to 
48 hpf. MeHg caused a specific loss of the GFP expression in the caudal fin growth 
zone of the transgenic line Tg(-2.4shha-ABC:GFP)sb15, and such an effect was 
induced in a significant number of embryos even in MeHg concentration as low as 6 
μg/l. Although there was a slight increase in the number of apoptotic cells in the 
caudal fin region, no rescue of the caudal fin tissue destruction was observed when 
induction of apoptosis was inhibited, excluding the possibility that apoptosis is the 
major cause of caudal fin fold tissue disruption. Through the toxicogenomic screen, 
22 genes were shown to be ectopically expressed in the caudal fin fold of MeHg-
treated embryos. Among these genes, the involvement of mmp9 and mmp13a in the 
caudal fin fold malformation was further investigated. Pharmacological inhibition of 
mmp9 and mmp13a could rescue partially the caudal fin phenotype induced by MeHg, 
suggesting a role for these two extracellular matrix remodelling proteins in causing 
the caudal fin tissue disruption. 
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Zusammenfassung 
 
Methylquecksilber (MeHg) ist ein bekanntes Teratogen und eine neurotoxisch 
wirkende Chemikalie. Der Kontakt des Menschen mit Methylquecksilber ist auf 
Grund der weiten Verbreitung in der Umwelt nicht zu vermeiden. Es gibt damit den 
Bedarf an Modelorganismen und Biosensoren für ein besseres Monitoring in der 
Umwelt und zum Erforschen der zugrunde liegenden Wirkungsmechanismen. 
 
Der Zebrabärbling wurde in dieser Studie aufgrund seiner ökotoxikologischen, 
entwicklungsbiologischen und genetischen Eigenschaften als Modelorganismus 
herangezogen. Ein umfassender Blick auf Änderungen in der Genexpression nach 
akuter sublethaler Exposition gegenüber MeHg wurde ermöglichst. Als Antwort auf 
die MeHg-Exposition wurden in einer Mikroarrayanalyse 464 aufregulierte und 379 
herunterregulierte Gene identifiziert (p<0.05 und M>1.3 or M<-1.3; unter dem M-
Wert versteht man das log2 des Fold-Change). Die aufregulierten Gene sind assoziiert 
mit Funktionen des oxidativen Stress, Redoxgleichgewicht in der Zelle, Apoptose, 
Entzündungsprozesse, Blutkreislauf, Hormonstimuli und so weiter, wohingegen die 
herunterregulierten Gene in Prozesse wie Oxidationsreduktion, RNS-Splicing, RNS-
Elongation, Fettsäurenmetabolismus, DNS-Reparatur und so weiter involviert sind. 
Basierend auf den Ergebnissen des Mikroarrays wurden 88 Gene für in situ 
Hybridisierung (ISH) an ganzen Embryonen ausgewählt. Die ISH ergaben zu 69.3% 
eine positive Übereinstimmung mit den Ergebnissen des Mikroarrays. Ektopische 
Genexpression wurde an verschiedenen Organen festgestellt: Gehirn, Augen, 
Riechkolben, Kiemenbögen, Herz, Leber, Darm oder Magen, Pronephros, Somiten, 
Lateralline, Brustflossen, Schwanzflossenfalte, Rumpf- und Schwanzblutgefäßen, 
Hautepithelium, syncytiale Dotterschicht. Wir quantifizierten ebenfalls das 
Expressionslevel von 12 Genen mit Hilfe von real-time PCR nach Expositionen 
gegenüber 30 µg MeHg/L und 60 µg MeHg/L. Elf von zwölf untersuchten Genen 
wurden bei einer Konzentration von 60 μg MeHg/L als signifikant reguliert 
nachgewiesen. arfl, c4-2, c6, cbx7l, prdx1, txnl und zgc:101661, waren auch bei 30µg 
MeHg/L signifikant reguliert. Die sensitive Änderung der Expression dieser sechs 
Gene lässt auf deren Eignung als Biomarker für die Detektion von MeHg in der 
Umwelt schließen. 
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Die Effekte von MeHg auf das Nervensystem und die Schwanzflossenfalte wurden in 
der vorliegenden Studie weitergehend untersucht. Mit Hilfe der toxikogenomischen 
Untersuchung konnten, obwohl keine eindeutige Regulation bestimmter Markergene 
des Zentralnervensystems bzw. des Neurotransmittersystems festgestellt wurde, 24 
Gene identifiziert werden, die in Antwort auf die Exposition gegenüber MeHg 
signifikant im Gehirn reguliert wurden. Desweiteren verursacht die Behandlung mit 
MeHg einen Verlust in der Zahl von Neuromasthaarzellen der Seitenlinie. Die 
Expression von elf Genen in der Seitenlinie war nach MeHg-Exposition verändert. 
Änderungen bezüglich der Verbindung der Neuronen zu der neuromuskulären 
Verbindung wurden ebenfalls untersucht und zeigten keinen Defekt in der Verteilung 
der Motorneuronen oder in deren Verbindung nach Behandlung mit MeHg. 
 
MeHg konnte den Verlust der Lücke in dem Melanophorenstrich, die Störung der 
Wachstumszone der Schwanzflosse, sowie die Störung des Gewebes der 
Schwanzflossenfalte induzieren. Die Störung des Melanophorenstrichs durch MeHg 
war auf ein Expositionszeitfenster von 12 bis 48 Stunden nach Befruchtung (hpf) 
beschränkt. MeHg konnte ebenfalls einen spezifischen Verlust der GFP-Expression in 
der Schwanzflossenwachstumszone des transgenen Linie Tg(-2.4shha-
ABC:GFP)sb15 verursachen, der auch noch bei einer MeHg Konzentration von 6 μg/l 
in einer signifikanten Anzahl an Embryonen auftrat. Auch wenn ein geringer Anstieg 
in der Zahl apoptotischer Zellen in der Schwanzflossenregion zu beobachten war, so 
konnte die Zerstörung des Schwanzflossengewebes auch bei Inhibition des Apoptose 
nicht verhindert werden. Dies schließt die Möglichkeit der Apoptose als Hauptursache 
des für die Störung des Schwanzflossengewebes aus. Mit Hilfe des 
toxikogenomischen Screens konnten 22 Gene identifiziert werden, die ektopisch in 
der Schwanzflossenfalte von MeHg-exponierten Embryos exprimiert werden. Unter 
diesen Genen befanden sich mmp9 and mmp13a, die ektopisch und spezifisch in 
MeHg-exponierten Embryos exprimiert werden. Die pharmakologische Inhibition von 
mmp9 and mmp13a konnte den durch MeHg induzierten Phänotypen teilweise 
verhindern. Dies legt eine Rolle von mmp9 and mmp13a - beide Gene sind in der 
Regulation der extrazelluläen Matrix beteiligt - im Zusammenhang mit der Störung 
des Schwanzflossengewebes nahe. 
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 1 
 Introduction 
1.1 Toxicogenomics 
Toxicogenomics is a scientific field that studies the interaction between the genomes 
of cells and/or organisms and toxic substances (Gomase and Tagore, 2008; Hamadeh 
et al., 2002). When cells and organisms are exposed to toxicants or stresses, alteration 
of the gene expression patterns of the cells and organisms will be triggered as a mean 
to cope with the unfavourable environment. Such an alteration can be monitored by 
the DNA microarray technology, which enables the detection of the activity of 
thousands of genes simultaneously (de Longueville et al., 2004, Nuwaysir et al., 
1999). Since the introduction of toxicogenomics in the area of toxicological research 
in the late 1990’s, the principles and technologies relevant to toxicogenomics have 
been widely adopted in both the academic and industrial fields (Nuwaysir et al., 
1999). Toxicogenomics allows a more comprehensive insight on how cells and 
organisms adapt to the changes in the external environment at the molecular level 
than traditional toxicological studies. This advancement of molecular technique 
provides a powerful tool for classifying chemicals, predicting potential toxicity, 
exploring mechanisms of toxicity and identifying potential biomarkers of toxic 
substances (Afshari et al., 2010; Gatzidou et al., 2007; Hamadeh et al., 2002, Pennie 
et al., 2001; Pennie and Kimber, 2002; Tennant, 2002; Tugwood et al., 2003; Suter et 
al., 2002; Yang et al., 2007). Knowing the mechanisms of toxicity allows us to 
identify ways to reduce or prevent the toxic effects by pinpointing biochemical and 
molecular functions that have been perturbed by toxic substances while the 
development of biomarkers helps to monitoring environmental toxicants and 
screening of drugs. 
 
1.2 Toxicity of methyl mercury 
1.2.1 Sources of environmental mercury 
Mercury (Hg) presents naturally in the Earth’s crust and it is estimated that 25,000 to 
150,000 tons per year are emitted into the environment through normal geological 
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processes like soil erosions and volcano eruptions (USEPA, 1995). An additional 
20,000 tons are produced anthropogenically each year by industrial activities such as 
electric utilities, waste incineration, residential, commercial, and industrial coal 
burning, mining, chlor-alkali facilities and mobile sources (Sams, 2004; Seigneur et 
al. 2004; USEPA, 1995).  
 
1.2.2 Human contact with Hg and its derivatives and their 
depositions in the body 
Due to the widespread prevalence of Hg and its derivatives in the environment, the 
contact of human with these toxic chemicals is unavoidable. The consumption of 
methyl mercury (MeHg)-contaminated seafood, the use of Hg-containing dental 
amalgam for tooth fillings and the uptake of ethylmercury (EtHg) in the form of 
thimerosal added as an antiseptic in vaccines are the three most common ways that 
poses the risk of Hg poisoning nowadays (Clarkson, 2002).  
 
The accumulation of MeHg in seafood is of particular concern since MeHg is present 
in virtually all edible marine and freshwater organisms. Analytical studies which 
measured MeHg in surface water, groundwater and ocean water in Europe and the 
United States indicated that Hg concentrations in the water bodies were highly 
variable (USEPA, 1997). Total Hg levels in the water body were generally under 
20ng/l (NJDEPE, 1993). However, in areas where were heavily polluted by 
anthropogenic mercury sources could have MeHg level more than 2,000 ng/l (Dooley, 
1992). Once entering the aquatic environments, Hg will be modified biologically and 
chemically into organic Hg including MeHg (Celo et al., 2006; King et al., 2000). 
The concentration of MeHg increases by bio-accumulation in fish via the food chain. 
As MeHg has a long half-life in biological tissues, this facilitates the bio-
accumulation and bio-magnification of MeHg by transferring MeHg from one to 
another tropic level (Clarkson, 1993; Madenjia et al., 2008). The concentrations of 
MeHg in long-lived piscivorous fishes and marine mammals, which located at the 
high tropic levels of the food chain, have been estimated to be up to million-folds of 
the surrounding environment (USEPA, 2001). Although most fish were reported to 
have MeHg content of less than the U.S. Environmental Protection Agency (U.S. 
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EPA) advisory guideline of 0.3 μg/g in their muscle, large piscivorous fish could 
accumulate up to more than 1 μg/g (Chalmers et al., 2011; Greigl and Krzynowek, 
1979; Hellou et al., 1992). Upon consumption of MeHg containing food, about 95% 
of MeHg in the diet will be absorbed by the gastrointestinal tract and distributes to all 
the tissues and organs through the bloodstream in about 30 hours (Clarkson, 2002). 
MeHg can pass through the blood-brain barrier and accumulates in the brain, and be 
readily transferred to the fetus through the placenta during pregnancy and distribute 
throughout fetal tissues including the brain (Ask et al., 2002; Cernichiari et al., 1995). 
MeHg levels in the cord blood are proportional but slightly higher than those in the 
maternal blood (Vahter et al., 2000). While the brain to blood ratio in adult is of 
approximately similar range, this ratio is about 5 to 7 times higher in the fetus in 
human and other primates (Cernichiari et al., 1995; Grandjean et al., 1997). The 
growing scalp hair also show high levels of MeHg accumulation and the 
concentrations are proportional to simultaneous concentrations in blood and target 
organs including the brain (Al-Shahristani et al., 1976; Berglund et al., 2005; 
Cernichiari et al., 1995). Thus, scalp hair and blood samples are frequently used as 
indicators of adult and fetal brain MeHg levels in MeHg exposure studies (Bencko 
1995; Crump et al., 1998; Grandjean et al., 1997; Myers et al., 2003). MeHg has a 
biological half-life of 35 to 100 days (Al-Shahristani et al., 1976; Smith and Farris, 
1996). It has been suggested that MeHg would be converted to Hg by intestinal 
microorganisms and eliminated from the body through fecal excretion in the form of 
Hg (Kozak and Forsberg, 1979; Smith and Farris, 1996). 
 
Dental amalgam has been used for the restoration of carious lesions or structural 
defects in teeth for over 150 years. It is a metallic material comprises several metals, 
including Hg, silver, tin and copper, with Hg being the principal component and 
constituting about 50% of the amalgam by weight (Marshall and Marshall, 1992; Ray 
1993). Hg vapour levels of 0.1 to 10 μg were calculated to be released per day from 
each amalgam filling into the oral cavity. About 80% of the inhaled Hg vapour was 
estimated to be absorbed by the respiratory system (Ekstrand et al., 1998; Olsson and 
Bergman, 1992). The total Hg levels in plasma and urine was shown to be highly 
positively correlated with the number of dental amalgam fillings (Berglund et al., 
2005). Animal model studies indicated that Hg accumulates in the retina, cerebral 
cortex, cerebellum and kidney (Warfvinge, 2000; Warfvinge and Bruun, 2000; 
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Warfvinge et al.¸1994). Studies measuring the concentrations of Hg in urine and 
faeces showed that Hg has a biological half-life of 21 to 121 days in the human body 
(Björkman et al., 1997; Sandborgh-Englund, 1998; Ekstrand et al., 1998). However, 
some other studies indicated that the deposition and toxicity of Hg could last many 
years (Hargreaves et al. 1988; Kobal et al., 2004; Letz et al., 2000; Opitz et al., 1996). 
 
Thimerosal is an Hg-containing compound comprising 49.6% of Hg by weight and 
will be converted to EtHg and thiosalicylate through metabolisation or degradation 
(Geier et al., 2007; Tan and Parkin, 2000). It is widely used as an antimicrobial 
preservative in a number of biological and drug products, including many topical 
medications and vaccines, in the U.S. since the 1930s (Geier et al., 2007). In the U.S., 
a normal dose of a pediatric vaccine contains around 17.5 to 25 μg Hg per 0.5 ml dose 
(USFDA). It was reported that infants who were immunised according to the 
recommended schedule might have cumulative Hg level up to 187.5 μg during the 
first 6 months of life, exceeding the U.S. EPA limits for Hg exposure, which was 
calculated based on the MeHg data (Ball et al., 2001). Due to the limited data on 
thimerosal or EtHg metabolism in the body, the estimation of health risks possessed 
by thimerosal was mainly based on the assumption that the toxicity of EtHg is similar 
to that of MeHg (Magos et al., 1985). It has been hypothesised that thimerosal 
exposure is associated with autism or other developmental disorders. However, the 
evidences supporting such an association are controversial (reviewed in Schultz 
2010). Nonetheless, as a precautionary measure, the U.S. Public Health Service (U.S. 
PHS) and the American Academy of Pediatrics (AAP) published a joint statement in 
1999 recommending that thimerosal-containing vaccines should be removed as soon 
as possible (CDC, 1999). 
 
1.2.3 Occurrence and symptoms of MeHg poisonings 
Hg compounds have long been known to be highly toxic, but they, particularly MeHg, 
started to receive special attention after several serious Hg poisonings in the last 
century (Bakir et al., 1973; Elhassani, 1982; Harada, 1995). The first outbreak 
occurred in the Minamata city in Japan in the year 1953 and was caused by the 
consumption of seafood that had been contaminated by MeHg due to the 
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inappropriate discharge of sewage into the sea from an acetaldehyde plant in which 
inorganic Hg compounds were used as catalyst (Harada, 1995). It led to devastating 
consequences to the fishermen, their families, seafood consumers, fish, birds and cats 
in the polluted area, and resulted in 2,264 officially recognised victims (Ekino et al., 
2007). Several outbreaks also occurred later in Iraq due to the ingestion of wheat 
and/or barley seeds treated with organomercurial fungicides (Greenwood, 1985). This 
resulted in 100 cases with 14 deaths in the year 1956, an estimate of 1000 cases in the 
year 1960 and 6530 cases with 459 deaths in the year 1972 (Bakir et al., 1973; Jalili 
and Abbasi, 1961). Follow-up studies of the poisonings, termed Minamata disease 
(MD) named after the city, showed that in human, acute MeHg poisoning could result 
in blurred vision, hearing impairment, olfactory and gustatory disturbances, ataxic 
gait, clumsiness of the hands, dysarthria, and somatosensory and psychiatric disorders 
(Ekino et al., 2007; Eto et al., 2010; Harada, 1995). Children with maternal exposure 
to MeHg showed impairments in chewing, swallowing, speech, gait, and other 
coordination and involuntary movement due to extensive damage of the brain, 
particularly the cerebral and cerebellar cortices. Infection, cancer, cerebrovascular 
disorder, cardiac failure and hepatic disorder were also observed in MD patients 
(Harada, 1995). Investigation on patients with chronic MeHg exposure, the residences 
living in the vicinity of Minamata city, indicated that chronic MeHg poisoning could 
lead to somatosensory disturbances, sensory ataxia and pseudoathetoid movements, 
disorders of visual and hearing discrimination (Ekino et al., 2007). Autopsy 
examinations of the brains showed that depopulation of neurons in calcarine, 
temporal, pre- and post-central cortices and diffuse degeneration of the deep white 
matter were commonly observed in chronic MD patients (Eto, 1997; Eto et al., 2010). 
Although depositions of Hg were also detected in liver and kidney, no functional 
disorder was clinically recognised (Eto, 1997). Epidemiologic studies have also 
showed that there was an increase risk of cardiovascular diseases and hypertension in 
people with high body Hg levels (Bautista et al., 2009; Salonen et al., 1995; 
Yoshizawa et al., 2002).  
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1.2.4 Large-scale studies of the neurotoxicity of MeHg to 
children 
The developing brain of fetus is much more susceptible to toxic chemicals than the 
adult brain (Rice and Barone, 2000). In order to gain a better insight on the toxicity of 
MeHg to children’s brain development, large-scale, chronic low-level dietary 
exposure studies were conducted on human in the Faroe Islands (Grandjean et al., 
1997), New Zealand (Crump et al., 1998) and the Republic of Seychelles (Myers et 
al., 2003), where the residents had high fish consumption. In the Faroe study, the Hg 
concentrations in the cord blood and the maternal hair of a cohort of 917 new born 
infants and in the hair of the children at the age of 12 months and 7 years were 
measured (cord blood: mean = 22.9 μg/l, interquartile range (IR) = 11-41.3; maternal 
hair: mean = 4.27 μg/g, IR = 2.6-7.7; 12-month-old: mean = 1.12 μg/g, IR = 0.69-
1.88; 7-year-old: mean = 2.99 μg/g, IR = 1.7-6.1), and detailed neurobehavioral 
examinations were performed on the children at the age of approximately 7 
(Grandjean et al., 1997). Although the clinical examination and neurophysiological 
testing did not show any clear-cut relationship between MeHg exposure and 
abnormalities, Hg-related neuropsychological dysfunctions were pronounced in the 
domains of language, attention and memory, and also to a lesser extent in visuospatial 
and motor functions. In the New Zealand study, prenatal exposure to MeHg in a 
cohort of 237 children was determined by measuring the mother’s hair Hg 
concentration during pregnancy (mean = 20 μg/g), and a range of scholastic and 
psychological tests were administrated to the children at the age of 6 to 7 years 
(Kjellstrom et al., 1986, 1989). Statistical analysis revealed that the scores on six tests 
were significantly associated with the mothers’ hair Hg level (Crump et al., 1998). In 
the Seychelles Child Development Study (SCDS), the effects of prenatal exposure to 
MeHg were examined in 779 mother-infant pairs by measuring the MeHg 
concentrations of the mothers’ hair during pregnancy (mean 6.89 = μg/g, standard 
deviation (SD) = 4.52) and correlating them with the performance of the 
developmental tests examined on the children periodically from the age of 6.5 months 
to 10.5 years (Myers et al., 2003), while the effects of postnatal MeHg exposure were 
determined by measuring the hair Hg levels of 537 to 739 children (66-month-old: 
mean = 6.5 μg/g, SD = 3.3; 107-month-old: mean = 6.1 μg/g, SD = 3.6) and 
examining the children’s intelligence quotient (IQ) at the age of 66 and 107 months 
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(Myers et al., 2009). A follow-up study examining the school achievements of 215 
children or teenagers in the SCDS main cohort at the age of 9 (prenatal MeHg: mean 
= 6.77 μg/g, SD = 4.21; 9-year-old: mean = 6.09 μg/g, SD = 17) and 17 (prenatal 
MeHg: mean = 6.95 μg/g, SD = 4.67; 17-year-old: mean = 8.00 μg/g, SD = 4.68) was 
also performed (Davidson et al., 2010). All the SCDS results indicated that there was 
no consistent pattern of associations to support a causal relationship between MeHg 
exposure from fish consumption and children’s brain development since children’s 
brain development might benefit from the nutrients obtained from fish consumption 
despite the concomitant MeHg intake.  
 
Based on these three studies with special reference to the Faroe Island one, the U.S. 
Environmental Protection Agency (U.S. EPA) and the National Academy of Sciences 
(NAS) recommended a Hg reference dose (it is an estimate of a level of exposure to 
the human population without causing any adverse effect on health when the exposure 
is encountered on a daily basis for a whole lifetime) of no more than 0.1 μg/kg body 
weight per day (NAS, 2000; Rice et al., 2003; USEPA, 2001). Similarly, the Food and 
Agriculture Organization of the United Nations (FAO) and the World Health 
Organization (WHO) recommended 1.6 μg/kg body weight per week (that is 0.23 
μg/kg body weight per day) as the provisional tolerable weekly intake (PTWI) 
(FAO/WHO, 2010). 
 
1.2.5 Neurotoxicity of MeHg to animal models 
In order to gain more insight into the toxicity of MeHg, studies using animal models 
have been widely employed. Studies performed on mammalian models have showed 
that prenatal and postnatal exposure to MeHg could result in neurobehaviorial, 
neurodevelopmental and neuropathological defects (Castoldi et al., 2008; Johansson 
et al., 2007). Monkeys exposed to MeHg prenatally exhibited visual and auditory 
impairment (Burbacher et al., 2005; Rice, 1998), decrease in social play behavior and 
increase in non-social passive behavior (Burbacher et al., 1990) and subtle change in 
fixed interval/fixed ratio performance (Gilbert et al., 1996). Rodents treated with 
MeHg prenatally and postnatally also showed various neurobehavioral defects such as 
decreased learning and memory performances (Baraldi et al., 2002), hearing 
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impairment (Beyrouty et al., 2006), lowered locomotion activity (Elsner et al., 1998), 
and reduced swimming activity (Elsner et al., 1998). Rodents exposed to MeHg 
during development exhibited a range of neuroanatomical defects including cerebellar 
dysplasia (Sakamoto et al., 2002), neural degeneration and inhibition of spontaneous 
neuronal differentiation in the brainstem, cerebral cortex, cingulate cortex, striatum, 
thalamus, hippocampus, or amygdala (Kakita et al., 2000a,b; Sakamoto et al., 2004), 
reduced thickness of the molecular and granular layers of the cerebellum (Markowski 
et al., 1998; Sager et al., 1984), change in distribution, structure or number of 
Purkinje cells and granule neurons in the cerebellar cortex (Chiang et al., 1977 a, b; 
Sager et al., 1984), disruption of myelin sheath (Chiang et al., 1977b; Wakabayashi et 
al., 1995), and mitotic arrest of cells in the cerebellum (Rodier et al., 1984; Sager et 
al., 1984). Alterations in the neuroendocrine and neurochemical systems, such as 
monoaminergic (Beyrouty et al., 2006; Cagiano et al., 1990), glutamatergic (Cagiano 
et al., 1990; Carratu et al., 2006) and cholinergic (Zanoli et al., 1994) 
neurotransmitter systems, and in the electrophysiological systems, like membrane 
potential, amplitude of spikes and degree of excitability (Vilagi et al., 2000), have 
been also observed in rodents treated with MeHg during development. Besides 
neurological disorders, MeHg has also been reported to cause cardiovascular disease, 
affect reproduction, suppress immune functions and induce autoimmunity in multiple 
species (Silbergeld et al., 2005). 
 
1.2.6 Mechanisms of MeHg toxicity 
MeHg exposure has been shown to result in various cellular changes such as lipid 
peroxidation, DNA damage, membrane structure alteration, mitochondrial 
dysfunction, cell cycle alteration, apoptosis and necrosis (Clarkson and Magos, 2006). 
The interactions with sulfhydryl groups, the induction of oxidative stress and the 
disruption of calcium (Ca) ion homeostasis have been reported to be the three major 
and critical mechanisms. With its property of being a sulfhydryl-reactive metal, 
MeHg has a high affinity for free thiol (sulfhydryl) groups (Vallee and Ulmer, 1972). 
Thiol-containing amino acid cysteine and thus, virtually all proteins, especially 
cysteine-rich glutathione (GSH) and metallothionein (MT), are potential targets of 
MeHg (Kidd 1997; Quig, 1998; Vallee and Ulmer, 1972). MeHg decrease body’s 
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antioxidative capacity as it leads to the depletion of GSH antioxidant and the decrease 
in activities of other antioxidants molecules including superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPx) (Stohs and Bagchi, 1995). The pro-
oxidant property of MeHg is, at the same time, further exacerbated by the increase in 
the production of reactive oxygen species (ROS) as shown by biochemical studies 
(Ali et al., 1992; Sarafian, 1999; Shanker et al., 2004). A cell culture study 
demonstrated that MeHg affected the redox-sensitive mitogen-activated protein (MAP) 
kinase/AP-1 and NF-kB pathways, which are implicated in cell cycle progression, cell 
proliferation and apoptosis (Korashy and El-Kadi, 2008). The formation of ROS and 
the induction of oxidative stress are believed to contribute to the neuropathogenesis of 
MeHg as co-treatment of brain cell cultures with MeHg antioxidants could attenuate 
the production of ROS and neurotoxicity (Park et al., 1996; Shanker and Aschner, 
2003; Shanker et al., 2005). Metallothionein (MT) is an intracellular metal-chelating 
protein, which binds to both physiological and xenobiotic heavy metals, (Stillmann, 
1995) and plays a neuroprotective role against Hg exposure (Yoshida et al., 2005, 
2006). MT has been shown to be induced by Hg directly and indirectly through the 
displacement of Zinc (Zn) ion (Aschner et al., 2006; Coyler et al., 2002). Under 
normal physiological condition, MT serves as a storage depot for Zn (Henkel and 
Krebs, 2004). When Hg is present, Hg will displace Zn to from a complex with MT 
due to the higher affinity of MT to Hg than Zn (Stillman, 1995, Stillmann et al., 
2000). The increased intracellular Zn ion concentration induces the expression of MT, 
and thus, in return, increases the binding capacity for Hg and Zn (Davis and Cousins, 
2000). MeHg is also known to disrupt intracellular Ca ion homeostasis. Such a 
disruption was suggested to be caused by blocking the function of Ca ion channels 
(Atchison, 2003; Shafer et al., 1990). The blocking is irreversible and it remains even 
after MeHg was washed out of the bathing solution (Sirois and Atchison, 2001). The 
interfering with Ca ion channels attenuates or blocks completely cell current and 
affects skeletal and cardiac muscle contractility as well as neurotransmitter release 
(Follonier Castella et al., 2010; Ho, 2010; Lee and Michalak, 2010). Massive 
increases in intracellular calcium can be detrimental for the cell and will cause cell 
death (Brnjic et al., 2010; Harr and Distelhorst, 2010; Szydlowska and Tymianski, 
2010). 
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1.2.7 Hg and MeHg biosensors 
In order to monitor the presence of bioavailable MeHg in the environment through a 
rapid, non-invasive and non-labour intensive way, biosensors have been developed. 
Zebrafish containing a luciferase-green fluorescent protein (LUC-GFP) fusion protein 
under the regulation of the antioxidant response element (ARE) has been generated 
(Kusik et al., 2008). The ARE promoter would drive the expressions of the reporter 
genes in response to oxidative stress. Increase in luciferase activity was observed in 
embryos exposed to 40 μg/l MeHg, although the GFP expression could not be 
detected. Systems involving lower class organisms of C.elegans and E.coli transfected 
with plasmid containing a cysteine located in close proximity of GFP showed specific 
induction of fluorescence signal in the presence of ionic Hg with a lower detection 
limit of 400 ng/l (Chapleau et al., 2008; Chapleau and Sagermann, 2009). A 
luminescence-based MeHg-specific system using E.coli transfected with a plasmid 
carrying the luciferase gene luxAB under the control of the Hg inducible regulatory 
part of mer-operon has also been developed recently (Nagata et al., 2010). It exhibited 
a detection limit of 2 ng/l MeHg.  
 
1.2.8 Toxicity of MeHg or Hg to zebrafish 
Zebrafish have been previously shown to be highly sensitive to MeHg. Exposure of 
zebrafish embryos to 20 and 30 μg/l MeHg led to impairment of caudal fin fold tissue 
and posterior tail flexure (Samson and Shenker, 2000). Doses between 10 and 20 μg/l 
MeHg induced faint heartbeats, severely enlarged body cavities and upward flexures 
of the spinal cord, body cavity and head edema, reduced swimming activity, impaired 
prey capture performance and delayed mortality syndrome and behavioural deficits 
(Samson et al., 2001). Concentration of 32 μg/l Hg could inhibit hatching completely 
(Dave and Xiu, 1991). Embryos exposed to 10, 50 and 80 μg/l Hg showed decreased 
cell proliferation rate in the neural tube (Hassan et al., 2011). Global transcriptome 
studies on zebrafish embryos showed that acute exposure to 60 μg/l MeHg induced 
genes involved in acute inflammatory response, detection of stimulus, amino acid 
derivative metabolism and transmembrane receptor protein tyrosine kinase signalling 
pathway and insulin receptor signalling pathway (Yang et al., 2007). Similar genomic 
study in adult zebrafish indicated that sub-lethal acute or chronic exposure to MeHg 
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or Hg also caused genes expression changes in a variety of biological and molecular 
functions, such as gene expression change in oxidative stress, immune defence, DNA 
damage, apoptosis, lipid peroxidation, glycolysis/gluconeogenesis and so forth, in 
individual organs (Cambier et al., 2010; Klaper et al., 2008; Richter et al., 2011; Ung 
et al., 2011). A research on the localisation of MeHg in adult zebrafish after trophic 
and chronic MeHg exposure revealed that the brain accumulated highest level of 
MeHg among the three organs examined (Gonzalez et al., 2005). Another study 
concerning the visual system showed that MeHg could pass through the blood-retina 
barrier and accumulated in various regions of the retina, especially in the 
photoreceptor layer and in the inner and outer nuclear layers in adult zebrafish (Mela 
et al., 2010). It has also been shown in whole zebrafish embryos and larvae by X-ray 
fluorescent imaging that the lens epithelium had the highest level of MeHg deposition, 
with lower levels in the brain, optic nerve and other organs, after acute exposure to 
MeHg (Korbas et al., 2008). MeHg continued to accumulate in the lens even after the 
removal of MeHg from the solution (Korbas et al., 2010).  
 
1.3 Advantages of using zebrafish embryo as an 
animal model 
Zebrafish was introduced as a model organism for research study for more than three 
decades (Laale, 1977). It has a small size of 4 to 5 cm in length which allows low 
housing space and maintenance cost. The short generation time, rapid embryonic 
development and large number of offspring enable the generation of vast amount of 
data within short period of time. The transparent body of the embryo and the 
development outside the body of the mother provide a vertebrate model whose 
development is easy to observe and is not complicated by the physiology of the 
mother as in mammals while it possesses a body plan in which the basic structure 
does not differ much from mouse or human (Kimmel et al. 1995). Animal embryos 
are not regarded as animals according to the legislation of the Council of European 
Communities (Commission of the European Communities, 1986). Thus, zebrafish 
embryo serves as non-animal model while, in contrast to cell lines, it offers the 
advantages of a multi-cellular, complex, in vivo system for experimental studies.  
 
 12 
Zebrafish may not only be an ecotoxicological relevant model, but may also be useful 
in elucidating underlying mechanisms through which chemicals, drugs or toxicants 
exerts its toxicity through the application of genomic and molecular techniques 
available (Hill et al., 2005; Yang et al., 2009). The zebrafish genome sequencing has 
almost complete by now (http://www.sanger.ac.uk/Projects/D_rerio/). It contains 
comprehensive information on the genes and regulatory sequences, facilitating the 
mining of genetic information. A wide range of molecular tools and techniques has 
been developed in zebrafish to allow monitoring and manipulating of gene functions. 
Gene mutations can be generated by the use of the alkylating agent ethylnitroso urea 
(ENU), retroviral insertion and zinc finger nuclease. Morpholino antisense 
oligonucleotide, which can block the translation of mRNA transiently, is widely 
employed for studying gene functions during early development. The use of loss-of-
function method in gene function studies is complemented by the gain-of-function 
approach such as injection or transfection of synthetic mRNAs. The generation of 
transgenic lines, which drive expression of fluorescent reporter genes in the cell of 
interest, helps to mark specific tissues or physiological changes. 
 
1.4 Hypotheses and aims  
It is known that the developing brain is much more susceptible to neurotoxicants than 
the adult brain, while there is a lack of data and enormous backlog of chemicals that 
require testing and some of these chemicals may poses effects on the developing brain 
like what MeHg does (Claudio et al., 2000; Grandjean and Landrigan, 2006; Rodier, 
1995). Therefore, there is a need of having model organisms for better monitoring and 
evaluating the effects of environmental pollutants and neurotoxicants. As MeHg is 
known to be a teratogen and neurotoxicant, the underlying hypothesis of this study is 
that zebrafish embryos exposed to sub-lethal concentration of MeHg will result in 
developmental defects and neural developmental defects, and the toxic effects of 
MeHg are associated with the modulation of expression of specific genes in the 
embryos.  
 
One of the aims of this study is to establish biomarkers which could be used to 
develop in vivo biosensors to monitor waterborne MeHg or other toxicants that 
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showed similar toxicological profile as MeHg. Since morphological and behavioural 
endpoints are frequently not very informative with respect to the underlying 
mechanisms of the toxic effect, another aim of this study is to screen genes which are 
differentially expressed in MeHg-treated embryos to provide information for 
dissecting the underlying mechanisms through those MeHg exerts its toxicity.  
 
In this study, a MeHg toxicity test was first performed to determine a suitable 
concentration of MeHg for further sub-lethal dosage study. As toxicogenomics has 
been shown to be a comprehensive and sensitive tool for examining the responses of 
genes toward changing environments in the molecular level, a toxicogenomic-based 
gene screening has been adopted in this study for identifying candidate genes which 
are regulated by MeHg. Herein, I reported the results of the toxicogenomic-based 
gene screen of MeHg-responsive genes in zebrafish embryos in response to acture 
MeHg exposure. Based on the phenotype observed and the current knowledge on 
MeHg toxicity, I further focused the study on 2 biological structures: the nervous 
system and the caudal fin. I also reported the study of one of the candidate genes 
complement component c7-1 which was expressed specifically in the retina after 
MeHg treatment. 
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2 Materials and methods 
2.1 Fish strains and fish maintenance 
All adult zebrafish were maintained in aerated fish water at 28.5°C, subjected to a 
photoperiod of 10 hours light and 14 hours dark, and fed with dry flake food and brine 
shrimp as described (Westerfield, 2000). The Tg(-2.4shha-ABC:GFP)sb15 transgenic 
line contains the 2.4 kb shha promoter upstream of and the elements ar-A, ar-B, ar-C 
of the shha introns 1 and 2 downstream of the gfp coding sequence (Ertzer et al., 
2007; Hadzhiev et al., 2007; Müller et al., 1999; 2000). The Tg(-
1.7CaTuba1:GFP)mi2 line contains the 1.7 kb goldfish (Carassius auratus) α1-
tubulin promoter fragment and the first intron upstream of the gfp coding sequence 
(Goldman et al., 2001; Gulati-Leekha and Goldman, 2006) 
 
2.2 Chemical treatment 
Methyl mercury chloride (MeHgCl), lead (II) chloride (PbCl2), arsenic (III) oxide 
(As2O3) and cadmium chloride (CdCl2) were purchased from Sigma-Aldrich 
(Missouri, USA). Working solutions of 6 to 120 μg/l MeHg, 20 mg/l of PbCl2, 79 
mg/l of As2O3 and 15 mg/l of CdCl2 were prepared by diluting the chemicals from 
stock solution of 100 mg/l MeHg, 5 g/l of PbCl2, 10 g/l of As2O3 and 4 g/l of CdCl2, 
respectively, with embryo medium (60 µg/ml of Instant Ocean, Red Sea, Houston, 
USA) (Westerfield, 2000). Embryos were exposed to the chemicals from 4 to 72 hpf 
unless otherwise stated (descriptions and schematic diagrams of zebrafish embryos at 
selected stages are shown in the appendix Tab. A1 and Fig. A1, respectively). As 
reported by Yang et al. (2007), toxicant concentrations were chosen so that more than 
60% of the treated embryos showed malformations but with minimal lethality. 
 
2.3 RNA extraction 
Total RNA was extracted from independent groups of 6, 30, 60 µg/l MeHg-treated 
and control embryos according to the RNeasy Mini Kit (Qiagen, Netherlands) 
protocol. One µg of total RNA was used in each sample for performing reverse 
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transcription following standard procedures (Sambrook et al., 1989). M-MLV 
Reverse Transcriptase (Promega, USA) and oligo(dT) primer (Promega, USA) were 
used for reverse transcription. 
2.4 DNA Microarray 
2.4.1 Microarray experiment 
Two-colour DNA microarrays using the zebrafish gene expression microarray chip 
4x44K (Agilent Technologies, USA) were performed according to Agilent Low RNA 
Input Linear Amplification Kit protocol (Agilent Technologies, USA; Fig. 2.1). In 
brief, total RNA was extracted from control and MeHg-treated samples as described 
in section 2.3. Three independent biological repeats were performed for both control 
and MeHg-treated samples. Two microgram of total RNA from each sample was 
reverse transcripted into cDNA. cRNA was trancripted from the cDNA and labelled 
with Cyanine3 (Cy3) –CTP and Cy5-CTP fluorescent dyes (PerkinElmer/NEN Life 
Science, USA). The cRNA samples were purified with the RNeasy Mini Kit (Qiagen, 
Netherlands) and fragmented. Microarray chips were handled according to the user 
guide available with the Agilent Microarray hybridisation Chamber Kit (Agilent 
Technologies, U.S.A). cRNA was carefully loaded to the chips. Dye swap was 
performed for each set of biological repeat to avoid bias of the signal given by any of 
the dye. Cover slips were placed gently on top of the chips and the chips were 
incubated at 65oC for 17 hours with rotation. After hybridisation, the probes were 
washed away from the chips. The fluorescent signals of the chips were detected by 
GenePix 4000B dual-channel microarray scanner (Molecular Device, USA) using the 
GenePix Pro 6.01 software (Molecular Device, USA). Signals for both Cy3 (532 nm) 
and Cy5 (635 nm) were scanned in parallel and the gain of the scanner 
photomultiplicator (PMT) was tuned so that the overall signal ratio of the two colours 
would be equal to 1. The captured images were stored as 16-bit TIFF files. Files in 
GenePix Result (GPR) format that contained a data part, including raw signal and 
background values, several statistical parameters including mean, standard deviation 
and the annotation provided by the microarray supplier, and a header with general 
scanning and image analysis information, such as colour channel used, laser settings, 
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date and time of scanning, feature type and grid-file used were generated using 
GenePix Pro 6.01 for data analysis.  
 
 
Fig. 2.1 Schematic representation of the procedure of DNA microarray. 
 
2.4.2 Microarray data analysis 
To maximise the true positive rate and minimise the false positive rate and to sort out 
the most robustly differently expressed genes from the raw microarray, a number of 
mathematical and computing steps (Russell et al., 2009) were performed using the 
software MATLAB (version R2010a; the Math Works, USA) or MATLAB toolbox 
Gait-CAD (Mikut et al¸ 2008), which is a graphical user interface allowing easy 
analysis of different datasets via MATLAB. An add-on consisting of different 
filtering functions, normalisation methods and statistical tests were implemented in 
MATLAB for microarray analysis (Legradi, 2011).  
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The data analysis was performed as described below: 
1) The raw data was uploaded into Gait-cad.  
2) Log2 transformations were performed on the data set to obtain a more 
symmetric distribution for better comparison. The log2 transformed values 
were termed M-values.  
3) Quality values for low-signal or flagged spots were calculated. The 
determination of the threshold value for low signal filtering was based on the 
analysis of the background signal of all the microarrays from one experiment. 
As the values of almost all the background (region without any spots) were 
below 200, the lowest signal limit was set to 200. Spots with low signals in 
both colour channels were marked as bad quality. Spots were flagged when 
the signals were generated due to artifacts like dusts or scratches or when the 
data values were missing due to empty spots. As these flagged spots could 
lead to problems in downstream data analysis, and might interfere with 
statistical tests or affect the stability of gene cluster, they were also penalised.  
4) Locally weighted scatterplot smoothing (LOWESS) normalisation and 
centering normalisation was performed to correct for intensity dependent dye 
bias and array differences. 
5) Quality plots showing the data distribution of each microarray were examined 
for quality control. The spike controls were also analysed. 
6) All the data sets of the experiment, including all the biological repeats and the 
dye swaps, were fused together to make one data set. 
7) The average values of the data from dye swaps were calculated and were used 
for quality measurement. 
8) T-test was performed with the p-values and other parameters calculated from 
the averaged dye swap values. 
9) As there were about 44,000 data points in each microarray, a t-test with a p-
value of less than 0.05 (that is p < 0.05) would result in about 2,200 false-
positive results. To decrease the false-positive rate, adjustment of the data set 
was required. Taken the advantage that false positives usually have rather 
small M-values, and based on a plot of the coefficient of variation (CV) 
against the M-values of the whole data set (Fig. 2.2), M-value of 1.3 was 
chosen as the cut-off value.  
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10) The data was then exported as a tab delimited text file. 
 
Fig. 2.2 A plot of the CV against the M-values from one microarray data set. 
Each red dot represents one data point from the microarray. The black line indicates the maximal 
variance for a particular M-value. This figure is provided by J. Legradi. 
 
2.5 Whole-mount in situ hybridisation 
Whole-mount in situ hybridisation (ISH) was carried out as described (Westerfield, 
2000). Antisense RNA probes of ache from Dr. Cousin (Bertrand et al., 2001), cb1 
(Lam et al., 2006), crestin from Prof. Halpern (Rubinstein et al., 2000), mmp9 (Yang, 
2007), mmp13a (Yang, 2007), nurr1 from Prof. Laudet (Escriva et al.¸1997), pax6a 
from Prof. Fjose (Krauss et al.¸1991), serta from Dr. Shirabe (Wang et al., 2006), 
shha from Prof. Ingham (Krauss et al., 1993) and txnl (Yang, 2007) were kindly 
provided. All other RNA probes used in this thesis were obtained by cloning from 
cDNA extracted from 72 hpf embryos, I.M.A.G.E. clones (Source BioScience 
imaGenes, Germany) or cDNA library screen according to the standard protocol 
(Sambrook et al.¸1989), and the information on the generation of these probes is listed 
in Tab. 2.1. 
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Tab. 2.1 Information of RNA probes for in situ hybridisation. 
Gene Primers/ probe sequence* (5’ ? 3’) Vector Restriction enzyme Transcriptase 
adam8a F: GTGTGACTGCGGAACTGTTG; R: ATGGCAGAAGGTGGTACAGG pGEM-T Easy SacII Sp6 
agt F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG; R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
AI397362 F: GATTGAAGATGAGCTACCATGC; R: GAGCTGACAGCGAGACAGAG pGEM-T Easy SalI T7 
AI544649  F: GGGTCACATTCTTCACAGGTAGT; R: GCTGATTGGCTGACTATCGAA pGEM-T Easy SacII Sp6 
AI793818 F: GAGCTGGAGCACCAGGAGAT; R: GAAGCACATCCTGTCAATCACC pGEM-T Easy Sac II Sp6 
apoeb F: TCTGGCAGTATGTGTCTGAACTC; R: AATAGCCTCCAAGACAGACAAG pGEM-T Easy SalI T7 
arfl F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG; R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
atf3 Nil FLC III CeuI T7 
AI793818 F: GCCGGAAGGAGCTCTCTGTA; R: GAAGCACATCCTGTCAATCACC pGEM-T Easy SacII Sp6 
AW115990  F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG; R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
BE016163  F: GCTGAGCACTGTATTTAAAGAACCA; R: GCTGAATGTATTTGTGACCCATAGC pGEM-T Easy SacII Sp6 
BG727211  F: GGTGGATGACACTACATGTAACACC; R: GTGAACATGATCCTCAATACACAGG pGEM-T Easy SacII Sp6 
BG891932  F: GGCATACGGTGAAACATTTG; R: GATTGACCAGTGGTTGAATGG pGEM-T Easy SacII Sp6 
BI474700 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG; R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
BI883993  F: CAAGATTCGTTATCCTCTGGTG; R: GTAGTCAATTCATCAACACCTGGA pGEM-T Easy SacII Sp6 
BI892110 F: GATTCCCCTGCCTAGCTATTATAAG; R: GCCCGCATTCTCTCCACCAATATAT pGEM-T Easy SacII Sp6 
BI983579  Nil pBluescript SK- EcoRI T7 
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Gene Primers/ probe sequence* (5’ ? 3’) Vector Restriction enzyme Transcriptase 
BM036361  Nil pBluescript SK- EcoRI T7 
BM101698 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
c3a F: GGAAGGTCGTCACACGATTC; R: GCCGAGTAAGGCATCTTGAG pGEM-T Easy SacII Sp6 
c4-2l Nil pBluescript SK- EcoRI T7 
c5-1 F: ATCTGCACGAACCGTCACTC; R: TAGAGTCTGCCACCAGCTCAG pGEM-T Easy SacII Sp6 
c6 F: GGTCTGTGTTGAGGCCATCT; R: GCACTTCATTGCAGCCATA pGEM-T Easy SacII Sp6 
c7-1  F: GACCGTATGGAGACTGGTCA; R: GCCTCACATTCTGACATCATCT pGEM-T Easy SacII Sp6 
c7-2 F: GAACCTGTGCATTGCTTGTG; R: TGACAGGCGGAGTCTTCAG pGEM-T Easy SacI T7 
c8a F: ACCGTGTCAATCATGCACAG; R: GCACTGGAACGCCATTATTC pGEM-T Easy SacII Sp6 
c8b F: TCTGCGCTGTAATGGAGATG; R: TGAGCTCCAGCACATGCTAC pGEM-T Easy SalI T7 
c8g F: TTGCTGTGATGATTCGCTTC; R: TCGTTGTGTTGTGTAACTCTGAAC pGEM-T Easy SacII Sp6 
c9 F: ACGATCCACCACCAGTTGAC; R: CAGCACTGCCAGCATTACC pGEM-T Easy SacII Sp6 
cartIl F: GGCTGCAGAAATGGACTTTG; R: AAGAGCAGCAAGGAACTAAACG pGEM-T Easy SacII Sp6 
cbx7l F: CCAGTCCAAGAATCCGTCTG; R: GTAATGGCGACTGCTGGAAG pGEM-T Easy SacII Sp6 
cebpg Nil FLC III CeuI T7 
cfb Nil pSPORT1 EcoRI Sp6 
copeb Nil pBlueScript SK XhoI T3 
cxc46l F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
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Gene Primers/ probe sequence* (5’ ? 3’) Vector Restriction enzyme Transcriptase 
cyldl F: GGAGGTAGCATCAGGAGCAG; R: GAGATTCCATCCTGCCTCAT pGEM-T Easy SacII Sp6 
drl F: GCATGGAGGGAAACAAGAAA; R: CTTCCCATTCTGGGGAAACT pGEM-T Easy SacII Sp6 
elf3 F: GAGCGAATCTGAACGTCACC; R: GCCGGAAGGAGCTCTCTGTA pGEM-T Easy SacII SP6 
fn1b F: ACCTGCCTTAAGTGGACGTG; R: CAGAGTGGCAGTTGTGGATG pGEM-T Easy SacI T7 
fos Nil FLC III CeuI T7 
foxb1.2 Nil pBlueScript SK XhoI T3 
gclm F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
gldc F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
gpx1a F: GGCAGGAACCATGAAGAAGT; R: GACTGCACAGTCGGTCTATATCA pGEM-T Easy SalI T7 
gpx4a F: GACTATGTCTGCACAGCTAGAGG; R: GCATGTCTCTTCATCTGTCCTCTC pGEM-T Easy SacII SP6 
hhex Nil pBlueScript SK XhoI T3 
homez Nil FLC III CeuI T7 
irf9 F: CCGTCTGCGTTCATGGATAG; R: TTGCAATGGACTCTCTGAAGG pGEM-T Easy SalI T7 
junb F: TCGGAGCATCACAGAGGAG; R: ACAGGATCTGCTCTTCCAGTG pGEM-T Easy SalI T7 
klf10l GGATCAAGATGTCTCAACAAGTTTC pBlueScript SK XhoI T3 
klf11b Nil pBlueScript SK XhoI T3 
lamp1l GGATCAAGATGTCTCAACAAGTTTC pBlueScript SK XhoI T3 
lcp1 F: GCCAAGGTGGTTCATGACTT; R: CCAGTCGATGTCCTGGTTTT  pGEM-T Easy SacI T7 
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Gene Primers/ probe sequence* (5’ ? 3’) Vector Restriction enzyme Transcriptase 
mafba Nil pBlueScript SK XhoI T3 
maff Nil pBlueScript SK XhoI T3 
mmp9 F:CAGCAACACTGCTTGCACTT; R:AGGAAACCCATCATGACCAA pCS2+ BamHI T7 
mmp13a F:GGCACGAGAAACATGAAGACC; R:CACACACAAATGATTTTCAAGGA pCS2+ EcoRI T7 
mmp14a F: AGCTACGCTCTCGGCAATG; R: TAGTCCTGTGCCAAGCTCCT pGEM-T Easy SacI T7 
mpx F: CTGCCCATGGTTAGACTGGT; R: AAGACGTTCGCAATGGTAGG pGEM-T Easy SacII SP6 
mpz F: GTTGGCAGCGAAACTCAAAC; R: GGCAGAATGGAGACAGAGGT pGEM-T Easy SacI T7 
noxo1 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
opn1lw1 F: GGCCAGTGACAGCAGATAAT; R: GGCAGGCATCTACCAATCA pGEM-T Easy SalI T7 
opn1mw1 F: GGACAGAAGGGAGCAACTTCTA; R: GGAGTAGATATTGTGCATAGATCCAG pGEM-T Easy SacII SP6 
opn1sw1 F: GTTGACTCCACCAGGACACA; R: GAGCAGACAGTGAACGATTCC pGEM-T Easy SacII SP6 
pax2a Nil FLC III CeuI T7 
pax6a Nil pBlueScript SK XhoI T3 
pck1 GGATCAAGATGTCTCAACAAGTTTC pBlueScript SK XhoI T3 
pfkfb4l F: GGAGGTGAAGATTGAGGAACC; R: GCTTCGAAGGCATTAACATTG pGEM-T Easy PstI T7 
plac8l1l F: GCAGTGACCTACTTGTCTGTGCTCT; R: GGTCTGGAACTGTAATTATGTCTCT pGEM-T Easy SacI T7 
plp1b F: CGTCCAGGACTTCACTGTCA; R: GAGCACCATCATTGATCAGG  pGEM-T Easy SpeI T7 
prdm1a Nil FLC III CeuI T7 
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Gene Primers/ probe sequence* (5’ ? 3’) Vector Restriction enzyme Transcriptase 
prdx1 F: GTATCGCGAGACTTGAGCAC; R: GCATTAATTCACATCACTTCTGTC  pGEM-T Easy SalI T7 
rrad F: GCGAGGATATTCGGTGGAG; R: CTTGGCTGAGTTACGAACCTG pGEM-T Easy SalI T7 
rx1 Nil pBlueScript SK XhoI T3 
s100z F: AACTACTCCGGCAGTGAAGG; R: CACAGCAAGAACCTCACAGG pGEM-T Easy SacII Sp6 
sar2 Nil pBluescript SK- EcoRI T7 
sepw1 F: GAGGCACAGCACAACCAAT; R: GTTGTGCGTTGTAGCAAAGG pGEM-T Easy SacII Sp6 
sgk1 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
si:ch1073-126c3.2 Nil pSPORT1 EcoRI Sp6 
si:ch211-106h4.4 F: GGAGAGATGGAGTGGACCAA; R: GGTGGAGAAGTGGGATCTGA pGEM-T Easy SacII Sp6 
six3a Nil FLC III CeuI T7 
six3b Nil pBlueScript SK XhoI T3 
slc16a9a F: GAGAATGGCTGCTGTGAAGA; R: GTCCAGTCGAAGAACCAACC pGEM-T Easy SalI T7 
slc16a9b GGATCAAGATGTCTCAACAAGTTTC pBlueScript SK XhoI T3 
socs3a F: GGTAACGCATAGTAGGCTTGACAG; R: GCTTGCACTGCGGTCATC pGEM-T Easy ApaI Sp6 
socs3b F: GCCGAGACTCGACACTCTGTAT; R: GTGTGTTCAGTCTTGCTATGTTGT pGEM-T Easy ApaI Sp6 
sox7 Nil FLC III CeuI T7 
sp9 Nil pBlueScript SK XhoI T3 
sqrdl F: ATTTAGGTGACACTATAGGAATTACAACAGTACTGCGATGAG;  R: CCTGATTCTGTGGATAACCGTATTACCGCCTTACGC  pDNR-LIB XhoI T7 
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Gene Primers/ probe sequence* (5’ ? 3’) Vector Restriction enzyme Transcriptase 
sqstm1 GGATCAAGATGTCTCAACAAGTTTC pBlueScript SK XhoI T3 
tp53 Nil pBlueScript SK XhoI T3 
txnl4a F: GAGGGCGATGTAGATATCAGTTAGTA; R: GCTAAACAAGACCATTAAACTGTCC pGEM-T Easy SacII Sp6 
ucp1 GGATCAAGATGTCTCAACAAGTTTC pBlueScript SK XhoI T3 
ugt5a2 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
uox Nil pExpress-1 EcoRI T7 
zgc:56382 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
zgc:92254 Nil pSPORT1 EcoRI Sp6 
zgc:101661 F: CCGGATCCGGTGGTGCAAATCAAAGAACTGCTCCTCAGTG;  R: CAGAGATGCATAATACGACTCACTATAGGGAGAGACAAACCACAACTAGAATG pME18S-FL3  Nil T7 
zgc:162126 F: GTCTGTCAGCTCCAGAACGA; R: GGATCTGCTCGCATAACTCC pGEM-T Easy SacII Sp6 
* F, forward primer; R, reverse primer
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2.6 Immunohistochemistry 
Immunohistochemistry (IHC) using primary antibodies of rabbit anti-activated 
Caspase-3 (casp3; 1:500 dilution; R & D systems, USA), mouse anti-acetylated 
tubulin (1:1000 dilution; Sigma-Aldrich, USA), anti-slow myosin F59 (1:10 dilution; 
Developmental Studies Hybridoma Bank, USA), mouse anti-tyrosine hydroxylase 
(TH; 1:200 dilution; Chemicon, USA), and secondary antibodies of Alexa fluor 488 
(1:500 dilution; Molecular Probes, Invitrogen, USA) and Alexa flour 546 (1:500 
dilution; Molecular Probes, Invitrogen, USA) were carried out as described 
(Westerfield, 2000). 
 
2.7 α-Bungarotoxin staining  
α-Bungarotoxin (α-BTX) staining using Alexa Flour 647 conjugated α-BTX (1:1500 
dilution; Molecular Probes, Invitrogen, USA) was performed as described (Downes 
and Granato, 2004). 
 
2.8 Morpholino knock-down 
p53 morpholino oligos (5’-GACCTCCTCTCCACTAAACTACGAT-3’) (Robu et al., 
2007) and c7-1 morpholino oligos (5’-GCACATCTGAAAAACACCAGTGTTA-3’) 
were synthesised by Gene Tools, LLC (Oregon, USA). Stock solutions of 1 mM were 
prepared by dissolving the oligos in water and stored at 4 or -20oC. Working solutions 
of 0.5 mM were prepared from the stock and phenol red was added to a final 
concentration of 0.1%. The morpholino oligos were microinjected into the yolk of 
embryos at zero to two cell stages with a microinjector (Eppendorf, USA) according 
to published protocol (Ekker and Larson, 2001).  
 
2.9 Real-time polymerase chain reaction 
Real-time polymerase chain reaction (PCR) of selected genes were carried out 
according to the supplier’s instructions (Applied Biosystems) using the fluorescent 
dye SYBR Green (Qiagen, Netherlands) and the comparative Ct method. Gene-
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specific primer sets flanking intron(s) to avoid errors due to genomic DNA 
contamination were designed for all the genes using the software ProbeFinder 
provided by Roche Applied Science (Germany; https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000). Sequences of the primers used 
were listed in Tab. 2.2. Amplification and fluorescence signal detection were 
performed by the StepOnePus Real-Time PCR System (Applied Biosystem, USA) 
and the StepOne software v2.1 (Applied Biosystem, USA). Melting curve analyses 
were performed at the end of the PCR reactions to ensure there was no primer dimer 
formation. All signals were normalised against the reference control elongation factor 
1α (ef1a). At least three independent biological repeats were performed for each gene. 
Raw data were processed and analysed by the Microsoft Excel software (Microsoft 
Corporation, USA). The transcript levels were calculated using the 2-Δ Δ Ct method. 
 
Tab. 2.2 Primers for real-time PCR. 
Gene Primers* (5’ ? 3’) 
agt F: TGCTAGTTCAGTGCATTTCAAAG; R: CTGGAGTTCTTTTGAGTCCAGAA 
arfl F: TCAGAACACCAAGGGTCTGAT; R: GCGTCTCTCATCTCGTCCTC 
atf3 F: CAGAGGAGAACGACCGAAG; R: GCTCTGCATTGATGGACTCA 
c4 F: GGCCTGGCCTTCATCTCT; R: CCAGACTCACAGCTGAAACCTT 
c6 F: AAAAGCTGTTCGTGAAAGTGC; R: GAAGGCCTGTTGGAAATTGA 
c7-1 F: CATGTCCTTGGAGAGCAACC; R: CTCCAGGCAGACCAGCAG 
cbx7l F: TGTTTGCGGTGGAGTCAATA; R: TGCCACTTTAAAAGATATTCCACA 
ef1a F: CTTCTCAGGCTGACTGTGC; R: CCGCTAGCATTACCCTCC 
homez F: CAACCCTGAGAGAAATTCAAGC; R: GAAGGTTCCATCTTGCCTTTT 
irf9 F: TTGGAGGGAGATAACATCTCTGA; R: TGAAGGCCTTGACCTCTTCT 
opn1mw1 F: TTTCTTTACCTATGGCAGTCTGG; R: GGACTCAGATTCCTGCTGTTG 
prdx1 F: TCATTGGTGCTTCTGTCGAT; R: CTTGTTTCCGGGGTGTTTT 
sgk1 F: CCTGCTGCAAAAAGACAGAAC; R: GAACATGTGGTTCTTGATTTCAGT 
zgc:101661 F: TCCAGACCTGCATCAGTCAA; R: CCTGGCACTGGTACAGCAT 
* F, forward primer; R, reverse primer 
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2.10 Acridine orange hydrochloride staining  
For detection of apoptotic cells, embryos were incubated in 0.5 μl/ml of acridine 
orange hydrochloride (AO; Sigma-Aldrich, USA) for 1 hour as described (Ton et al., 
2006). 
 
2.11 Mmp activity assay 
Mmp activity assay using fluorescein conjugated collagen type IV substrate (Molcular 
Probes, Invitrogen, USA) was performed as describe with slight modifications 
(Crawford and Pilgrim, 2005). Lysates were obtained from 100 embryos in each 
treatment group and suspended in 1 ml cold lysis buffer. Negative control containing 
10 μl of the collagen substrate together with 190 μl lysis buffer was included in each 
measurement. All samples were loaded to the chambers of 96-well plates. FITC 
fluorescence was measured every 15 minutes for 3 hours at 28oC using Lambda 
Fluoro 320 plus microplate reader (Bio-Tek Instruments, USA) and KC4 software 
(Bio-Tek Instruments, USA). The averages of the relative fluorescent unit after 
background fluorescence subtraction and error bars indicating the SEM are presented. 
 
2.12 Mmp inhibitor treatment 
Zebrafish embryos were treated with 0.1 mM GM 6001 (general Mmp inhibitor, 
Calbiochem, USA), 1% DMSO, 100 μg/l MeHg or 0.1 mM MMP-9/MMP-13 
Inhibitor II (Mmp9 and Mmp13 specific inhibitor, Calbiochem, USA), 1% DMSO, 
100 μg/l MeHg in embryo medium. Controls were exposed to 100 μg/l MeHg, 1% 
DMSO in embryo medium without the Mmp inhibitors or to embryo medium with 1% 
DMSO. All the treatments were conducted from 4 to 72 hpf. At 72 hpf, MeHg and the 
Mmp inhibitors were removed by washing the embryos with embryo medium 3 times, 
5 minutes each. Photos of the tail region of the embryos were captured and the area of 
the fin fold was calculated by the software ImageJ (Abramoff et al., 2004).  
 
 28 
2.13 Histological section 
Plastic sections were performed according to the standard protocol (Westerfield, 
2000). Samples were sectioned using a microtome (RM2065, Leica, Germany). 
 
2.14 Birefringence analysis 
Birefringence was analysed as described previously (Behra et al., 2002). 
 
2.15 Function analysis of MeHg-regulated genes 
The zebrafish regulated genes obtained from microarry were first assigned to the 
closet human homologues using the website BioMart (http://www.biomart.org/) 
(Durinck et al., 2005). The gene ontology (GO) analyses were then carried out with 
the website Gene Set Analysis Toolkit V2 (http://bioinfo.vanderbilt.edu/wg_gsat/) 
(Zhang et al., 2005; Duncan et al., 2010). Lists of the human homologues were 
uploaded on the website and blasted against the human genome. Hypergeometric test, 
Benjamini & Hochberg (1995) multiple test adjustment (MTC), and a significance 
level of 0.01 were used for the analysis. Three genes were selected as the minimum 
number for a category to be determined as enriched.  
 
2.16 Imaging 
Images of embryos or sections were captured by CCD cameras (Diagnostic 
instruments, Inc.) connected to a stereomicroscope (MZ16F, Leica, Germany) or a 
compound microscope (DM5000B, Leica, Germany).  
 
2.17 Statistics analysis 
One-way ANOVA followed by Bonferroni’s or Dunnett‘s multiple comparison tests 
were used for the statistics analysis of calculating the significance of various 
treatment group using the GraphPad Prism 4 (v4.0) software (GraphPad Software, 
USA). 
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3 Results 
3.1 Dose-dependent effect of MeHg on zebrafish 
embryos 
In order to determine which concentration of MeHg should be used in the study, a 
dose-response of toxicity to zebrafish embryos was first performed. The mortality of 
embryos exposed to different concentrations of MeHg was scored. According to the 
lethal endpoints of the fish egg test (FET), a 72-hour post fertilisation (hpf)-old 
embryo was scored as dead when there was it appeared as coagulation, tail not 
detached, no somite formation and no heart-beat (Braunbeck et al., 2005). A dose-
dependent effect was observed in zebrafish embryos exposed to 30 to 120 µg/l MeHg 
from 4-72 hpf (Fig. 3.1). Lethality of 5% was observed in the control group. At 60 
µg/l, 10% lethality (LC10) was induced and malformation were noted. The mortality 
rate increased with increasing MeHg concentration.  
 
 
Fig. 3.1 Mortality of zebrafish embryos exposed to different concentrations of MeHg. 
Zebrafish embryos were exposure to 30, 60, 90 and 120 µg/l MeHg from 4 to 72 hpf and the mortality 
rates were scored at 72 hpf. The mean ± standard error of the mean (SEM) are reported. n = 7, 20 
embryos each. Increased mortality rate of zebrafish embryos with increasing concentrations of MeHg 
examined was observed.  
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Various types of malformations at different frequencies were noted in zebrafish 
embryos exposed to 30 to 120 μg/l MeHg from 4 to 72 hpf (Fig. 3.2). Caudal fin fold 
tissue abnormality in which the caudal fin fold showed disorganised tissue structure 
and smaller size instead of being clear, thin and fan-shaped was detected. Very 
interestingly, I also observed the disruption of trunk pigmentation with a smaller gap 
size of the melanophore stripe in the tail. This melanophore stripe gap marks the 
growth zone of the tail. Some of the embryos also exhibited posterior tail flexure with 
flexed spinal cord and notochord at the posterior part of the tail instead of ones that 
remained straight to the posterior-most tip of the tail. The caudal fin abnormality of 
caudal fin fold tissue disruption, loss of melanophore stripe gap, and/or posterior 
flexure was detected in 59.5% of the embryos treated with 30 µg/l MeHg and the 
occurrence of this phenotype was even up to 87% or more in embryos exposed to 
higher MeHg concentrations. Besides the tail malformation, pericardial edema, 
smaller head and eye, stunted body and trunk flexure were also detected in embryos 
exposed to MeHg concentrations of 60 µg/l or higher. Based on the result of the 
toxicity test, MeHg concentration of 60 µg/l, which caused 10% lethality and induced 
morphologically observable phenotypes, was chosen for the study. 
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Fig. 3.2 Malformations in zebrafish embryos exposed to MeHg. 
All the embryos shown in the thesis were positioned in a way that the lateral views are anterior to the 
left and dorsal to the top, and the dorsal views are anterior to the left. Lateral views of control (A, C, E, 
G) and MeHg-treated embryos (B, D, F, H) at 72 hpf. (A, B) Caudal fin fold abnormality, posterior tail 
flexure and disruption of trunk melanophore were observed in embryos exposed to MeHg. The dotted 
lines in (A) outline the notochord and the caudal fin fold. Other phenotypes including pericardial 
edema, (C, D, arrowhead), smaller head and eye (C, D), stunted body (E, F, double-headed arrow) and 
trunk flexure (G, H) were also detected. (I) The frequency of occurrence of caudal fin abnormality, 
pericardial edema, trunk flexure and stunted body exposed to 30, 60, 90 and 120 µg/l MeHg from 4 to 
72 hpf was scored. The mean ± SEM are presented. n = 7, 20 embryos in each exposure with dead 
embryos excluded from the scoring. Abbreviations, cff, caudal fin fold; e, eye: fb, forebrain; h, heart; 
hb, hindbrain; mb, midbrain; mg, gap of the melanophore stripe; nt, notochord; t, trunk; tl, tail; ys, yolk 
sac. Scale bar, A-D, 90 μm; E, F, H, 215 μm; G, 425 μm. 
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3.2 Toxicogenomic screen of MeHg-responsive genes 
3.2.1 Microarray analysis of MeHg-regulated genes 
In order to examine the underlining mechanisms through which MeHg exerts its 
effects and to identify genes which can serve as sensitive biosensors for monitoring 
environmental MeHg, a toxicogenomic screen of genes has been performed in this 
study. In addition to the information reported by Yang (2007), another microarray 
analysis, which had much larger gene coverage, was conducted for obtaining a more 
comprehersive view of MeHg-regulated genes. The microarray analysis indicated that 
a total of 464 genes were up-regulated with M-values (log2 of the fold change) greater 
than or equal to 1.3 (p < 0.05) and 379 genes were down-regulated with M-values less 
than or equal to -1.3 (p < 0.05). The M-values of these MeHg-responsive genes are 
listed in the appendix Tab. A2 and Tab. A3.  
 
Gene ontology (GO) enrichment analysis was performed on these differentially 
expressed genes to examine the alteration of the putative biological processes and 
molecular functions in response to MeHg. The result of the functional analysis 
indicated that MeHg caused dysregulation of various biological processes and 
molecular functions (Fig. 3.3). The most significantly up-regulated biological 
functions were those related to cell death, apoptosis, response to wound, inflammatory 
response and response to oxidative stress (adjusted p < 0.001) (Fig. 3.3 A). Other 
biological processes including calcium-independent cell-cell-adhesion, extracellular 
matrix organisation, blood circulation, response to hormone stimulus, response to 
oxidative stress, response to ROS, and regulation of homeostatic process, cell redox 
homeostasis, prostaglandin (a group of lipid derived from fatty acid) metabolism, 
aromatic compound catabolic, were also significantly regulated (adjusted p < 0.01). 
MeHg also caused the up-regulation of genes associated with DNA or protein binding 
and with catalytic activities (Fig. 3.3 A’). It affected transcription factor activity, 
endopeptidase activity, aryldialkylphosphatase, MAP kinase phosphatase activity and 
arylesterase activity (adjusted p < 0.01). On the other hand, for genes which were 
down-regulated by MeHg, they were implicated in biological processes of oxidation 
reduction, RNA splicing, RNA elongation, fatty acid metabolism and DNA repair 
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(adjusted p < 0.01) (Fig.3.3 B). MeHg also led to down-regulation of genes which 
were involved in binding and catalytic activity (Fig. 3.3 B’). These included the 
translation factor activity, nucleic acid binding, coenzyme binding, oxidoreductase 
activity, protein kinase activity and isomerase activity (adjusted p < 0.01). 
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(Fig. 3.3 Continued) 
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Fig. 3.3 Gene ontology enrichment analysis of MeHg-regulated genes. 
Gene ontology (GO) enrichment analysis of MeHg-up-regulated (A, A’) and down-regulated (B, B’) 
genes. (A, B) Biological processes; (A’, B’) molecular functions. GO categories that adjusted p < 0.01 
are coloured red. Those in black are the parents of the red GO categories. The number of genes which 
fell into each of the red GO categories and the adjusted p-value are indicated. 
B’ 
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3.2.2 In situ hybridisation analysis of MeHg-regulated genes 
According to the microarray data performed in this study and that obtained by Yang 
(2007), candidate genes were further analysed by whole-mount ISH to examine any 
change in the expression patterns of the genes. For better selection of candidate genes 
for ISH analysis, the gene identity and gene ontology of the EST clones used in 
microarray analysis was determined by blasting the EST sequences against RefSeq 
RNA database or UniGene database in NCBI (Cates, 2006), the ZFIN database (ZFIN 
Staff, 2002) and the ensemble database (Flicek et al., 2005). Through the blast search, 
I was able to find out the gene identity of about three-forth of the EST clones. 
However, for the remaining one-forth of the EST clones, either no information on the 
gene identity was available or even no matches of the clones to other sequences in the 
database were obtained, and I wrote the gene name of these clones as “to be 
determined (TBD)” in Tab. 3.1 and appendix Tab. A4. Based on the result of the 
database search, I chose genes which were highly regulated by MeHg for the 
establishment of sensitive biomarkers for monitoring the environmental MeHg and 
genes which were transcription factors for examining the underlying mechanisms 
through which MeHg induced its toxicity. Eighty-eight MeHg-responsive genes 
which are involved in different molecular functions and biological processes 
including regulation of transcription, antioxidant defence, immune response, 
enzymatic activity and transmembrane transport were chosen. Details of the gene 
ontology of these genes are listed in the appendix Tab. A4. Some of the genes with 
unknown function or without known gene identity were also chosen for the discovery 
of the possible important functions of these unknown genes.  
 
The result of the screen is summarised in Tab. 1. The expression patterns in different 
organs including brain, eyes, olfactory bulb, branchial arches, heart, liver, intestine or 
gut, pronephos, somites, lateral lines, pectoral fins, caudal fin fold, blood vessels, 
dermal epithelium, yolk syncytial layer (YSL), and others, were classified. The 
column labelled ‘overall’ indicated the overall change in the expression level in the 
whole embryos. Among the 88 MeHg-regulated genes analysed by ISH, 60 genes 
were confirmed to be positively correlated with the microarray result. However, I was 
not able to determine the overall change in the expression levels of three of the genes, 
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elf3, noxo1 and slc16a9a, by ISH (indicated as ‘TBD’ in the ‘overall’ column of Tab. 
3.1) due to the fact that the expression of these genes were highly up-regulated in 
certain parts of the body, but were also strongly down-regulated in other parts of the 
body.  
 
The changes in the expression patterns some of the genes regulated by MeHg 
exposure are shown in Fig. 3.4 as a demonstration of the anatomical structures 
indicated in Tab. 1. For example, in response to MeHg, prdx1 was highly up-
regulated in the lateral line and liver, and slightly up-regulated in the hypothalamus of 
the brain (Fig. 3.4 A, A’); increased expression of pck1 was observed in the YSL of 
the yolk and the yolk sac extension (YSE) (Fig. 3.4 B, B’); fn1b showed a strong up-
regulation in the dermal epithelium throughout the whole embryo (Fig. 3.4 C, C’); 
mmp13a was up-regulated in blood cells scattered all over the body, the posterior 
blood island (PBI), where blood cells are produced, the edges of the pectoral fins and 
the caudal fin fold (Fig. 3.4 D, D’); the expression of noxo1 was increased in the 
lateral line, pectoral fin and dermal epithelium (arrow in Fig. 3.4 E’), but decreased in 
the branchial arches of the jaw (Fig. 3.4 E, E’); elf3 also showed a decrease in 
expression in the branchial arches, but an increase in the pronephos (embryonic 
kidney) was noted (Fig. 3.4 F, F’); the expression of opn1mw1 in the eyes decreased 
and was restricted to the anterior part of the eyes (Fig. 3.4 G, G’). BI474700 exhibited 
a ubiquitous increase in expression and was up-regulated in various organs including 
the brain, eye, liver and gut (Fig. 3.4 H, H’); BM101698 was up-regulated in both the 
olfactory bulb and the outer region of the pectoral fins (Fig. 3.4 I, I’); increased 
expression of c6 was observed in the adenohypophysis (anterior pituitary) (Fig. 3.4 J, 
J’); c4-2 was up-regulated in the trunk blood vessels, showing expression in the dorsal 
aorta (DA), dorsal anastomotic vessel (DLAV), posterior caudal vein (PCV) and 
inter-segmental vessels (ISV) (Fig. 3.4 K, K’); sqstm1 showed an up-regulation in the 
pigment cells and the caudal fin fold (Fig. 3.4 L, L’); the expression of cartI was 
increased in the notochord and the somites (Fig. 3.4 M, M’); txnl was up-regulated in 
the lateral line, the caudal fin fold and the proctodeum, which is the posterior 
ectodermal part of the alimentary canal (Fig. 3.4 N, N’). 
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Tab. 3.1 Result of whole-mount in situ hybridisation analysis of MeHg-regulated genes in 72 hpf-old zebrafish embryos. 
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NM_200637 
a disintegrin and 
metalloproteinase domain 8a 
(adam8a) 
                  NC 
NM_200964 activating transcription factor 3 (atf3) + +       +         + (proctodeum) + 
AI477644 ADP-ribosylation factor-like (arfl); Zgc:112199 +                 
+ (scattered cells 
over the body) + 
BG727310 angiotensinogen (agt) + +    +  +         +  + 
NM_131098  apolipoprotein eb (apoeb)           + +    +   + 
NM_131886 CCAAT/enhancer binding protein (C/EBP), gamma (cebpg) +                  + 
NM_001017853 chromobox protein homolog 7-like (cbx7l); zgc:110152 + +        -    +     + 
DN857240 
cocaine and amphetamine 
regulated transcript protein type I-
like (cartIl) 
+            +      + 
AF047413 complement component 3a (c3a); si:dkey-76b14.4      +           +  + 
BI672168 complement component 4-2 (c4-2)      +        +   +  + 
BI474371 complement component 6 (c6)     +  +    +      + + (oesophagus) + 
BC100054 complement component 7-1 (c7-1)  +                 + 
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AW019018 complement factor b (cfb)      +           +  + 
NM_201461 core promoter element binding protein (copeb)     +       +       + 
BI845861 CXC chemokine 46-like (cxc46l)  +        + + +  +     + 
BE016427 ubiquitin carboxyl-terminal hydrolase CYLD-like (cyldl)                   NC 
AI385059 E74-like factor 3 (elf3)   + -   + +  +        + (proctodeum) TBD 
NM_001013261 fibronectin 1b (fn1b)                +   + 
NM_131285 forkhead box B1.2 (foxb1.2)                   NC 
BG304082 glutamate-cysteine ligase modifier subunit (gclm) + +    + +   + +     +   + 
AW232474 glutathione peroxidase 1a (gpx1a)      - - -  -         - 
BI896246 glutathione peroxidase 4a (gpx4a)      - -            - 
BM777961 glycine dehydrogenase (decarboxylating) (gldc)                   NC 
NM_130934 hematopoietically expressed homeobox (hhex)     + +             + 
NM_001007120 homeodomain leucine zipper gene (homez) +          + +  +  +   + 
NM_205710 interferon regulatory factor (irf9) +    +              + 
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NM_213556 Jun B proto-oncogene (junb)           + +    +   + 
AI641738 kruppel-like factor 10-like (klf10l)                   NC 
NM_001077604 kruppel-like factor 11b (klf11b)                   NC 
AI793516 
lysosomal-associated membrane 
glycoprotein 1-like (lamp1l); 
zgc:64072 
+ +        +       +  + 
AW174507 matrix metalloproteinase 9 (mmp9)          + + +    +  + (blood cells) + 
AW305943 matrix metalloproteinase 13a (mmp13a)           + +      
+ (blood cells and 
PBI) + 
NM_194416 matrix metalloproteinase 14a (mmp14a)            +       + 
BI878214 NADPH oxidase organizer 1 (noxo1)    -      + + +    +   TBD 
AF109371 opsin 1 (cone pigments), long-wave-sensitive, 1 (opn1lw1) - -                 - 
AF109369 opsin 1 (cone pigments), medium-wave-sensitive, 1 (opn1mw1)  -                 - 
AF109373 opsin 1 (cone pigments), short-wave-sensitive 1 (opn1sw1)  -                 - 
NM_131184 paired box gene 2a (pax2a)                   NC 
NM_131304 paired box gene 6a (pax6a)                   NC 
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BI980610 peroxiredoxin1 (prdx1); zgc:110343 +     + +   +         + 
BG727092 phosphoenolpyruvate carboxykinase 1 (pck1)      +           +  + 
BI888564 
6-phosphofructo-2-
kinase/fructose-2,6-biphosphatase 
4-like (pfkfb4l) 
+ +                 + 
BE557057 PLAC8-like protein 1-like (plac8l1l)                   NC 
NM_199515 PR domain containing 1a, with ZNF domain (prdm1a)  +         + +       + 
BI889255 protein phosphatase 1 regulatory subunit 15A (ppp1r15a) + +       +          + 
NM_199798  Ras-related associated with diabetes (rrad)     +    +  +        + 
NM_131225 retinal homeobox gene 1 (rx1)                   NC 
BC095285 S100 calcium binding protein Z (s100z)                   NC 
BM102635 SAR1a gene homolog 2 (S. cerevisiae) (sara2) +                  + 
AW128247 selenoprotein W, 1 (sepw1)                   NC 
AW343560 sequestosome 1 (sqstm1)   +  +     + + +   + + +  + 
BI673466 serum/glucocorticoid regulated kinase 1 (sgk1)        +   + +  +   +  + 
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BG302634 si:ch211-106h4.4                   NC 
AI974163 si:ch1073-126c3.2                   NC 
NM_131362 sine oculis homeobox homolog 3a (six3a) + +                 + 
NM_131363 sine oculis homeobox homolog 3b (six3b)                   NC 
AW421040 
solute carrier family 16 
(monocarboxylic acid 
transporters), member 9a 
(slc16a9a) 
- -   -      +   +     TBD 
BE016639 
solute carrier family 16 
(monocarboxylic acid 
transporters), member 9b 
(slc16a9b) 
                  NC 
NM_212960 sp9 transcription factor (sp9)            +       + 
NM_001080750 SRY-box containing gene 7 (sox7)                   NC 
BI882244 Sulfide quinone reductase-like (sqrdl)                   NC 
BI878700 suppressor of cytokine signaling 3a (socs3a)                   NC 
BG727181 suppressor of cytokine signaling 3b (socs3b)                +   + 
BI864190 thioredoxin-like (txnl); zgc:92903   +       + + +    +  + (proctodeum) + 
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BI886657 thioredoxin-like 4A (txnl4a)                   NC 
NM_131327 tumor protein p53 (p53)            +       + 
AW127886 UDP glucuronosyltransferase 5 family, polypeptide A2 (ugt5a2) +                  + 
AW420321 uncoupling protein 1 (ucp1)     +    +   +       + 
AW019321 urate oxidase (uox)                   NC 
NM_205569 v-fos FBJ murine osteosarcoma viral oncogene homolog (fos) +  +      +        +  + 
NM_131015 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein B (avian) (mafba) 
                  NC 
NM_200336 
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog f 
(avian) (maff) 
         +         + 
BM101640 zgc:56382   +        + +    +   + 
AW019036 zgc:92254                   NC 
AI657551 zgc:101661 + +    +         +  +  + 
AI397362 AI397362   + +        +  +  +   + 
AI544649 AI544649                   NC 
46 
 
 
Anatomical structures 
GenBank 
accession 
number 
Gene name (gene symbol) 
B
r
a
i
n
 
E
y
e
s
 
O
l
f
a
c
t
o
r
y
 
b
u
l
b
 
B
r
a
n
c
h
i
a
l
 
a
r
c
h
e
s
 
H
e
a
r
t
 
L
i
v
e
r
 
I
n
t
e
s
t
i
n
e
,
 
g
u
t
 
P
r
o
n
e
p
h
o
s
 
S
o
m
i
t
e
s
 
L
a
t
e
r
a
l
 
l
i
n
e
s
 
P
e
c
t
o
r
a
l
 
f
i
n
s
 
C
a
u
d
a
l
 
f
i
n
 
f
o
l
d
 
N
o
t
o
c
h
o
r
d
 
B
l
o
o
d
 
v
e
s
s
e
l
s
 
P
i
g
m
e
n
t
 
c
e
l
l
s
 
D
e
r
m
a
l
 
e
p
i
t
h
e
l
i
u
m
 
Y
S
L
 
O
t
h
e
r
s
 
O
v
e
r
a
l
l
 
AI793818 AI793818    +            +   + 
AW115990 AW115990 + +    +     + +    +   + 
BE016163 BE016163 +                  + 
BG727211 BG727211                   NC 
BG891932 BG891932                   NC 
BI474700 BI474700 + + + + + + +  +  +        + 
BI883993 BI883993                   NC 
BI892110 BI892110                   NC 
BI983579 BI983579  +    +        +  + +  + 
BM036361 BM036361 + +                 + 
BM101698 BM101698   +        + +    +   + 
+, increase in expression; -, decrease in expression; NC, no change; TBD, to be determined 
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(Fig. 3.4 Continued) 
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(Fig. 3.4 Continued) 
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Fig. 3.4 Changes in gene expression patterns in after MeHg exposure. 
Dorsal (A, A’, E, E’ – I-I’) and lateral (B, B’ – D, D’, J, J’ – N, N’) views of 72-hpf-old control (A, B, C, D, E, F, G, H, I, J, K, L, M, N) and MeHg-treated (A’, B’, C’, D’, 
E’, F’, G’, H’, I’, J’, K’, L’, M’, N’) embryos. The whole embryo (A, A’ – D, D’), and the anterior part (E, E’ – J, J’), the trunk (I, I’) and posterior part (K, K’ – N, N’) of the 
embryos are shown. The embryos were staining with in situ hybridisation using probes complementary to prdx1 (A, A’), pck1 (B, B’), fn1b (C, C’), mmp13a (D, D’), noxo1 
(E, E’), elf3 (F, F’), opn1mw1 (G, G’), BI144700 (H, H’), BM101698 (I, I’), c6 (J, J’), c4-2 (K, K’), sqstm1 (L, L’), cartI (M, M’), txnl (N, N’). The dotted lines in D, D’, I, I’ 
quote the pectoral fins; the dotted lines in E, E’, F, F’ mark the outer region of the jaws; the dotted lines in H, H’ outline the gut; the dotted lines in M mark the notochord. 
Abbreviations, DA, dorsal aorta; DLAV, dorsal anastomotic vessel; cff, caudal fin fold; e, eye, fb, forebrain; g, gut; hb, hindbrain; hy, hypothalamus; ISV, inter-segmental 
vessel; j, jaw; l, liver; ll, lateral line; mb, midbrain; nt, notochord; ob, olfactory bulb; oe, oesophagus; p, pronephos; PBI, posterior blood island; pc, pigment cell; PCV, 
posterior caudal vein; pf, pectoral fin; pt, proctodeum; sm, somite; y, yolk; yse, yolk sac extension. Scale bar, A, A’ – D, D’, 200 μm; F, F’, J, J’ – N, N’, 100 μm; E, E’, G, 
G’ – I, I’, 80 μm.  
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3.2.3 Quantitative analyses of MeHg-regulated genes by 
real-time PCR 
To further quantify the expression levels and to determine if these changes could be 
induced by lower levels of MeHg, real-time PCR was performed. Zebrafish embryos 
were exposed to 30 and 60 μg/l MeHg and the samples were then subjected to real-
time PCR analyses. Genes arfl, atf3, c4-2, c6, cbx7l, homez, irf9, prdx1, ppp1r15a, 
txnl, zgc:101661 and opn1mw1 that showed obvious changes in the expressions in 
both microarray and ISH were investigated. As indicated by real-time PCR, the 
expression levels of all the genes examined, except homez, were significantly 
regulated by 60 μg/l-MeHg exposure (Fig. 3.5). arfl, c4-2, c6, cbx7l, prdx1 and txnl 
have M-values of more than 2 (that is more than 4-fold induction), atf3, irf9, 
ppp1r15a and zgc:101667 exhibited M-values of more than 1 (that is more than 2-fold 
induction), and opn1mw1 showed a negative M-value of more than 2 (that is more 
than 4-fold repression) after exposing to 60 μg/l MeHg. arfl, c4-2, c6, cbx7l, prdx1, 
txnl and zgc:101661 even showed significant changes of more than 1 (that is more 
than 2-fold induction) at lower MeHg concentration of 30 μg/l. The sensitive changes 
in the expression levels of arfl, c4-2, c6, cbx7l, prdx1, txnl and zgc:101661 suggested 
that they may serve as marker genes for detecting the presence of MeHg in the 
environment. 
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Fig. 3.5 Changes in gene expression levels measured by quantitative real-time PCR in response to 
MeHg. 
The changes in the expression levels of arfl, atf3, c4-2, c6, cbx7l, homez, irf9, prdx1, ppp1r15a, txnl, 
zgc:101661and opn1mwl were determined by real-time PCR of control and MeHg-treated samples. 
Graphs of MeHg concentration against the M-value (log2 of the fold change) relative to controls are 
plotted. The mean ± SEM are presented. T-test and Dunnett adjustment, p < 0.05 (*). 
 
3.2.4  Summary 
A toxicogenomic-based screen on MeHg-regulated genes was performed. A total of 
464 MeHg-up-regulated and 379 MeHg-down-regulated genes were obtained from 
the microarray analysis. The microarray result was verified and the changes in the 
expression patterns of 88 candidate genes after MeHg exposure were examined by 
whole-mount ISH. The result of the ISH indicated that 60 out of the 88 genes were 
positively correlated with the microarray result. Ectopic expressions of the genes were 
noted in various organs including the brain, eyes, olfactory bulb, branchial arches, 
heart, liver, intestine or gut, pronephos, somites, lateral lines, pectoral fins, caudal fin 
fold, blood vessels, dermal epithelium, and YSL. The expression levels of 12 genes 
including arfl, atf3, c4-2, c6, cbx7l, homez, irf9, prdx1, txnl, zgc:101661, ppp1r15a 
and opn1mw1, in embryos exposed to 30 and 60 μg/l MeHg were further quantified 
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by real-time PCR. Eleven genes were shown to be significantly regulated at 60 μg/l 
MeHg. The expression levels of arfl, c4-2, c6, cbx7l, prdx1 and zgc:101661 were 
significantly regulated even at 30 μg/l MeHg. The sensitive expression changes of 
these 6 genes suggested that they may serve as marker genes for detecting the 
presence of MeHg in the environment. 
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3.3 Zebrafish nervous system 
3.3.1 Study on zebrafish brain after MeHg exposure 
Under normal development, the cellular fate of different regions of the blastoderm has 
been established by the onset of gastrulation (at 6 hpf when the embryo was 
maintained at temperature of 28.5oC) (Driever et al., 1995; Kimmel et al., 1995; 
Solnica-Krezel, 2005). The positions of the precursors for different tissues and organs 
including the brain, spinal cord, notochord, epidermis, heart, somite, blood, 
pronephros and perichordal plate have been specified. At 18 hpf, the first half of 
segmentation, the morphological segmentation of the brain is visible and about ten 
distinctive swellings, the neuromeres which mark the telencephalon, diencephalon, 
mesencephalon and seven hindbrain rhombomeres, are formed along the brain 
rudiment (Kimmel et al., 1995; Lowery and Sive, 2004; Fig. 3.6). At 24 hpf, more 
prominently sculptured regions of the brain can be seen. Anatomical brain structures 
of cerebellum, epiphysis, floor plate and rudiment of hypothalamus are formed, and 
partitioning of the midbrain into the dorsal tectum and the ventral tegmentum is 
visible. 
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Fig. 3.6 Sculpturing of the brain rudiment during the segmentation period. 
(A) At 12 hpf, no morphological subdivisions of the brain region are visible. (B) By 24 hpf, 
prominently sculptured regions of the forebrain composed of diencephalon (D) and telencephalon 
(Tel), the midbrain including tectum (Tm), tegmentum (Tg) and epiphysis (E), the hindbrain consisting 
of cerebellum (C) and rhombomeres (r1-7), and the floor plate (FP) are visible. Scale bars: 200 μm. 
This figure is modified from Kimmel et al. (1995). 
 
3.3.1.1 No obvious change in the expression pattern of genes 
expressed in the brain after sub-lethal concentration of 
MeHg treatment 
As MeHg is known to cause neural developmental defects in mammals and decreased 
swimming activity was noted in zebrafish embryos (Samson et al., 2001), I 
hypothesised that low dosage of MeHg exposure would cause neurotoxic effects like 
retardation of neurological development or interference of neurochemical processes at 
later stage of development instead of affecting the general structure of the brain. To 
determine any abnormal change in the expression patterns of genes in the central 
nervous system (CNS) or in the neurotransmitter system, whole mount ISH and IHC 
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were performed to study the expression of acetylcholinesterase (ache; Bertrand et al., 
2001), which is a member of acetylcholinic neurotransmitter system and responsible 
for degrading acetylcholine, paired box gene 6a (pax6a), which is a homeodomain 
transcription factor and is very important for the development of eye and other 
sensory organs, cannabinoid receptor 1 (cb1; Lam et al., 2006), which is a G protein-
coupled receptor of the inhibitory Gamma-aminobutyric acid (GABA) 
neurotransmitter system, serotonin transporter a (serta; Wang et al., 2006), which is 
an monoamine transporters that transports the neurotransmitter serotonin from 
synaptic spaces into presynaptic neurons, nuclear receptor-related factor 1 (nurr1; 
Escriva et al., 1997), which is an orphan nuclear receptor and involved in the 
maintenance of the dopaminergic neurotransmitter system, sonic hedgehog a (shha; 
Krauss et al., 1993), which plays key roles in the development of organs including the 
brain, crestin (Luo et al., 2001), which marks the neural crest cells and tyrosine 
hydroxylase (TH), which is responsible for catalysing the conversion of the amino 
acid L-tyrosine to dihydroxyphenylalanine, a precursor of dopamine. However, no 
obvious change in the expression patterns was observed in any of the genes or 
proteins examined (Fig. 3.7).  
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Fig. 3.7 Expression patterns of genes or proteins expressed in the central nervous system or 
neurotransmitter system of zebrafish embryos after MeHg exposure. 
In situ hybridisation (regions which expressed the genes were stained in deep purple) (A-N) and 
immunohistochemistry (regions which the proteins were present were fluorescent green) (O,P) 
stainings were performed on control (A, C, E, G, I, K, M, O) and MeHg-treated (B, D, F, H, J, L, N, P) 
embryos at 72 hpf (A-L, O, P) and 24 hpf (M, N). Lateral views of the head region (A-L) and whole 
embryos (M, N) and dorsal views, anterior to the left and right side up, of the head region of the 
embryos (O, P) are shown. (A, B) ache; (C, D) pax6a; (E, F) cb1; (G, H) serta; (I, J) nurr1; (K, L) 
shha; (M, N) crestin; (O, P) TH. No obvious change in the expression pattern of the genes or proteins 
examined was observed. Abbreviations, e, eye; fb, forebrain; hb, hindbrain; mb, midbrain; tk, trunk; ys, 
yolk sac. Scale bar, A-L, O, P, 200 μm; M,N, 650 μm. 
 
3.3.1.2 Genes showing ectopic expression in the brain of MeHg-
treated embryos 
To order to identify genes which show changes in the brain in response to MeHg 
exposure and may play a role in causing the decreased swimming activity in zebrafish 
embryos, the toxicogenomic screen is performed in parallel to the study of the marker 
genes of the CNS or the neurotransmitter system. Through the toxicogenomic screen, 
I identified 24 genes which were specially regulated in the brain under MeHg 
exposure. These genes are involved in diverse biological processes and molecular 
functions. 
 
In response to MeHg exposure, the expression of ADP-ribosylation factor-like (arfl) 
was up-regulated in scattered cells in the brain (Fig. 3.8 A, A’) and such an expression 
was also observed in other parts of the body (supplementary disc). arf are members of 
the Arf family of the Ras superfamily of GTPase enzymes which can bind and 
hydrolyse GTP (Gillingham and Munro et al., 2007; Wennerberg et al., 2005). They 
are involved in the regulation of membrane traffic and organisation of the 
cytoskeleton (Donaldson and Honda, 2005; D'Souza-Schorey and Chavrier, 2008).  
 
activating transcription factor 3 (atf3) was induced in patches of cells in the brain in 
MeHg-treated embryos (Fig. 3.8 B, B’). It is a transcription factor of the ATF/cyclic 
AMP response element-binding (ATF/CREB) family (Liang et al., 1996). It is an 
adaptive-response gene which can be induced by various stress signals and has been 
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implicated in immune responses and oncogenesis (Hai et al., 2010; Thompson et al., 
2009).  
 
The expression of angiotensinogen (agt) was slightly increased in the boundaries 
between forebrain and midbrain and between midbrain and hindbrain and in the outer 
region of the tectum in embryos exposed to MeHg (Fig. 3.8 C, C’). agt is a part of the 
renin-angiotensin system that plays an important role in the regulation of blood 
pressure and water balance. In both human and rat brains, Agt was shown to be 
expressed by astrocytes (Intebi et al., 1990; Stornetta et al., 1988; Wosik et al., 2007). 
In the human brain, AGT was required for blood-brain barrier maintenance (Wosik et 
al., 2007).  
 
The expression of CCAAT/enhancer binding protein (C/EBP), gamma (cebpg) was 
up-regulated in the outer region of the tectum after MeHg treatment (Fig. 3.8 D, D’). 
cebpg is a transcription factor of the C/EBP family which regulates viral and cellular 
CCAAT/enhancer element-mediated transcription. A pervious study showed that the 
levels of expressions of cebpg correlated with those of antioxidant and DNA repair 
genes in normal bronchial epithelial cells (Mullins et al., 2005).  
 
chromobox protein homolog 7-like (cbx7l) was induced in patches of cells in the brain 
in MeHg-treated embryos ((Fig. 3.8 E, E’, arrows). It belongs to the polycomb group 
proteins which repress transcription epigenetically through the remodelling of 
chromatin and are involved in the control of cell cycle and oncogenesis (Morey and 
Helin, 2010; Schwartz, Pirrotta, 2008). Studies using human cancer cell lines showed 
that CBX7 was highly expressed in cells of urothelial carcinomas (Hinz et al., 2008), 
prostate cancer (Bernard et al., 2005), follicular lymphomas (Scott et al., 2007) and 
gastric cancer (Zhang et al., 2010), but down-regulated in those of thyroid carcinoma 
(Pallante et al., 2008) and pancreatic cancer (Karamitopoulou et al., 2010).  
 
The expression of cocaine and amphetamine regulated transcript protein type I-like 
(cartIl) in small groups of cells located in the brain was slightly increased after MeHg 
exposure (Fig. 3.8 F, F’, arrows). Cart has been shown to be involved in multiple 
physiological functions, including feeding, endocrine regulation, and mediation of the 
stress response (Kuhar et al., 2000). In human and rat, Cart was more widely 
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expressed and the expression was noted in neurons in the hypothalamus (Elias et al., 
2001).  
 
The expression of v-fos FBJ murine osteosarcoma viral oncogene homolog (fos) was 
strongly induced in the dorsal part of the brain after MeHg exposure (Fig. 3.8 G, G’). 
Fos is a transcription factor with a leucine-zipper DNA binding domain. It is 
important in normal and pathological conditions, and its deregulation has been shown 
to be linked with a variety of pathological conditions including oncogenesis, hypoxia, 
and neurological, immunological and skeletal defects (Herdegen and Waetzig, 2001; 
Milde-Langosch, 2005; Prabhakar and Kumar, 2004; Saitoh et al., 1993; Wagner and 
Eferl, 2005). In rodents, medium- or long-term dietary intake of Hg-contaminated rice 
were also shown to increase Fos expression levels in the brain (Cheng et al., 2005; 
2009). 
 
glutamate-cysteine ligase modifier subunit (gclm) showed a general up-regulation in 
the brain in MeHg-treated embryos (Fig. 3.8 H, H’). It encodes a part of the enzyme 
glutamate cysteine ligase which is critical for the synthesis of the GSH antioxidant 
(Lu, 2009). Increased Gclm expression levels were observed in conditions of 
oxidative stress caused by various substances (Lavoie et al., 2009; Thompson et al., 
2009; Woo et la., 2008). In human patients, polymorphism of GCLM has been 
reported to be associated with coronary endothelial vasomotor dysfunction and 
myocardial infarction (Koide et al., 2003; Nakamura et al., 2003).  
 
homeodomain leucine zipper gene (homez) was strongly up-regulated in the brain, 
especially in the dorsal hindbrain region after MeHg treatment (Fig. 3.8 I, I’). It is a 
transcription factor containing leucine-zipper like motifs (Bayarsaihan et al., 2003). In 
mouse, it showed restricted expressions in the brain, the optic vesicle and the otic 
placode during later stages of embryonic development (Bayarsaihan et al., 2003).  
 
interferon regulatory factor (irf9) showed a ubiquitous up-regulation in the brain in 
MeHg-treated embryos (Fig. 3.8 J, J’). Irf are transcription factors that involve in the 
protective defences of the immune system through the regulation of the transcription 
of interferons which can activate immune cells, increase the recognition of infection 
or tumor cells by up-regulating antigen presentation to T lymphocytes, and increase 
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the ability of uninfected host cells to resist new infection by virus (Gastl and Huber, 
1988; Pestka et al., 1987; Taniguchi et al., 2001).  
 
The expression of lysosomal-associated membrane glycoprotein 1-like (lamp1l) was 
up-regulated in the brain, especially in the epithelium lining the brain ventricle (Fig. 
3.8 K, K’). Lamp1 together with Lamp2 account for about 50% of all the proteins of 
the lysosome membranes (Hunziker et al., 1996). In mouse embryonic fibroblasts, 
lacking both Lamp1 and Lamp2 resulted in an accumulation of autophagic vacuoles 
and disturbed cholesterol metabolism (Eskelinen et al., 2004).  
 
opn1lw1 showed a general decrease in expression levels in the epiphysis in addition to 
in the eye after MeHg exposure (Fig. 3.8 L, L’). opn1lw1 encodes a long-wavelength 
sensitive cone opsin having maximum light absorption at the red light region. Opsins 
are light-responsive membrane-bound G protein-coupled receptors of the retinylidene 
protein family (chromophore, vitamin A derivatives) found in photoreceptor cells 
(Nickle and Robinson, 2007).  
 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4-like (pfkfb4l) showed an 
increase in expression in the whole brain after MeHg treatment (Fig. 3.8 M, M’). 
pfkfb4 is a member of the Pfkfb enzymes which induce glycolysis through activating 
6-phosphofructo-1-kinase and blocking gluconeogenesis by inhibiting fructose-1,6-
bisphosphatase (Pilkis et al., 1995). The expressions of PFKFBs have been shown to 
be induced in cancer cells and by hypoxia (Minchenko et al., 2005a, 2005b, 2005c).  
 
ppp1r15a was up-regulated in the tegmentum and rhombomeres after MeHg exposure 
(Fig. 3.8 N, N’). Ppp1r15a encodes the growth arrest and DNA damage 34 
(GADD34) protein which dephosphorylates the alpha subunit of translation initiation 
factor 2 (eIF2α), promoting the recovery of protein synthesis in the unfolded protein 
response (a response to the accumulation of unfolded or misfolded proteins in the 
lumen of endoplasmic reticulum) (Novoa et al., 2001). Ppp1r15a mutant cells exhibit 
impaired recovery of protein synthesis while Ppp1r15a knockout mice are 
phenotypically indistinguishable from wild type (Kojima et al., 2003; Novoa et al., 
2003).  
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The expression of peroxiredoxin1 (prdx1) was slightly up-regulated in the 
hypothalamus after MeHg exposure (Fig. 3.8 O, O’). Prdx1 is a member of the 
antioxidant thioredoxin-dependent peroxidase family (Immenschuh and Baumgart-
Vogt, 2005; Rhee et al., 2005). It protects cellular components by removing the low 
levels of ROS produced as a result of normal cellular metabolism and is a stress-
inducible antioxidant (Ishii and Yanagawa, 1997; Rhee et al., 2005). Prdx1 is also 
known as natural killer enhancing factor A (NkefA) and in human cell lines, it has 
been shown to be implicated in enhancing natural killer cell activity and antivirual 
activity (Geiben-Lynn, et al., 2003; Shau et al., 1993).  
 
SAR1a gene homolog (sara2) showed mild up-regulation in the brain in embryos 
exposed to MeHg (Fig. 3.8 P, P’). sara2 is a zebrafish homologue of the yeast S. 
cerevisiae SAR1, which is also a small GTPase of the Arf family as arfl (Gillingham 
and Munro et al., 2007). It is found in COPII vesicles (a type of vesicle which 
transports proteins from the rough endoplasmic reticulum (ER) to the Golgi 
apparatus) (Bi et al., 2002) and it regulates the membrane constriction, assembly and 
fission of the vesicles and the transport of ER (Bielli et al., 2005; Long et al., 2010).  
 
The expression of sine oculis homeobox homolog 3a (six3a) in the forebrain was up-
regulated after MeHg exposure (Fig. 3.8 Q, Q’). six3a is a member of the Six gene 
family which was first identified in Drosophila for compound-eye formation 
(Kawakami et al., 2000). In zebrafish, six3a plays important roles in both eye and 
rostal forebrain developments (Kobayashi et al., 1998; Seo et al., 1998).  
 
solute carrier family 16 (monocarboxylic acid transporters), member 9a (slc16a9a) 
showed a general decrease in the expression in the whole brain after MeHg treatment 
(Fig. 3.8 R, R’). slc16a9a is a member of Slc16 gene family (Meredith and Christian, 
2008). Some members of this family catalyse the transport of monocarboxylates such 
as lactate, pyruvate and ketone or bodies aromatic amino acids (Halestrap and 
Meredith, 2004; Meredith and Christian, 2008). However, the substrate(s) of slc16a9a 
is still unknown.  
 
UDP glucuronosyltransferase 5 family, polypeptide A2 (ugt5a2) was up-regulated in 
the dorsal region of the brain of MeHg-treated embryos (Fig. 3.8 S, S’). ugt5a2 
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belongs to the UDP-Glucuronosyltransferase (Ugt) superfamily. Members of this 
superfamily encode enzymes responsible for the glucuronidation of the xenobiotics, 
producing the more water soluble glucuronic acid-bound xenobiotics, and thus, aid 
the excretion of the xenobiotics from the body (King et al., 2000; Miners et al., 2002). 
The Ugt5 family exist only in teleosts and amphibians, but not in reptiles, birds or 
mammals (Huang and Wu, 2010).  
 
Eight other genes with unknown identity including zgc:101661, AW115990, 
BE016163, BI474700 and BM036361 were also ectopically expressed in the brain 
after MeHg exposure (Fig. 3.8 T, T’ – X, X’). The changes in the expression patterns 
of these 24 genes in the brain might suggest the induction of the behavioural changes 
reported by Samson et al. (2001) after MeHg exposure. 
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(Fig. 3.8 Continued) 
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(Fig. 3.8 Continued) 
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Fig. 3.8 Changes in gene expression in the zebrafish brain after MeHg treatment.  
Lateral (A, A’- E, E’, G, G’- K, K’, M, M’ – N, N’, P, P’- V, V’) and dorsal (F, F’, L L’, O, O’, W, W’, 
X, X’) views of 72-hpf-old control (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, 
X) and MeHg-treated (A’, B’, C’, D’, E’, F’, G’, H’, I’, J’, K’, L’, M’, N’, O’, P’, Q’, R’, S’, T’, U’, 
V’, W’, X’) embryos performed with in situ hybridisation are shown. The dotted line in A indicates the 
position of the eye; the arrows in L, L’, X, X’ mark the epiphysis. Up-regulations of arfl (A, A’), atf3 
(B, B’), agt (C, C’), cebpg (D, D’), cbx7l (E, E’), cartIl (F, F’, the patches of cells with increased 
expression are indicated by the arrows), fos (G, G’), gclm (H, H’), homez (I, I’), irf9 (J, J’), lamp1l (K, 
K’), pfkfb4l (M, M’), ppp1r15a (N, N’), prdx1 (O, O’, the asterisks indicate the hypothalamus), sara2 
(P, P’), six3a (Q, Q’, eyes removed for better observation of the expression pattern in the brain), utg5a2 
(S, S’), zgc:101661 (T, T’), AW115990 (U, U’), BE016163 (V, V’), BI474700 (W, W’) and BM036361 
(X, X’), and down-regulations of opn1lw1 (L, L’) and slc16a9a (R, R’) were observed in the brain of 
embryos exposed to MeHg. Abbreviations, e, eye; fb, forebrain; hb, hindbrain; mb, midbrain. Scale bar, 
A, A’- E, E’, G, G’- K, K’, M, M’ – N, N’, P, P’- V, V’, 100 μm, F, F’, L L’, O, O’, W, W’, X, X’, 80 
μm.  
 
3.3.2 Study on the lateral line system in MeHg-treated 
embryo 
Lateral line is a sensory organ of the peripheral nervous system in fish and is 
responsible for sensing the local disturbances of the water flow and detecting the 
orientation of the animal in the surrounding water current. It is essential for detecting 
prey, escaping from predators, and performing social interactions. In zebrafish, the 
lateral line runs lengthwise on each side of the body, from the vicinity of the 
operculum to the base of the tail (Metcalfe et al., 1985). It comprises a stereotyped 
array of sensory structures called neuromasts, each of which is composed of 
mechanoreceptive hair cells, support cells and mantel cells and is innervated (Ghysen 
and Dambly-Chaudière, 2004; Fig. 3.9 A). The neuromasts located on the head are 
termed anterior lateral line system (ALL), whose ganglion is located between the ear 
and the eye, while those present on the trunk and tail are referred to posterior lateral 
line system (PLL) whose ganglion is just posterior to the ear (Dambly-Chaudière et 
al., 2003; Metcalfe et al., 1985; Raible and Kurse, 2000). The PLL is formed by a 
migrating primordium. During embryonic development, the migrating primordium 
moves in an anterior-to-posterior manner along the horizontal myoseptum all the way 
to the tip of the tail and deposits clusters of cells at regular intervals, each of which 
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will later differentiate into individual neuromast (Dambly-Chaudière et al., 2003; Fig. 
3.9 B).  
 
 
Fig. 3.9 Pattern and structure of the zebrafish lateral line at the end of embryogenesis. 
(A) Scheme of a neuromast, showing the organisation of hair cells, the surrounding support cells and 
mental cells and afferent fibers. (B) Schematic diagram of the lateral line of a zebrafish embryo at 48 
hpf. The red dotted arrow indicates the direction of neuromast formation in posterial lateral line (PLL) 
during development and the green dots represent the positions of the PLL neuromasts. The round dots 
and small circles in the head region mark the positions of the anterior lateral line (ALL) neuromasts. 
This figure is reproduced after Ghysen and Dambly-Chaudière (2004). 
 
3.3.2.1 Decreased number of neuromast hair cells in the PLL 
The neuromasts are in direct contact with the environment and it has been reported 
that waterborne contaminants, such as copper, aminoglycoside and neomycin, could 
lead to disruption of the neuromasts and death of hair cells (Froehlicher et al., 2009; 
Harris et al., 2007; Hernández et al., 2006; Owens, et al., 2007). This led to the 
speculation that exposure to MeHg would also result in disruption of the neuromasts 
of the lateral line system in the zebrafish embryo. I examined this by employing the 
transgenic line Tg(-1.7CaTuba1:GFP)mi2, which GFP in the hair cells (Gulati-
Leekha and Goldman, 2006). The transgenic embryos were exposed to 60 μg/l MeHg 
from 4 to 80 hpf and the number of hair cells in the transgenic lines was scored at 80 
hpf at which the embryonic pattern of PLL is completed (Gompel et al., 2001; Ledent, 
2002). Compared to the control, there is a significant decrease in the number of hair 
cells in embryos exposed to MeHg while no change in the location of the neuromasts 
was observed in MeHg-treated embryos (Fig. 3.10). 
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Fig. 3.10 Decreased number of neuromast hair cells in the lateral line in embryos exposed to MeHg. 
Lateral views of control (A, A’) and MeHg-treated (B, B’) Tg(-1.7CaTuba1:GFP)mi2 transgenic 
embryos at 80 hpf. GFP is expressed in the hair cells of the neuromasts. The 9 neuromasts in the trunk, 
posterior lateral line (PLL) 1 (the anterior-most) to PLL 9 (the posterior-most) are indicated by the 
arrows in (A). (A’, B’) Magnified images of neuromasts. (C) The number of hair cells in the 
neuromasts PLL 4 to PLL 6 was scored. The mean ± SEM are reported (control, n = 15; MeHg-treated, 
n = 16). The number of hair cells in MeHg-treated embryos is significantly lower than that of the 
control. T-test, p < 0.001 (*). Scale bar, A, B, 200 μm; A’, B’, 15 μm.  
 
3.3.2.2 Genes induced in the lateral line of MeHg-treated embryos 
In the toxicogenomic screen, changes in the expression levels of 12 genes were 
observed in the neuromasts of the MeHg-treated embryos. peroxiredoxin1 (prdx1), 
CXC chemokine 46-like (cxc46l), E74-like factor 3 (elf3), v-fos FBJ murine 
osteosarcoma viral oncogene homolog (fos), glutamate-cysteine ligase modifier 
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subunit (gclm), lysosomal-associated membrane glycoprotein 1-like (lamp1l), 
NADPH oxidase organizer 1 (noxo1), , sequestosome 1 (sqstm1), v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog f (avian) (maff) and 
thioredoxin-like (txnl) showed up-regulations in the lateral line while the expression 
of chromobox protein homolog 7-like (cbx7l) and glutathione peroxidase 1a (gpx1a) 
in the lateral line was down-regulated (Fig. 3.11). These genes showed mild to strong 
changes in the expressions in response to MeHg. From the magnified images of the 
neuromasts, it was noticed that these genes were ectopically expressed in different 
parts of the neuromasts (Fig. 3.11 inserts). However, further investigations are 
required to identify in which cell types these genes are expressed in the neuromast. 
The specific changes of these 12 genes in the neuromasts may suggest their 
correlation with the decrease in neuromast hair cell number in MeHg-exposed 
embryos. 
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(Fig. 3.11 continuted) 
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Fig. 3.11 Changes in the gene expression levels in the lateral line after MeHg exposure. 
Lateral views of control (A, B, C, D, E, F, G, H, I, J, K, L) and MeHg-exposed (A’, B’, C’, D’, E’, F’, 
G’, H’, I’, J’, K’, L’) 72-hpf-old embryos subjected to in situ hybridisation. The arrows in A and A’ 
indicate the neuromasts. The inserts are higher magnification of the posterior lateral line (A, A’ – I, I’, 
K, K’, L, L’) or anterior lateral line (J, J’) neuromast and the dotted lines outlines the neuromasts. 
Increased expressions of prdx1 (A, A’), cxc46l (C, C’), elf3 (D, D’), fos (E, E’), gclm (F, F’), lamp1l 
(H, H’), noxo1 (I, I’), sqstm1(J, J’), maff (K, K’) and txnl (L, L’) and decreased expression of cbx7l (B, 
B’) and gpx1a (G, G’) were detected in the lateral lines of embryos treated with MeHg. Scale bar, A, 
A’ – K, K’, 200 μm, inserts, 20 μm. 
 
3.3.3 No observable defects in the myofibril or motor neuron 
structures 
As MeHg-treated embryos exhibited a decrease in spontaneous swimming activity 
(Samson et al., 2001) and this promoted us to examine if any defect in the 
arrangement or the integrity of myofibers would be the cause of the problems. I 
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addressed this question by comparing the birefringence of embryos under polarised 
light (Behra et al., 2006; Fig. 3.12 A, B). Both control and MeHg-treated embryos 
showed similar brightness of the birefringence, indicating that there was no obvious 
different in the axial musculature. This result was confirmed by the slow muscle 
myosin staining using the anti-slow myosin F59 antibody (Crow and Stockdale, 1986) 
that the arrangement and integrity of the slow muscle myosins looked similar to those 
of the control ones.  
 
As defects in the axial musculature do not seem to be the cause of the impaired 
motility, I next asked if the motor neurons were properly formed. I examined 
populations of interneurons and sensory neurons, and the connections of the neurons 
to the neuromuscular junction by co-staining the embryos with anti-acetylated tubulin 
antibody (Behra et al., 2002; Piperno and Fuller, 1985), and with α-bungarotoxin, a 
toxin which specifically binds to nicotinic acetylcholine receptor (Downes and 
Granato, 2004; Panzer et al., 2005; Fig. 3.12 C-F). The co-staining revealed that there 
was no obvious difference in the interneuron and sensory neuron distribution or the 
connection between the neurons and the neuromuscular junctions. So, it is concluded 
that the decreased spontaneous swimming activity was neither due to structural 
defects in myofibers nor motor neuron distribution and connection. 
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Fig. 3.12 No observable change in myofibers structure or motor neuron distribution and connection in 
embryos exposed to MeHg. 
Lateral views of the trunks and tails of 72 hpf control (A, C, E) and MeHg-treated (B, D, F) embryos 
are shown. (A, B) Birefringence images. The inserts in A, B are the bright field images. (C, D) slow 
muscle myosin stained with the antibody F59. (E, F) Staining with antibody against acetylated-tubulin 
(green) and with α-bungarotoxin (red). Scale bar, A, B, 250 μm, C-F, 75 μm. 
 
3.3.4 Summary 
The effects of MeHg on the nervous system, including the brain, the lateral line and 
the neuromuscular junction connection, of zebrafish embryos were investigated in this 
study. Although no obvious changes in some of the marker genes of CNS or the 
neurotransmitter system examined were detected, through the toxicogenomic based 
approach, 24 genes which showed changes in the expression levels or patterns in the 
brain in response to MeHg exposure were identified. MeHg treatment also caused a 
decrease in the number of neuromast hair cells in the lateral line. The expressions of 
12 genes were shown to be regulated by MeHg in the lateral line. The changes in the 
connections of the neurons to the neuromuscular junction were also examined. No 
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defects in the motor neuron distribution or connection in the embryos after MeHg 
treatment were detected. 
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3.4 Study on the melanophore stripes and caudal fin 
fold in the tail in MeHg-exposed embryos 
In zebrafish, tail morphogenesis occurs rapidly and the tail can be well-recognised by 
the end of the first day of development (Dane and Tucker, 1985; Kimmel et al., 1995; 
Fig. 3.13). The tail bud becomes visible at 10.3 hpf and derives from a distinct 
swelling at the posterior end of the embryonic axis the so-called tail bud. Most of the 
cells of the tail bud will contribute progeny to the tail. Tail morphogenesis continues 
to occur and the tail bud becomes more prominent as the embryo develops. At 16.5 
hpf, the tail bud begins to protrude from the body of the embryo. As the tail extends, 
the overall body length of the embryo increases. At 24 hpf, the tail bud becomes very 
small. Cells flanking the sides of the tail bud become flattened and this leads to the 
formation of the caudal fin fold around the tail bud. At 30 hpf, fast tail morphogenesis 
has finished and the embryo begins to have a slower rate of body lengthening. 
Melanophores, which are melanin-containing cells and possess a dark brown or black 
colour, start to form three lengthwise stripes on the trunk and tail with one located 
dorsally, one ventrally and one laterally. At 36 hpf, arrays of extracellular matrix 
fibers called actinotrichia are present in the subepidermal space of the caudal fin fold. 
Melanophores in the dorsal stripe exist sparsely from the diencephalon region of the 
head to the tip of the tail, and those in the ventral strip locate dispersedly to about 
halfway to the tip of the tail. At 42 hpf, the caudal fin fold is prominent. The dorsal 
melanophore stripe becomes very well filled out and the ventral stripe now also 
contains melanophores up to the end of the tail. However, gaps exist in the ventral 
stripe at the tail region and one of these occurs at the posterior end where the caudal 
fin primordium locates (Hadzhiev et al., 2007; Iovine, 2007). At 72 hpf, the caudal fin 
fold is even more prominent and adopts a fan shape. Both the dorsal and ventral 
stripes become very well-defined and densely populated with melanophores. However, 
a small gap in the ventral stripe of the caudal fin primordium persists with absence of 
melanophores. 
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Fig. 3.13 Zebrafish tail development. 
Lateral views of the tail part of zebrafish at 19.5 hpf (A), 24 hpf (B), 42 hpf (C) and 72 hpf (D). (A) 
The primordium of the notochord (white arrowhead) and the spinal cord (black arrowhead), develop 
from the tail bud mesenchyme. The arrow indicates the pronephric duct. (B) At 24 hpf, the tail bud (tb) 
becomes very small and is surrounded by the caudal fin fold (cff). The notochord primordium (nt) and 
the spinal cord floor plate (fp) become more distinct. (C) At 42 hpf, the tail bud disappears. The spinal 
cord and notochord narrow to a blind-ended tube with a simple cuboidal lining. The caudal fin fold 
becomes more prominent and surrounds the entire structure. The melanophores (arrows) are 
differentiating. (D) At 72 hpf, the caudal fin fold shows a clear, thin and fan-shaped appearance. The 
melanophores have differentiated and migrated to form two well-defined stripes with one above and 
one below the tail at the boundary to the fin fold in the developing zebrafish embryo. The ventral stripe 
is characterised by a gap (arrow) in the row of pigment cells slightly anterior to the tip of the tail and 
this gap marks the caudal fin primordium. Scale bar, A-C, 50 μm; D, 125 μm. (A-C) Reproduced after 
Kimmel et al. (1995). 
 
3.4.1 Disruption of the melanophore stripes and caudal fin 
fold in embryos exposed to MeHg 
Disruption of trunk pigmentation with a smaller gap size of the melanophore stripe 
was observed in MeHg-exposed embryos. In order to examine if these malformations 
are specific to MeHg or can be induced by other heavy metals, I exposed embryos to 
sub-lethal concentrations of lead chloride (PbCl2), arsenic oxide (As2O3) and 
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cadmium chloride (CdCl2), which triggered related toxicogenomic responses (Yang et 
al., 2007). Interestingly, only embryos exposed to MeHg, but not other heavy metals 
examined, showed the malformations in the tail (Fig. 3.14). Thus, I concluded that the 
tail malformations are specific to MeHg. 
 
 
Fig. 3.14 MeHg-specific disruptions of the caudal fin fold tissue and the melanophore gap. 
Lateral views, anterior to the left and dorsal side up, of the posterior part of the tails of embryos at 72 
hpf. The dotted lines outline the outer region of the caudal fin folds and the arrows indicated the 
position of the melanophore gap. Embryos were exposed to MeHg (B), lead chloride (PbCl2) (C), 
arsenic oxide (As2O3) (D) and cadmium chloride (CdCl2) (E) or embryo culture only as control (A). 
Tail malformations of disruption of the caudal fin fold tissue and melanophore gap were only observed 
in embryos exposed to MeHg (B), but not to the 3 other heavy metals examined (C-E). Scale bar, 50 
μm. This figure is provided by L. Yang. 
 
3.4.2 Loss of GFP expression in the caudal fin primordium 
in the Tg(-2.4shha-ABC:GFP)sb15 transgenic line after 
MeHg treatment 
Strikingly, the phenotypes induced by MeHg exposure were very similar to those 
resulted from the loss of sonic hedgehog (shh) expression in zebrafish embryos, 
including the disruption of the melanophore gap (Hadzhiev et al., 2007). It has been 
shown that the caudal fin primordium, which is a region located at the posterior region 
of the developing fin bud and serves as a signaling center to instruct the developing 
fin bud to migrate and generate appropriate structures along the anterior-posterior axis, 
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is located at the melanophore gap (Hadzhiev et al., 2007; Iovine, 2007). GFP from the 
transgene Tg(-2.4shha-ABC:GFP)sb15 is specifically expressed in this primordium 
(Hadzhiev et al., 2007).  
 
I was tempted to speculate that MeHg affects the development of the caudal fin 
primordium through interacting with the shh signaling pathway. I wanted to know if 
exposure to MeHg would diminish the GFP expression in the caudal fin primordium. 
Transgenic embryos were exposed to 60 μg/l MeHg from 4 to 72 hpf. A high 
proportion of embryos (86%, n = 5, 20 embryos each) showed a complete loss of 
expression of GFP in the caudal fin primordium (Fig. 3.15). This correlated with loss 
or reduction of the gap in pigmentation. Transgene expression in the floor plate or in 
the pectoral fins was not affected by the MeHg treatment, indicating that MeHg 
specifically impaired GFP expression in the caudal fin primordium. 
 
 
Fig. 3.15 Induction of caudal fin fold defects and caudal fin primordium disruption in embryos exposed 
to MeHg. 
The lateral views of the pigment gap of control (A-A’’) or MeHg-treated embryos (B-B’’) at 72 hpf are 
shown. (A, B) Bright field images; (A’, B’) fluorescence images; (A”, B”) overlay images. The caudal 
fin primordium (outlined by dashed lines) is marked by GFP expression in the Tg(-2.4shha-
ABC:GFP)sb15 transgenic line in control embryos (A-A’’). The GFP expression in the primordium is 
reduced or absent in embryos exposed to MeHg (B-B’’, arrowheads). Abbreviations, nt, notochord; fp, 
floor plate. Scale bar, 50 μm.  
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3.4.3 Reduction of caudal fin GFP expression at MeHg 
concentration as low as 6 μg/l 
I wanted to know the lowest effective concentration at which MeHg could induce the 
loss of GFP expression in the caudal fin primordium. I exposed zebrafish embryos to 
MeHg concentrations of 6, 30 and 60 μg/l from 4 to 72 hpf. According to the degree 
of loss in the GFP domain, I classified the reduction into two categories, type I and 
type II. For the type I class, the GFP domain was reduced (Fig. 3.16) while for the 
type II class, no GFP expression could be observed at all. There was already a 
significant increase in the number of embryos with reduced GFP expression (type I 
plus type II) at 6 μg/l MeHg. The percentage of embryos showing the severer type II 
phenotype increased with the concentrations of MeHg. At 60 μg/l, almost all of the 
treated embryos fell into the type II class. 
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Fig. 3.16 Reduction or loss of GFP expression at the caudal fin primordium of MeHg-exposed 
embryos. 
Lateral views of the primordium of the caudal fin of 72 hpf embryos are shown. (A) Control; (B, C) 
MeHg-treated embryos. Depending on the degree of reduction or loss of GFP expression at the 
primordium, embryos were classified either as type I when they displayed a smaller GFP expression 
domain (B) in comparison to control (A) or as type II when the GFP expression was completely absent 
(C). (D) Graph showing the frequency of occurrence of type I (white bar) and type II (gray bar) or type 
I plus type II (black bar) reduction or loss of GFP expression at the caudal fin primordium. Embryos 
were exposed to 0, 6, 20, 30 and 60 μg/l MeHg. MeHg concentration of 6 μg/l could already lead to a 
significant increase in the number of embryos with reduced GFP expression. At 60 μg/l, almost all of 
the treated embryos fell into the type II reduction. Mean ± SEM are reported. N = 6, 20 embryos each. 
Type I: ANOVA, F = 94.51 and Dunnett, p < 0.01 (*); type II: ANOVA, F = 108.1 and Dunnett, p < 
0.01 (*); type + type II: ANOVA, F = 1601 and Dunnett, p < 0.01(*). 
 
3.4.4 Critical period of MeHg exposure lying between 12 hpf 
and 48 hpf 
In order to address the critical period of MeHg exposure, zebrafish embryos were 
exposed to 60 µg/l MeHg at different time windows for 6 or 12 hours during 
embryonic development from 4 to 72 hpf, and the occurrence of the phenotype was 
assessed at 6 dpf at which the melanophore stripe in the tail region is well-defined 
(Kelsh et al., 1996). No significant change in number of larvae having a smaller gap 
of the melanophore stripe in the tail was observed when treated before 12 hpf while 
significant increases were observed in all the time windows afterwards (Fig. 3.17). 
However, no obvious difference was noted among the time windows in between 12 to 
48 hpf. Comparison of the frequency distribution of pigmentation disruption also 
indicated that the longer the duration of exposure the more the embryos were affected 
as, in general, embryos exposed to MeHg for 12 hours resulted in higher frequency of 
occurrence of the phenotype than those for 6 hours. Hence, I concluded that the 
critical period of MeHg exposure started from 12 hpf and the longer the duration of 
exposure the stronger the phenotype. 
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Fig. 3.17 Disruption of melanophore gap in embryos exposed to MeHg for all the time windows within 
12 and 48 hpf. 
Embryos were treated with MeHg for 6- or 12-hour-periods between 4 and 72 hpf (n = 5, 20 embryos 
each). The percentage of occurrence of disrupted melanophore gap in the tail region of embryos 
exposed to different time windows of MeHg is presented. The mean ± SEM are reported. Significant 
differences were noted in all the time windows within 12 and 48 hpf, but not in those before 12 or after 
48 hpf. ANOVA, F = 30.11; Dunnett adjustment, p < 0.01 (*). 
 
3.4.5 Slight increase in the number of apoptotic cells in the 
caudal fin fold and no rescue of caudal fin fold 
abnormality by inhibition of apoptosis 
No information on the mode of action how MeHg causes this phenotype is available. 
As the size of the caudal fin fold of MeHg-treated embryos was smaller than that of 
the control, I speculated that MeHg-induced cell apoptosis might be the cause of the 
caudal fin fold abnormality. The ISH analysis indicated that there was a slight up-
regulation of tumor protein p53 (p53), which is one of the key mediators of apoptosis, 
in the caudal fin fold (Fig. 3.18 A, B). To verify any increase in apoptosis, MeHg 
embryos were stained with acridine orange (AO) which detects DNA denaturation 
(Fig. 3.18 C-C”, D-D”). There was a very slight increase in the number of AO-
positive cells in the tip of the caudal fin fold in MeHg-treated embryos. To confirm 
the result of AO staining, apoptosis was examined by determining activation of 
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Caspase-3 (Casp3), which is important for the initiation of apoptosis (Nicholson, 
1995, Nicholson, 1997). Similarly, the number of Casp3-activated cells increased 
slightly in the caudal fin fold of embryos exposed to MeHg (Fig. 3.18 E-E”, F-F”). 
 
 
Fig. 3.18 Slight increase in the number of apoptotic cells in the caudal fin fold. 
The caudal fin folds of 72-hpf-old control (A, C-C”, E-E”) and MeHg-treated (B, D-D”, F-F”) 
zebrafish embryos stained with in situ hybridisation using probe complementary to p53 (A, B), acridine 
orange (AO) (C-C”, C-C”) and immunohistochemistry using antibody against Casp3 (E-E”, F-F”) are 
shown. (A, B, C, D, E, F) Bright field images; (C’, D’, E’, F’) fluorescence images; (C”, D”, E”, F”) 
overlay images. (A, B) Moderate increase in the mRNA expression level of p53 (B, black arrow) was 
observed in the caudal fin fold of MeHg-treated embryos. Slight increases in the number of AO-
positive cells (D’ and D”, arrowheads) and Casp3-positve cells (F’ and F”, white arrows) were also 
detected in the caudal fin folds after exposure to MeHg. Scale bar, A, B, 140 μm , C-C’’ – F-F’’, 75 
μm. 
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Since a slight increase in apoptosis was observed in the MeHg-treated embryos, I 
examined if inhibition of apoptosis could rescue the caudal fin fold abnormality. 
Knockdown of p53 by microinjection of morpholino (MO) into zebrafish embryos 
was performed to inhibit apoptosis (Ekker et al., 2001; Robu et al., 2007). The p53 
morphants (morpholino treated organisms) were then treated with MeHg and the 
occurrence of caudal fin fold abnormality was assessed at 72 hpf. No rescue of the 
caudal fin fold abnormality by knockdown of p53 was observed in MeHg-treated 
embryos (Fig. 3.19).  
 
 
Fig. 3.19 No rescue of MeHg-induced caudal fin fold disruption in p53 morphants. 
Embryos were microinjected with p53 morpholino (MO-p53) and then exposed to 60 µg/l MeHg. 
Control groups with the replacement of MO-p53 with water were set up. No significant difference 
between the p53 knockdown group and the control group was detected. The mean ± SEM are reported 
(n = 9, 20 embryos each). 
 
I concluded here that MeHg treatment could induce moderate increase in the 
expression level of p53 and a slight increase in the number of apoptotic cells in the 
caudal fin fold while no rescue of the caudal fin fold abnormality was observed in 
embryos having inhibited p53-dependent apoptosis. 
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3.4.6 Involvement of mmp9 and mmp13a in the induction of 
caudal fin malformation in MeHg-treated embryos 
To unravel the underlying mechanism through which MeHg induces the caudal fin 
fold phenotype, I screened the MeHg-regulated genes to look for candidate genes 
which were ectopically expressed in the tail after MeHg exposure. matrix 
metalloproteinase 9 (mmp9) and matrix metalloproteinase 13a (mmp13a) seemed to 
be two of the good candidates since they were strongly and restrictedly expressed in 
the caudal fin fold of MeHg-treated embryos (Yang, 2007; Fig. 3.20 B, G), and they 
were able to degrade the components of the collagenous extracellular matrix (ECM), 
which is one of the major components of the caudal fin fold (Dane and Trucker, 
1985). 
 
Matrix metalloproteinases (Mmps) are a family of over twenty zinc-dependent 
endopeptidases. They play important roles in normal development and pathogenesis 
through the degradation of ECM components (Lemaître and D'Armiento, 2006; Page-
McCaw et al., 2007; Stamenkovic, 2003; Vu and Werb, 2000). mmp9, also known as 
gelatinase B, is responsible for degrading gelatins and collagen type IV, and mmp13a, 
also known as collagenase-3, is responsible for cleaving collagen type I, II and III 
(Chakraborti et al., 2003; Wyatt et al., 2009).  
 
3.4.6.1 Specific ectopic mmp9 and mmp13a expression in the caudal 
fin of embryos exposed to MeHg 
As I wanted to know if such the induction is specific to MeHg or is a more general 
response to heavy metals, ISH using mmp9 and mmp13a probes were performed on 
embryos exposed to Pb, As and Cd. Interestingly, although up-regulation of mmp13a 
was observed in scattered cells in the tail of embryos treated with Pb, As and Cd, no 
ectopic expression of mmp9 or mmp13a was induced in the caudal fin fold of these 
embryos (Fig. 3.20). 
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Fig. 3.20 Specific inductions of mmp9 and mmp13a in the caudal fins of embryos exposed to MeHg. 
Later views of the tip of the tail region of embryos at 72 hpf are showed. In situ hybridisation was 
performed using RNA probes against mmp9 (A-E) and mmp13a (F-J) on control (A, F), MeHg- (B, G), 
lead chloride (PbCl2)- (C, H), arsenic oxide (As2O3)- (D, I) and cadmium chloride (CdCl2)- (E, J) 
treated embryos. (B, G) Ectopic expressions of mmp9 and mmp13a were induced in the caudal fin fold 
in embryos exposed to MeHg (arrows). (C-D) No ectopic expression of mmp9 was induced in the 
caudal fin fold of embryos exposed to other heavy metals examined. (H-J) Although ectopic expression 
of mmp13a was detected in the tail of PbCl2, As2O3 and CdCl2 (arrow heads), no ectopic expression 
was observed in the caudal fin fold of these embryos. Scale bar, 50 μm. 
 
3.4.6.2 No ectopic expression of myeloid genes in the caudal fin fold 
of MeHg-treated embryos 
Both mmp9 and mmp13a have been reported to be expressed in various cell types 
including myeloid cells during embryonic development and wound healing in 
zebrafish (Qian et al., 2005; Yoong et al., 2007; Zhang et al., 2008). In order to 
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examine if the presence of mmp9- and mmp13a-expressing cells in the caudal fin fold 
in MeHg-treated was a result of an inflammatory response, I compared the expression 
patterns of the macrophage markers draculin (drl; NM_130977) and lymphocyte 
cytosolic plastin 1 (lcp1; NM_131320), and the neutrophil marker myeloid-specific 
peroxidase (mpx; NM_212779) (Bennett et al., 2001; Herbomel et al., 1999) with 
those of mmp9 and mmp13a. As shown by the result of ISH, no ectopic expression of 
any of these myeloid genes in the caudal fin fold was observed (Fig. 3.21), suggesting 
that the ectopic expression of mmp9 and mmp13a in the caudal fin fold was not 
because of an inflammatory response. 
 
 
Fig. 3.21 No ectopic expression of myeloid genes at the caudal fin fold of MeHg-treated embryos. 
Later views of the caudal fins of 72-hpf-old embryos are shown. In situ hybridisation was performed 
using probes complementary to drl (A, B), lcp1 (C, D) and mpx (E, F) on control (A, C, E) and MeHg-
treated (B, D, F) embryos. None of the myeloid genes examined showed an ectopic expression in the 
caudal fin fold (arrows). Scale bar, 75 μm. 
 
3.4.6.3 Increased Mmp activity in MeHg-treated embryos 
In order to examine if an increase in mmp9 and mmp13a transcript levels would result 
in an increase in Mmp9 and Mmp13a activity, in vitro Mmp activity assays, which 
 87 
have been shown to be an effective mean for determining Mmp activity (collagenase 
activity) quantitatively (Crawford and Pilgrim, 2005), were performed. Fluorescein-
conjugated collagen was used in the assay and would emit fluorescent signals upon 
degradation, serving indicators of collagenase activities. Protein lysates were 
extracted from control and MeHg-treated zebrafish embryos at 72 hpf and added to 
the fluorescein-conjugated collagen and incubated with the collagen substrate up to 3 
hours. The result of the assays showed that a much higher level of fluorescent signals 
was detected in the MeHg-treated samples than in the controls, indicating that the 
Mmp activity was highly increased in embryos treated with MeHg (Fig. 3.22).  
 
 
Fig. 3.22 Up-regulation of Mmp activity in embryos exposed to MeHg. 
The fluorescent intensities emitted from the mixtures of fluorescein-conjugated collagen together with 
the protein lysate of control or MeHg-treated embryos were measured. Significant increase in 
fluorescent signal and thus Mmp activity was detected in protein lysates of MeHg-treated embryos. The 
mean ± SEM are reported. T-test, p < 0.05 (*). 
 
3.4.6.4 Partial rescue of the MeHg-induced caudal fin phenotype by 
inhibition of Mmp activity 
The specific expression of mmp9 and mmp13a in the disrupted caudal fin fold in 
MeHg-treated embryos led to the speculation that mmp9 and mmp13a are responsible 
for the caudal fin fold abnormality. To examine the involvement of Mmp9 and 
Mmp13a in the disruption of the caudal fin fold tissue with a pharmacological 
approach. I co-treated embryos with MeHg and GM 6001, a general Mmp inhibitor, 
or MMP-9/MMP-13 Inhibitor II, a Mmp9 and Mmp13 specific inhibitor (Bai et al., 
2005; Yoshinari et al., 2009). Negative controls in which embryos were exposed to 
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MeHg and null controls in which embryos were incubated in embryo culture medium 
only were set up as well. At 72 hpf, the embryos were assessed for the phenotype. To 
quantify the measurement, images of the embryos were taken, and on each of the 
images, a vertical line was drawn through the tip of the notochord and the fin fold area 
posterior to the line was measured (Fig. 3.23 A-D). The result showed that inhibition 
of Mmp activitiy by GM 6001 and MMP-9/MMP-13 Inhibitor II could increase the 
fin fold area by 18 and 25%, respectively, relative to embryos treated with MeHg 
(Fig. 3.23 E). 
 
 
Fig. 3.23 Partial rescue of the MeHg-induced caudal fin phenotype by inhibition of Mmp activity. 
Lateral views of the tip of tails of control (A), MeHg-treated (B), MeHg- and GM 6001-co-treated (C), 
MeHg- and MMP-9/MMP-13 Inhibitor II-co-treated (D) embryos at 72 hpf. (E) Partial rescue of the 
MeHg-induced caudal fin phenotype by inhibition of Mmp activity was determined by quantitative 
measurement. The area of the caudal fin tip was quantified by drawing a vertical line through the tip of 
the notochord and counting the fin fold area posterior to the line. The presence of Mmp inhibitors 
increased the fin fold area by 18 and 25% relative to embryos treated with MeHg. The mean of the area 
of the fin fold from 86 to 92 measurements in four independent experiments and the SEM are 
presented. Bars marked with the letter ‘‘a’’ are not significantly different from each other. ANOVA, F 
= 150.9; Bonferroni, p < 0.05. Scale bar, 100 μm. 
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3.4.7 Induction of the gene expression in the caudal fin fold 
Besides mmp9 and mmp13a, some other genes were also shown to be up-regulated in 
the caudal fin fold region in this toxicogenomic screen and it included apolipoprotein 
eb (apoeb), core promoter element binding protein (copeb), CXC chemokine 46-like 
(cxc46l), homeodomain leucine zipper gene (homez), jun B proto-oncogene (junb), 
matrix metalloproteinase 14a (mmp14a), NADPH oxidase organizer 1 (noxo1), PR 
domain containing 1a, with ZNF domain (prdm1a), sequestosome 1 (sqstm1), 
serum/glucocorticoid regulated kinase 1 (sgk1), suppressor of cytokine signaling 3a 
(socs3a), sp9 transcription factor (sp9), thioredoxin-like (txnl), uncoupling protein 1 
(ucp1), zgc:56382, AI397362, AW115990 and BM101698 (Fig. 3.24). The ectopic 
expression of these genes in the fin fold region suggested that these genes may also 
contribute to the fin fold phenotype.  
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Fig. 3.24 Genes showing ectopic expression in the caudal fin fold after MeHg exposure. 
Lateral views of the posterior part of the tail of 72 hpf zebrafish embryos stained by In situ 
hybridisation are shown. Eighteen genes including apoeb (A, A’), copeb (B, B’), cxc46l (C, C’), homez 
(D, D’), junb (E, E’), mmp14a (F, F’), noxo1 (G, G’), prdm1a (H, H’), sqtm1 (I, I’), sgk1 (J, J’), socs3a 
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(K, K’), sp9 (L, L’), txnl (M, M’), ucp1 (N, N’), zgc:56382 (O, O’), AI397362 (P, P’) AW115990 (Q, 
Q’) and BM101698 (R, R’) were observed to be ectopically expressed in the caudal fin fold of zebrafish 
embryos treated with MeHg. Scale bar, 50 μm. 
 
3.4.8 Summary 
MeHg could induce the loss of the gap in the melanophore stripe, disruption of the 
caudal fin growth zone and destruction of the caudal fin fold. The disruption of the 
melanophore stripe by MeHg is restricted to a time window between 12 and 48 hpf. 
MeHg could induce the specific loss of the GFP expression in caudal fin growth zone 
in the transgenic line Tg(-2.4shha-ABC:GFP)sb15, and such a disruption could be 
induced in a significant number of embryos even in a MeHg concentration as low as 6 
μg/l. Although there was a slight increase in the number of apoptotic cells in the 
caudal fin region, no rescue of the caudal fin tissue destruction was observed when 
apoptosis was inhibited, excluding the possibility that apoptosis is the major cause of 
caudal fin fold tissue disruption. Twenty-two genes have been shown here to be 
expressed ectopically in the caudal fin fold of MeHg-treated embryos. Among these 
genes, mmp9 and mmp13a were further shown to be ectopically and specifically 
expressed in MeHg-exposed embryos. Pharmacological inhibition of mmp9 and 
mmp13a could rescue partially the caudal fin phenotype induced by MeHg, 
suggesting a role for these two ECM regulation genes in causing the caudal fin tissue 
disruption.  
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3.5 Study of complement component 7-1 (c7-1) 
3.5.1 Ectopic expression of c7-1 in the retina of MeHg-
treated embryos 
I further examineed the gene complement component 7-1 (c7-1, BC100054) due to its 
specific ectopic expression induced by MeHg. After MeHg exposure, c7-1 was found 
to be up-regulated in MeHg-exposed embryos by ISH. It was expressed ectopically in 
the retina, expecially the inner nuclear layer (INL), in 72-hpf-old zebrafish embryos 
after MeHg treatment (Fig. 3.25). 
 
 
Fig. 3.25 Ectopic expression of complement component 7-1 in the retina of MeHg-exposed embryos. 
Lateral views of the heads (A, B), dorsal views of the heads (A’, B’) and longitudinal sections of the 
eyes (A’’, B’’) of control (A-A’’) and MeHg-treated (B-B’’) embryos at 72 hpf are shown. The dashed 
lines in A’ and B’ indicate the position of the sections in A’’ and B’’, respectively. (B-B’’) Ectopic 
expression of complement component 7-1 (c7-1) was detected mostly in the inner nuclear layer of the 
retina of the embryos exposed to MeHg. Abbreviations, GCL, ganglion cell layer; INL, inner nuclear 
layer; l, lens; ONL, outer nuclear layer. Scale bar, A, A’, B, B’, 75 μm, A’’, B’’, 135 μm. 
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3.5.2 No ectopic expression of other membrane attack 
complex complement components genes in the retina 
after MeHg treatment 
C7 is a member of the complement system and it works together with other 
complement proteins to trigger the immune response (Kondos et al., 2010). Activation 
of the complement system will lead to the formation of C5b by proteolytic cleavage of 
C5, and C5b will initiate the sequential binding of C6, C7, C8 and multiple C9 
proteins, generating a trans-membrane structure called membrane attack complex 
(MAC). MAC will create a pore on the membrane of invading pathogens and 
abnormal cells, leading to subsequent lysis and death of the target cells. It can also 
lead to activation of various biological responses, such as secretion, adherence, 
aggregation, chemotaxis and cell division, at sub-lytic doses (reviewed in Morgan, 
1989).  
 
As C7 will cooperate with other complement components to form the MAC as an 
immune response, I wanted to know if expression of other genes that encode proteins 
which are involved in the initiation and formation of the MAC would also be induced 
in the retina after MeHg exposure. I wanted to examine this question by whole mount 
ISH. However, as the complement systems in zebrafish have not yet been well 
characterised, I performed a database search to obtain the information of other 
complement components for making RNA probes (Cates, 2006). From the database, I 
could identify all the zebrafish MAC forming genes, the MAC initiation gene and 
another c7 homologue in zebrafish, c7-2. Based on the database information, I 
designed primers for amplifying the genes for making RNA probes and performed 
whole-mount ISH for the genes c5-1 (BC139862), c6 (NM_200638), c7-2 
(XM_685854) c8a (NM_001003496), c8b (NM_001332783) and c8g (BC062865) 
and c9 (NM_001024435) (Fig. 3.26). However, none of the genes examined showed 
any ectopic expression in the retina of MeHg-treated embryos. 
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Fig. 3.26 No ectopic expression of other membrane attack complex complement components in the 
retina of embryos exposed to MeHg. 
In situ hybridisation was performed using antisense RNA probes complementary to other membrane 
attack complex complement components including c5-1 (A, B), c6 (C, D), c7-2 (E, F), c8a (G, H), c8b 
(I, J), c8g (K, L) and c9 (M, N). Dorsal views of the head regions of control (A, C, E, G, I, K, M) and 
MeHg-treated (B, D, F, H, J, L, N) embryos at 72 hpf are shown. (B, D, F, H, J, L, M) Ectopic 
expression of other complement components involved in the initiation or formation of MAC was not 
observed in the retina of embryos treated with MeHg. Scale bar, 75 μm. 
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3.5.3 Expression of c7-1 in scattered cells in the hindbrain, 
midline, trunk and tail during embryonic development 
In order to have a better understanding of zebrafish c7-1, a study of the expression 
pattern of c7-1 during development was performed by whole-mount ISH (Fig. 3.27). 
Results of ISH showed that c7-1 expression was detected in the yolk and yolk sac 
extension of the embryo at 24 hpf. At 48 hpf, the expression pattern became more 
restricted and it was expressed in discrete cells in the ventral hindbrain close to the 
midline. At 72 hpf, c7-expressing cells were detected in the hind- and midbrain in a 
rather symmetrical manner. The transcripts were also detected in two rows of cells in 
the trunk and tail with one immediately above the notochord and another one more 
dorsally located.  
 
 
Fig. 3.27 Expression patterns of c7-1 during development. 
Lateral views (A, B, C, E, G, H) and dorsal views (D, F) of embryos stained by in situ hybridisation 
with c7-1 probe. (C, D) Magnified images of the region boxed in (B). (A) 24 hpf; (B, C, D) 48 hpf; (E-
H) 72-hpf-old zebrafish embryos. (A) The expression of c7-1 could be detected at 24 hpf in the yolk 
and yolk sac extension (arrowhead). (B) The expression of c7-1 faded out in the yolk but became 
localised to the ventral hindbrain at 48 hpf. (C, D) The transcripts were noted in discrete cells that 
reside in the ventral hindbrain close to the midline (asterisk). (E, F) By 72 hpf, c7-expressing cells were 
detected in the hind- and mid-brain in a rather symmetrical manner. The transcripts were also detected 
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in two rows of cells in the trunk (G) and tail (H) with one immediately above the notochord (white 
arrows) and another one more dorsally located (black arrows). Abbreviations, h, head; hb, hindbrain; 
mb, midbrain; nt, notochord; t, trunk; tl, tail; ys, yolk sac; yse, yolk sac extension. Scale bar, A, B, 200 
μm, C-H, 80 μm. 
 
3.5.4 No ectopic expression of myelin marker genes in the 
retina after MeHg exposure 
Interestingly, the developmental expression pattern of c7-1 resembles those of genes 
which encode proteins forming the major structural components of myelin sheath, 
such as myelin basic protein (mbp), myelin protein zero (mpz), myelin associated 
glycoprotein (mag) and proteolipid protein 1b (plp1b) (Brösamle and Halpern, 2002; 
Lyons et al., 2005; Thisse et al., 2008). Myelin sheath is a layer of dielectric material 
wrapping around the axons of many neurons. It helps to increase the speed of electric 
impulses propagation along the myelinated fiber and is essential for proper 
functioning of the nervous system. In the CNS, axons are wrapped by the membrane 
of cells called oligodendrocytes to form myelin sheaths while in the peripheral 
nervous system (PNS), axons are myelinated by specialised glial cells called Schwann 
cells (Arroyo and Scherer, 2000). Disruption of myelin sheaths affects conduction and 
health of myelinated CNS and PNS axons, and has been reported to cause 
neurological disorders in human, including multiple sclerosis (MS) and Charcot-
Marie-Tooth diseases (CMT) (Bjartmar et al., 1999; Zhou and Griffin, 2003).  
 
The similar developmental expression patterns of these genes drove us to examine if 
the myelin proteins would also show an ectopic expression in the retina after MeHg 
exposure and try to get some clues whether the ectopic c7-1 expression of in the retina 
of MeHg-treated embryos is due to ectopic formation of myelin in the retina. I 
addressed this question by performing whole mount ISH using probes complementary 
to the two myelin marker genes, mpz (NM_194361) and plp1b (NM_001005586), on 
MeHg-exposed embryos. However, no such an ectopic expression in the retina was 
induced in any of the myelin marker genes examined (Fig. 3.28). 
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Fig. 3.28 No ectopic expression of mpz and plp1b in the eyes of embryos exposed to MeHg. 
Whole mount ISH was performed using antisense probes complementary to mpz (A, B) and plp1b (C, 
D). Dorsal views of the head regions of control (A, C) and MeHg-treated (B, D) embryos at 72 hpf are 
shown. (B, D) No ectopic expression of the two myelin genes was detected in the retina of MeHg-
treated embryos. Scale bar, 65 μm. 
 
3.5.5 Functional study of c7-1 
Both in vitro and in vivo data indicated that the C5b-C9 complex could have dual role 
on causing neuroinflammation and neuroprotection (Morgan et al., 1997; Rus et al., 
2005, 2006; van Beek et al., 2003). On one hand, it can induce demyelination, a 
process of destructive removal of the myelin sheaths from neurons, and complement 
is believed to cause multiple sclerosis (MS), an autoimmune nervous system disease 
in which the myelin producing oligodendrocytes are damaged due to abnormal 
immune response of the body as deposition of complement was found in MS lesions 
(Storch et al., 1998; Compston et al., 1989). However, genome screens in MS 
indicated that there is no evidence for the association of C7 with MS (Chataway et al., 
1999). On the other hand, the C5b-C9 complex has also been shown to help axon 
preservation or repair, limitation of glial scarring, remyelination, and protection from 
cell death within the CNS (Cudrici et al., 2006; Tegla et al., 2009). In human, 
Complement C7 deficiency (C7D) is frequently associated with the life-threatening 
meningococcal disease caused by the bacterium Neisseria meningitides infection 
(Barroso et al., 2010; Kang et al., 2006; O’Hara et al., 1998; Rameix-Welti et al., 
2007).  
 
Due to the specific induction of c7-1 by MeHg exposure, I wanted to know what the 
function of c7-1 is during development and under MeHg exposure, and why only c7-
1, but not other complement components, is ectopically expressed in the retina of 
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MeHg-exposed embryos. I tried to gain some insights in answering these questions by 
knocking down c7-1 in zebrafish embryos with a splice blocking MO, which blocks 
mRNA processing and thus the gene function by disrupting pre-mRNA splicing 
(Draper et al., 2001). 
 
To verify the effectiveness of MO-c7-1, mRNA was extracted form the c7-1 
morphants and PCR using primers targeting the exons flanking the splicing site was 
performed. MO-c7-1 was predicted to cause a deletion of the proximal exon (Morcos, 
2007) and would result in the formation of a shorter mRNA. A PCR fragment with 
smaller size was observed in the MO-c7-1 but not in MO-control samples, indicating 
that the MO-c7-1 can block the splicing of the gene effectively (Fig. 3.29). 
 
 
Fig. 3.29 Effective blocking of c7-1 by morpholino MO-c7-1. 
Gene rule DNA ladder mix (lane 1) was used as a marker to indicate the size of the PCR fragments. 
PCR fragments from MO-control (lane 2) and MO-c7-1 (lane 3) samples. A smaller DNA fragment 
was observed in the MO-c7-1 sample compared to the MO-control, indicating the c7-1 splicing defects.  
 
To examine if c7-1 performs any function during development, MO-c7-1 and MO-
control were microinjected into zebrafish embryos at zero- to two-cell stages and any 
malformation in the embryos were monitored during development. However, no 
observable difference was noticed in the c7-1 morphants and control embryos (Fig. 
3.30 A, B). I speculated that c7-1 would show its function only under MeHg 
exposure. Thus, I subjected the MO-injected embryos to MeHg treatment. Again, the 
c7-1 morphants and control embryos did not show any obvious morphological 
difference (Fig. 3.30 C, D).  
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Fig. 3.30 No observable morphological difference in c7-1 morphants. 
Lateral views of zebrafish embryos at 4 dpf (A, B) and 72 hpf (C, D). (A, C) Injection control embryos; 
(B, D) c7-1 morphants. (A, B) Control embryos exposed to embryos control medium (medium without 
MeHg); (C, D) embryos exposed to 60 μg/l MeHg. No obvious difference was observed in c7-1 
morphants (B, D) compared to injection control embryos (A, C) no matter the embryos were exposed to 
control medium (A, B) or to MeHg (C, D). Scale bar, 200 μm. 
 
3.5.6 Summary 
Specific induction of c7-1 expression in the zebrafish retina was observed after MeHg 
treatment. Although c7-1 is well-known to cooperate with several other complement 
components to form the MAC, such an ectopic induction in the retina was not 
observed in other MAC-forming complement components. The expression patterns of 
c7-1 which are very similar to those of myelin genes during development, while no 
ectopic expression of any of the myelin genes examined were observed in MeHg-
treated embryos. The type(s) of cells expressing c7-1 and the function of c7-1 in 
zebrafish embryos have yet to be determined. 
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4 Discussion 
4.1 Malformations in fish caused by MeHg exposure 
In consistence with the study performed by Samson and Shenker (2000), caudal fin 
fold abnormality and posterior tail flexures were observed in embryos exposed to 
MeHg. Very interestingly, I also observed the disruption of the melanophore gap, 
which marks the tail growth zone, by MeHg. This malformation has not been reported 
in any of the pervious studies. Besides the tail fin malformation, I also observed 
pericardial edema, smaller head and eye, stunted body and trunk flexure in the 
embryos treated with MeHg. Comparable malformations were observed in other 
MeHg-exposed fish embryos. Fathead minnow embryos with acute exposure to 20, 
40, 80, 160, 320 μg/l MeHg showed flexures of the embryonic axis, pericardiac 
edema, irregularly-shaped heart tube, irregular heartbeat, shortened and disorganised 
tissue of the medial fin fold, smaller lower jaw or smaller eyes and stunted body 
(Devlin, 2006). Those embryos also exhibited abnormal behaviours with decreased 
swimming activity and erratic and twitching movements. Medaka embryos exposed to 
15 μg/l Hg showed hemorrhaging, blood vessel deterioration, and loss of circulating 
blood cells and a decreased hatching rate (Heisinger and Green, 1975). Mummichog 
embryos exposed to 30 to 40 μg/l MeHg exhibited cardiovascular, skeletal and 
hatching defects (Weis and Weis, 1997; 1982). Cyclopia or intermediate conditions 
leading to cyclopia were also observed in the MeHg-exposed mummichog embryos. 
However, the occurrence of cyclopia was not observed in other fish species in 
response to MeHg. 
 
4.2 Toxicogenomic screen of MeHg-responsive genes 
The interactions with sulfhydryl groups, the induction of oxidative stress and the 
disruption of calcium ion homeostasis are believed to be the three major and critical 
mechanisms of MeHg toxicity. MeHg exposure will result in various cellular changes 
such as lipid peroxidation, DNA damage, membrane structure alternation, 
mitochondrial dysfunction, cell cycle alternation, apoptosis and necrosis.  
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In recent years, a few studies have been conducted to investigate the global genomic 
effects of acute or sub-acute MeHg or Hg exposure on individual organs of adult fish. 
Klaper et al. (2008) examined the gene expression changes in the liver and gonad of 
fathead minnow in response to MeHg exposure. Adult fathead minnows received a 
single intraperitoneal injection of MeHg of 2.0 μg/g body mass and after 96 hours, the 
minnows were scarified for a 15 k-gene microarray analysis. A total of 650 genes in 
the liver and 212 genes in the gonad were differentially regulated (p > 0.05 and M > 1 
or < -1). The dysregulated genes were associated with protein folding, protein 
transport, fatty acid biosynthesis, tRNA processing, immune function, antigen 
presentation and apoptosis in the liver, and the GO categories of transcription from 
RNA polymerase II, rhythmic process, sterol biosynthesis, antigen presentation, 
amino acid metabolism and steroid biosynthesis in the gonad. Cambier et al. (2010) 
performed a serial analysis of gene expression (SAGE) on the skeletal muscle of adult 
male zebrafish fed with MeHg contaminated food (13.5 μg of Hg/g (dry weight)) for 
25 days. They identified 60 up-regulated genes and 15 down-regulated genes ( p < 
0.05 and M > 1 or < -1) and observed the differential regulation of genes in the 
glycolysis pathways, oxidative pathways and mitochondria metabolism, 
detoxification, lipid metabolism, cell-cycle regulation, protein synthesis, structural 
compounds, muscle contraction, calcium ion homeostasis, reticulum endoplasmic 
apparatus, general metabolism, iron metabolism and transduction cascade. Ung et al. 
(2010) studied the Hg-induced effects in the liver of zebrafish using microarray 
spotted with 16,416 zebrafish oligo probes. Adult zebrafish were exposed to 200 μg/l 
HgCl2 for 8, 24, 48 and 96 hours. Transcriptome analysis indicated that around 350 
genes at 8 hours, 1000 genes at 24 hours, 1050 genes at 48 hours and 1650 genes were 
significantly regulated (p < 0.05) in response to HgCl2 exposure. A sequential 
enrichments of GO categories of electron transport chain, mitochondrial fatty acid 
beta-oxidation, nuclear receptor signaling and apoptotic pathway, followed by 
complement system and proteasome pathway, and thereafter DNA damage, hypoxia, 
Wnt signaling, fatty acid synthesis, gluconeogenesis, cell cycle and motility were 
observed. Richter et al. (2011) investigated the gene expression changes in the 
zebrafish brain in response to MeHg exposure. Adult female zebrafish were 
intraperitoneally injected with 0.5μg/g MeHg and investigation was performed with 
22K-probe microarray after 96 hours of exposure. Seventy-nine genes were up-
regulated and 76 genes were down-regulated significantly in the MeHg-treated 
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samples (p < 0.01). Functional and pathway analysis indicated that MeHg exposure 
led to the deregulation of genes in steroid biosynthetic process, nucleotide binging, 
ATPase activity, cell differentiation, cell redox homeostasis, unfolded protein binding 
response to heat, serine esterase activity, ATP synthase activity, hydrolase activity 
and protein folding. 
 
In this study, I provided a global transcriptome view of MeHg-induced acute toxicity 
in zebrafish embryo. The result of the microarray analysis was in consistent with a 
pervious toxicogenomic study performed by our group (Yang et al., 2007). The 
finding here of having differentially expressed genes associated with oxidative stress, 
immune defence, DNA damage, apoptosis and cell death, and fatty acid peroxidation 
in response to MeHg exposure is in agreement with the current understanding on how 
MeHg induced its toxicity and with pervious genome-wise, acute MeHg or Hg 
exposure studies in fish. However, I could observe that quite a number of enriched 
GO categories and pathways were not consistent across studies. For examples, GO 
categories such as extracellular matrix organisation, blood circulation, response to 
hormone stimulus and MAP kinase phosphatase activity were detected in this study, 
but were not reported in the pervious studies; while GO categories such as electron 
transport chain, glycolysis/ gluconeogenesis and hypoxia induced pathway, which 
were enriched in the previous studies, were absent from this study. The discrepancies 
among studies could be attributed to the fact that this study determined the overall 
gene changes in whole embryo in response to MeHg, instead of the response in 
individual organs in the previous studies. Besides, pervious studies were carried out 
on adult fish while ours was on embryos. The concentrations of MeHg or Hg for 
exposure and different analytical methods and parameters used in the studies might 
also contribute to the differences. 
 
I further investigating the change in the expression pattern of 88 MeHg-responsive 
genes by ISH. These genes are involved in various biological processes and molecular 
functions including regulation of transcription, antioxidant defence, immune response, 
enzymatic activity and transmembrane transport. Ectopic expressions of the genes 
were noted in various organs including the brain, eyes, olfactory bulb, branchial 
arches, heart, liver, intestine or gut, pronephos, somites, lateral lines, pectoral fins, 
caudal fin fold, blood vessels, dermal epithelium, and YSL. This study showed a 68% 
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positive correlation between ISH and microarray analyses. The consistent results of 
microarray analyses and ISH reinforced that toxicogenomics is a useful tool for 
examining the responses of an organism in the molecular level towards changes of the 
environment.  
 
Besides the brain, lateral line and caudal fin fold, ectopic expression of genes also 
frequently observed in the eye, liver, blood vessels, pectoral fin and dermal epithelium 
and, this, probably, suggested that these structures are also sites of MeHg action. A 
study concerning the visual system in adult zebrafish showed that MeHg could pass 
through the blood-retina barrier and accumulated in various regions of the retina, 
especially in the photoreceptor layer and in the inner and outer nuclear layer (Mela et 
al., 2010). Another study performed in larval axolotls showed that mercury exposure 
caused impaired rod photoreceptor morphology (Tessier-Lavigne et al., 1985). Thus, 
it is likely that there was high level of MeHg accumulation in the retina of embryos 
exposed to MeHg, causing damage to the retinal cells and triggering changes in the 
expression of corresponding genes in the retina.  
 
MeHg has been demonstrated to be hepatotoxic in adult zebrafish, rat and 
mummichog (Lin et al., 1996; Ung et al., 2010; Weis et al., 1986). I speculate that 
hepatotoxicity also occurred in MeHg-exposed zebrafish embryos and the change in 
gene expressions in the liver was a response to hepatotoxicity. The increase in 
expression of antioxidant genes in the liver in MeHg-treated zebrafish embryos, such 
as prx1, gclm and uricase, indicated that the liver was under oxidative stress and this 
could be a cause of hepatocellular damage (Jaeschke et al., 2002; Liu et al., 2008). 
However, histological examination will be required to examine if there is any 
hepatoxic effects of MeHg on the embryos. On the other hand, the increased 
expression of some of the genes in the liver could also be due to the activation of 
innate immunity of the whole embryo for protecting the organism against the toxicity 
of MeHg as liver is an organ with predominant innate immunity (Gao et al., 2008; 
Racanelli and Rehermann, 2006). For example, c3a, c4-2 and cfb, which were shown 
to be up-regulated in the liver in this study, are complement components and 
complement regulator proteins that are biosynthesised in the liver (Gao et al., 2008).  
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I observed the induction of 12 genes which are known for regulating blood circulation 
from the microarray analysis. I also detected increased expressions some of the genes 
in the blood vessels in embryos treated with MeHg. Fish embryos exposed to MeHg 
exhibited a variety of cardiovascular defects (Devlin, 2006; Heisinger and Gree, 1975, 
Weis and Weis, 1977). It was shown in a cell culture study that MeHg could cause 
oxidative-induced vascular endothelial dysfunction with increased permeability, 
depletion of glutathione and ATP, and inhibition of the activity of key thiol enzymes 
(Wolf and Baynes, 2007). I speculate that there was impaired blood vessel endothelial 
functions in MeHg-treated zebrafish embryos and the presence of pericardial edema in 
the MeHg-treated zebrafish embryos might possibly link to any endothelial 
dysfunction of the blood vessels. However, further studies on the vasculature are 
required to determine if there is any defect in the vasculature and the cause of 
pericardial edema in MeHg-treated embryos.  
 
It is interesting to notice that there were genes expressed in both the pectoral and 
caudal fins (apoeb, cxc46l, homez, junb, mmp9, mmp13a, noxo1, prdm1a, sqstm1, 
sgk1, txnl, zgc:56382, AW115990 and BM101698), while there were also some 
expressed either in the pectoral fin (c6, gclm, rrad, slc16a9a and BI474700) or in the 
caudal fin (copeb, mmp14a, sp9, p53, ucp1 and AI397362). The differences in the 
expression in these two structures might suggest that MeHg could induce some 
common mechanisms in both types of fins, but certain degree of divergence exists in 
these two structures in response to MeHg.  
 
I further quantified the expression levels of 12 genes, which showed obvious changes 
in the expression level, in embryos exposed to 30 and 60 μg/l MeHg by real-time PCR. 
Eleven out of 12 was shown to be significantly regulated at 60 μg/l MeHg. The 
expression levels of 6 genes including arfl, c4-2, c6, cbx7l, prdx1, txnl and 
zgc:101661 were significantly regulated even at 30 μg/l MeHg. The sensitivity of the 
change in the expression levels of these genes in response to MeHg suggested that 
they can serve as useful in vivo biosensors of waterborne MeHg.  
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4.3 The effects of MeHg on the nervous system of 
zebrafish embryos 
In this study, although there were no obvious changes in expression patterns of the 
brain and neurotransmitter markers examined, I could detect changes of 24 other 
genes in the brain of zebrafish embryos exposed to MeHg. The genes detected in this 
study cover a wide range of biological processes including transcription regulation 
(six3, atf3, homez, fos, agt, cbx7, cebpg and irf9), response to oxidative stress (gclm, 
fos and prdx1), apoptosis (agt and gclm), immune response (cebpg and prdx1), protein 
dimerisation activity (atf3, gclm, fos and cebpg), cytokine production (cebpg and irf9) 
and blood vessel regulation (agt and gclm). The changes in the expression patterns of 
genes in the brain might suggest the induction of the behavioural changes reported by 
Samson et al. (2001) after MeHg treatment. Besides, it has been reported that the 
activity, but not the gene expression level, of acetylcholinesterase was altered in the 
zebrafish adult brain after exposure to heavy metals, including Hg (Richetti et al., 
2010). It will be interesting to examine if there are any alternation in the 
neurotransmitter activities in zebrafish embryos after MeHg exposure, even though I 
could not observe any manifest change in the expression patterns of the 
neurotransmitters. 
 
In a pervious study carried out by Gonzalez et al. (2005), the effect of sub-chronic and 
chronic exposure to MeHg exposure on the brain of adult zebrafish was determined by 
dietary exposure of adult zebrafish to 5 and 13.5 μg/g MeHg for 7, 21 and 63 days. 
The changes in the expression levels of 13 genes known to be involved in anti-
oxidative defenses, apoptosis, metal chelation, active efflux of organic compounds, 
mitochondrial metabolism were determined by real-time PCR. Although there were 
changes in the expression levels of some of the genes examined in the muscle and 
liver after MeHg exposure, no such changes were observed in the brain. In another 
study performed by Richter et al. (2011), the acute effect of MeHg exposure on adult 
zebrafish brain was investigated by intraperitoneal injection of 0.5 μg/g MeHg into 
female zebrafish and after 96 hours, the fish were scarified for the examination of the 
in the gene expression levels by a 22K-probe microarray. Seventy-nine genes were 
shown to be up-regulated and 76 genes were down-regulated (p>0.01) in response to 
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MeHg. In contrast to the study performed by Gonzalez et al., they showed the 
regulations of anti-oxidative defenses and apoptosis genes in the brain after MeHg 
exposure. Consistent with Richter et al., this study also showed the regulation of 
genes involved in oxidative stress and apoptosis. The differences between this and 
Richter et al.’s studies and Gonzalez et al.’s study may be attributed to the duration of 
exposure. Gonzalez et al. focused on the response of sub-chronic and chronic MeHg 
exposure while this and Richter et al.’s studies were on acute exposures. It has been 
reported that different pathways will be triggered at different time points in response 
to MeHg exposure (Klaper et al., 2008; Ung et al., 2010; Yang et al., 2007). Besides, 
the coverage of genes studied by Gonzalez et al. and the concentrations of MeHg used 
in the studies might also contribute to the differences.  
 
As the neuromasts of the lateral line are in direct contact with the environment and it 
has been reported that waterborne contaminants could lead to disruption of the 
neuromasts and death of hair cells. I also observed a decrease in the number of hair 
cells in embryos exposed to 60μg/l MeHg while there was no change in the location 
of the neuromasts in MeHg-treated embryos. Through the toxicogenomic screening, I 
identified 12 genes showing ectopic expression or decrease in expression in the lateral 
line of MeHg-treated embryos. These genes were expressed in different parts of the 
neuromasts and this may suggest their different functions in the neuromasts in 
response to MeHg. These genes may be involved in induction of hair cell or 
neuromast death, removal of dead cells, recovery or renewal of damaged lateral line, 
or protecting the lateral line from oxidative or other cellular stresses. It has been 
shown in other biological systems that the transcription factors fos and maff could 
activate oxidative stress genes through the regulation of the antioxidant response 
element (ARE) promoter (Itoh et al., 1997; Jasiwal, 2004; Motohashi et al., 1997). 
gclm, prdx1 and txnl are genes of the glutathione and thioredoxin systems which are 
known to be implicated in antioxidative defence (Aracena et al., 2006; Collet and 
Messens, 2010; Jones and Go, 2010; Neumann e al., 2009). However, surprisingly, I 
also detected a decrease in the expression of another antioxidant gene gpx4, which can 
reduce hydrogen peroxide and phospholipid hydroperoxides to suppress lipid and 
other forms of peroxidation (Imai and Nakagawa, 2003; Savaskan et al., 2007), in the 
lateral line. To remove dead cells for repairing, inflammatory cells are recruited to the 
site of injury by damage signals released form the site of inflammatory (Martin and 
 107 
Leibovich, 2005; Redd et al., 2004). Given that cxc46l is a member of the cxc 
chemokine family which functions as a chemoattractant and is one of the mediators of 
the inflammatory response (Zaja-Milatovic and Richmond, 2008), I speculated that 
cxc46l could recruit immune cells to the site of inflammation and remove dead hair 
cells from the neuromasts. Pervious studies on zebrafish hair cell regeneration 
suggested that support cells and hair cell progenitors may serve as the source of newly 
differentiated hair cells during regeneration of neuromast hair cells (Ghysen and 
Dambly-Chaudière, 2004; Hernandez et al., 2007; Ma et al., 2008; Wibowo et al., 
2011). MeHg-regulated genes expressed in the support cells or hair cell progenitors 
the may play a role in the hair cell regeneration. However, studies will be required to 
investigate which neuromast cell types express the MeHg-regulated genes. 
 
4.4 The effects of MeHg on trunk pigmentation  
Besides the tail phenotypes described by Samson and Shenker (2000), disruption of 
trunk pigmentation in the tail was also frequently and consistently detected in the 
MeHg-treated embryos. The effective time window of MeHg exposure for the 
disruption of the size of melanophore gap was restricted to 12 hpf and 48 hpf with the 
malformation rate increased with increasing duration of exposure. This effect 
appeared to be specific to MeHg, at least among the chemicals examined in this study. 
 
Melanophores are derived from a population of trunk neural crest (TNC) cells. In 
zebrafish, TNC cells begin to migrate from the neural keel at around 15 hpf along 
stereotyped pathways to give rise to a diverse and well-defined set of cells types 
(Schilling and Kimmel, 1994; Vaglia and Hall, 2000). Under normal embryonic 
development, pigment cells flank both sides of the tail primordium and are absent 
from the tail primordium. I speculate that the change in melanophore gap size is due 
to the disruption of TNC migration to the region of the tail primordium and that 
genetic cues are generated from the tail primordium that keep the pigment cells away 
from this region. Disruption of the tail primordium takes the cues away and thus 
allows the intrusion of the pigment cells into the position where the fin primordium 
should normally be located. The observation that exposure to MeHg between 12 to 48 
hpf disrupted the melanophore localisation is in agreement with this speculation. 
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However, I did not find impairment of neural crest differentiation and migration as 
inferred from the patterns of crestin expression in 24-hpf-old MeHg-treated embryos. 
 
Various genes have been reported to be involved in the regulation of caudal fin 
development and shh is believed to be one of them (Hadzhiev et al., 2007; Iovine, 
2007). Shh is a key player of many fundamental processes in embryonic development 
including growth, patterning and morphogenesis through acting as a morphogen, 
which induces neighbouring cells to adopt distinct cell fates in a dose-dependent 
manner, as a mitogen, which regulates cell proliferation, or as an inducing factor, 
which controls the shape of a developing organ (Ingham and McMahon, 2001). 
Disruption of shh signalling genetically or chemically could affect the development of 
the caudal fin primordium and the tail fin in zebrafish embryos (Hadzhiev et al., 
2007). Interestingly, the phenotypes induced by MeHg were very similar to those 
resulted from the loss of shh expression in zebrafish embryos. Although a decrease in 
GFP expression in the caudal fin primordium of Tg(-2.4shha-ABC:GFP)sb15 
transgenic line was noted, it is rather not likely that MeHg affect the development of 
the caudal fin primordium through interacting with the shh signalling pathway since 
the time window that MeHg exerted its effects on tail fin development was restricted 
between 12 and 48 hpf while shh signaling seemed to be continuously required even 
at stages after 48 hpf (Hadzhiev et al., 2007). Besides, other Shh-regulated 
developmental processes, such as somite development and motor neuron induction 
(Barresi et al., 2000; Lewis and Eisen, 2001; Schauerte et al., 1998), were not affected 
by MeHg exposure. 
 
4.5 Study on the effects of MeHg on the caudal fin 
fold 
It was shown here that there was a mild increase in the expression of the apoptosis-
induced gene p53 and a slight increase in the number of apoptotic cells in the caudal 
fin fold. However, inhibition of p53-mediated apoptosis by knockdown of p53 could 
not rescue the caudal fin fold phenotype. Taken together, I concluded that MeHg 
treatment caused a slight induction of apoptosis in the caudal fin fold, but it did not 
seem to be a major cause of the caudal fin fold abnormality. 
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Besides p53, I identified 19 other genes which showed ectopic expression pattern in 
the caudal fin fold after MeHg treatment. These genes may play a role in the 
toxicological mechanism in inducing the caudal fin fold tissue disruption or may 
involve in the repair of the fin fold damage as some of these MeHg-regulated genes 
have also been shown to be implicated in fin regeneration (Yoshinari et al., 2009). I 
further examined the role which mmp9 and mmp13a play in the caudal fin tissue 
phenotype due to their strong and restricted expressions in the caudal fin fold in 
MeHg-treated embryos and their ability to degrade the collagenous ECM which is one 
of the structural components of the caudal fin fold.  
 
I first tested the specificity of the induction of mmp9 and mmp13a. Interestingly, 
although up-regulation of mmp13a was observed in scattered cells in embryos 
exposed with Pb, As and Cd, no ectopic expression of mmp9 or mmp13a was induced 
in the caudal fin fold of these chemical-treated embryos which did not show any 
caudal fin defects. Besides the increased in transcript levels, I also showed that there 
was an increase in the collagenase activity.  
 
Both mmp9 and mmp13a have been reported to be expressed in various cell types, 
including myeloid cells. I also investigated if the ectopic expression of mmp9 and 
mmp13a in the caudal fin fold was due to an inflammatory response by comparing the 
expression patterns of the macrophage and neutrophil markers with those of mmp9 
and mmp13a. However, I did not detect any up-regulation of these myeloid cell 
markers, suggesting that the mmp9 and mmp13a expression are not the reflection of 
an inflammatory response.  
 
Functional study on mmp9 and mmp13a was performed to investigate their roles in 
caudal fin fold development. I adopted a pharmacological approach in which I co-
treated embryos with a general Mmp inhibitor or a Mmp9 and Mmp13 specific 
inhibitor together with MeHg. The result showed that co-treatment with the general 
Mmp inhibitor could increase the fin fold area by 18% and application of Mmp9 and 
Mmp13 specific inhibitor could even increase the fin fold area by 25%. However, it 
was also noted that the inhibition of Mmp activity by this approach could not rescue 
the phenotype fully. This may be due to the incomplete inhibition of Mmp9 and 
 110 
Mmp13 activities in this study. It was also possible that other genes were also 
involved in causing the phenotype. As mentioned earlier in the discussion, we could 
observe the induction of ectopic expression of genes other than mmp9 and mmp13a in 
the caudal fin fold of MeHg-treated embryos.  
 
4.6 Ectopic expression of c7-1 in the eye after MeHg 
exposure 
In this study, c7-1 was shown to be ectopically and specifically expressed in the 
retina, especially the INL, after MeHg exposure. c7-1 is known to cooperate with 
several other complement components to form MAC involved in the lytic pathway of 
the complement system as a mean of immune defence. However, the result of this 
study showed that such an ectopic expression in the retina was unique to c7-1 and was 
not induced in other MAC-forming complement components. 
 
I also showed that during embryonic development c7-1 was specifically expressed in 
the ventral hindbrain, close to the midline, and then spread rostrally to the midbrain 
and caudally to the region dorsal to the notochord. The localisation of c7-1 transcripts 
was very similar to genes expressed in the myelin sheath during embryonic 
development. The similar developmental expression patterns of these genes drove us 
to examine if the myelin proteins would also show an ectopic expression in the retina 
after MeHg exposure in order to get some clues whether the ectopic c7-1 expression 
of in the retina of MeHg-treated embryos is due to ectopic formation of myelin in the 
retina. I examined the expression of the myelin marker genes in MeHg-treated 
embryos. No ectopic expression in the retina was induced in any of the myelin marker 
genes examined, indicating that the ectopic c7-expressing cells were not because of 
the ectopic myelin formation in the retina after MeHg exposure. 
 
The functions of the MAC in neuron survival are controversial as the complex has 
been shown to cause both neuroinflammation and neuroprotection. In human, 
Complement C7 deficiency (C7D) is frequently associated with the life-threatening 
meningococcal infection. Due to the specific induction of c7-1 by MeHg exposure, I 
wanted to know what the functions of c7-1 are during development and under MeHg 
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exposure, why only c7-1, but not other complement components, is ectopically 
expressed in the retina of MeHg-exposed embryos and what role does it play, and the 
effects on zebrafish embryos when c7-1 does not function. I tried to gain some 
insights in answering these questions by knocking down c7-1 in zebrafish embryos 
with splice-blocking MO. However, I could not observe differences in the c7-1 
morphants compared to the control during normal embryonic development or 
embryos subjected to MeHg. The lack of function may be due to the presence of gene 
duplication as through the database search, I found the existence of another c7 
homologue c7-2 in zebrafish, despite that c7-2 showed different expression pattern 
from c7-1. 
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5 Conclusion 
 
A global view of gene expression changes in zebrafish embryos in response to acute 
MeHg exposure was generated in this study. Through the toxicogenomic screen, 
genes showing alternations in response to MeHg in the brain were identified. In 
addition, genes which showed specific expression in the neuromasts in the MeHg-
treated embryos were reported and these genes could play a role in the impairment of 
neuromast in the presence of MeHg.  
 
The present study showed that sub-lethal concentration of MeHg induced caudal fin 
fold tissue abnormality, disruption of trunk pigmentation strip gap and reduced hair 
cell number in the neuromast of the lateral line. MeHg induced fin fold tissue 
abnormality and disruption of trunk pigmentation strip gap specifically among all the 
heavy metal examined. As the gfp expression of the transgenic line Tg(-2.4shha-
ABC:GFP)sb15 was specially expressed in the melanophore strip gap and the signal 
was abolished significantly in the presence of MeHg as low as 6 μg/l, this transgenic 
line can serve as a highly sensitive readout system of waterborne MeHg. A set of 
genes which were specifically induced in the caudal fin fold of MeHg-exposed 
embryos were identified. Among those genes, mmp9 and mmp13a have been revealed 
as two of the players of the caudal fin fold tissue disruption.  
 
This study helped to gain insight into the mechanisms of the MeHg-induced toxicity 
and provide clues for further mechanism studies. The identification of MeHg-sensitive 
biomarkers could be used to develop in vivo biosensors to monitor waterborne MeHg 
or other toxicants that showed similar toxicological profile as MeHg. This study also 
underscored the usefulness of zebrafish as a model organism to access developmental 
toxicity. 
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Appendix 
Tab. A1 Stages of zebrafish embryonic development. 
(This table is reproduced after Kimmel et al. (1995)) 
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Fig. A1 Schematic drawing of zebrafish embryos at selected stages between 4 and 72 hpf. 
Zebrafish at 4 (A), 12 (B), 18 (C), 24 (D), 48 (E) and 72 (F) hpf are shown. The embryos are positioned 
with the animal pole to the top (A) or anterior to the left and dorsal side up (B-F). Pigmentation on the 
body is omitted for better illustration of the anatomical structures. Anatomical structures in the 72-hpf-
old embryos are indicated. Scale bar, 250 μm. This figure is modified from Kimmel et al. (1995). 
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Tab. A2 MeHg-up-regulated genes determined by DNA-microarray with M > 1.30 and p < 0.05. 
Gene Name (gene symbol) GenBank accession number M-value 
matrix metalloproteinase 9 (mmp9) NM_213123 11.66 
matrix metalloproteinase 13a (mmp13a) NM_201503 9.13 
tissue inhibitor of metalloproteinase 2b (timp2b) NM_213296 8.51 
zgc:56537 (zgc:56537) NM_199950 8.16 
naa11e05.y1 Zebrafish whole eye. Unnormalized (naa) Danio rerio cDNA clone 
naa11e05 
DN857240 7.69 
complement component 7-1(c7-1) BC100054 7.66 
jun B proto-oncogene (junb) NM_213556 7.40 
zgc:101739 (zgc:101739) NM_001004629 6.83 
zgc:77038 (zgc:77038) NM_213304 6.71 
chemokine CXC-like protein (cxclpl) XM_685640 6.64 
zgc:63471 (zgc:63471) NM_199798 6.46 
FDR306-P00038-DEPE-F_A07 FDR306 Danio rerio cDNA clone FDR306-
P00038-BR_A07 
EH592105 6.44 
hepcidin antimicrobial peptide 1 (hamp1) NM_205583 6.16 
zgc:103438 (zgc:103438) NM_001006036 6.10 
fibronectin 1b (fn1b) NM_001013261 6.04 
solute carrier family 16 (monocarboxylic acid transporters), member 9a 
(slc16a9a) 
NM_200410 5.86 
insulin-like growth factor binding protein 1 (igfbp1) NM_173283 5.80 
mesogenin 1 (msgn1) NM_182882 5.33 
complement factor B (cfb) NM_131338 5.30 
chromobox protein homolog 7-like (cbx7l); zgc:110152 NM_001017853 5.16 
CCAAT/enhancer binding protein (C/EBP), beta (cebpb) NM_131884 5.16 
angiotensinogen (agt) NM_198063 5.05 
complement component 4-2 (c4-2) XM_001334604 5.01 
a disintegrin and metalloproteinase domain 8 (adam8) NM_200637 4.89 
zgc:92903 (zgc:92903) NM_001002461 4.87 
jun B proto-oncogene, like (junbl) NM_212750 4.83 
activating transcription factor 3 (atf3) NM_200964 4.78 
si:dkey-25e12.3 (si:dkey-25e12.3) NM_001025555 4.75 
zgc:154020 (zgc:154020) NM_001077607 4.67 
zgc:123218 (zgc:123218) NM_001037117 4.59 
v-fos FBJ murine osteosarcoma viral oncogene homolog (fos) NM_205569 4.40 
annexin A2a (anxa2a) NM_181761 4.37 
thioredoxin interacting protein a (txnipa) NM_200087 4.32 
Unknown CK394874 4.14 
putative transmembrane protein TA-2, like (ta2l) XM_688653 4.14 
zgc:73257 (zgc:73257) NM_213397 4.08 
Unknown A_15_P118168 3.98 
major vault protein (mvp) NM_201325 3.93 
wu:fl49b07(wu:fl49b07) BC055392 3.90 
hypothetical LOC565872 (LOC565872) XM_689134 3.89 
zgc:91912 (zgc:91912) NM_001002176 3.87 
glutathione S-transferase pi (gstp1) NM_131734 3.85 
bloodthirsty, like (btl) XM_001345747 3.82 
claudin c (cldnc) NM_131764 3.77 
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Gene Name (gene symbol) GenBank accession number M-value 
keratin 18 (krt18) NM_178437 3.77 
Unknown A_15_P101617 3.75 
zgc:110464 (zgc:110464) BC095285 3.74 
RAS-like, family 11, member B (rasl11b) NM_200140 3.72 
complement component 6 (c6l XM_001332137 3.71 
somatostatin 2 (sst2) NM_131727 3.70 
hypothetical LOC556467 (LOC556467) XM_679283 3.67 
zgc:85914 (zgc:85914) NM_213190 3.58 
cDNA clone IMAGE:7229274 CN013656 3.58 
hypoxia induced gene 1 (hig1) NM_200100 3.57 
MAP kinase-interacting serine/threonine kinase 2 (mknk2) TC303990 3.57 
zgc:112234 (zgc:112234) BC095697 3.54 
Unknown TC336408 3.52 
zgc:92066 (zgc:92066) TC355103 3.51 
zgc:92034 (zgc:92034) NM_001004605 14 
zgc:110010 (zgc:110010) NM_001020554 14 
zgc:77806 (zgc:77806) NM_205691 10 
dual specificity phosphatase 5 (dusp5) NM_212565 3.39 
Unknown A_15_P120379 3.35 
clusterin (clu) NM_200802 3.34 
zgc:92097 (zgc:92097) NM_205710 3.33 
Q4RTG9_TETNG (Q4RTG9) Chromosome 1 SCAF14998, whole genome 
shotgun sequence 
TC334607 3.30 
complement component 3-2 (c3-2) NM_001037236 3.28 
zgc:111983 (zgc:111983) NM_001017803 3.23 
zgc:109934 (zgc:109934) NM_001020531 3.20 
zgc:92192 (zgc:92192) NM_001002340 3.20 
claudin b (cldnb) NM_131763 3.12 
hypothetical protein LOC796518 (LOC796518) XM_001334489 3.11 
Unknown A_15_P101896 3.07 
sequestosome 1 (sqstm1) NM_213173 3.06 
growth arrest and DNA-damage-inducible, beta b (gadd45bb) NM_001012386 3.05 
cadherin 1, epithelial (cdh1) NM_131820 3.03 
zgc:73310 (zgc:73310) NM_200785 3.02 
S100 calcium binding protein A1 (s100a1) BC047833 3.00 
zgc:76966 (zgc:76966) NM_212869 2.93 
hydroxysteroid (17-beta) dehydrogenase 12a (hsd17b12a) NM_200881 2.92 
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1 
(elovl1) 
NM_199778 2.92 
zgc:109981 (zgc:109981) NM_001002569 2.92 
prostaglandin-endoperoxide synthase 2a (ptgs2a) NM_153657 2.91 
zgc:77906 (zgc:77906) NM_205648 2.89 
POU domain, class 5, transcription factor 1 (pou5f1) NM_131112 2.89 
zgc:91887 (zgc:91887) NM_001004542 2.85 
solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 
(slc7a3) 
NM_001007329 2.85 
guanine nucleotide binding protein (G protein), alpha transducing activity 
polypeptide 2 (gnat2) 
NM_131869 2.82 
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Gene Name (gene symbol) GenBank accession number M-value 
zgc:112226 (zgc:112226) NM_001024409 2.81 
zgc:91814 (zgc:91814) NM_001003479 2.81 
AL714172 Danio rerio embryonic inner ear subtracted cDNA Danio rerio cDNA 
clone BN0AA002ZF08 
AL714172 2.77 
claudin a (cldna) NM_131762 2.76 
zgc:153665 (zgc:153665) NM_001077463 2.75 
zgc:64051 (zgc:64051) NM_200371 2.74 
zgc:100919 (zgc:100919) NM_001002748 2.73 
thioredoxin interacting protein b (txnipb) BC055213 2.72 
zgc:92301 (zgc:92301) NM_001007314 2.72 
zgc:110380 (zgc:110380) NM_001017660 2.72 
zgc:109940 (zgc:109940) NM_001020532 2.72 
cDNA clone IMAGE:7403183 BC122156 2.69 
FDR306-P00024-DEPE-F_P05 FDR306 Danio rerio cDNA clone FDR306-
P00024-BR_P05 
EH587241 2.68 
FDR107-P00033-DEPE-F_C16 FDR107 Danio rerio cDNA clone FDR107-
P00033-BR_C16 
EH495313 2.67 
zgc:101897 (zgc:101897) NM_001007372 2.66 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4-like (pfkfb4l) NM_198816 2.66 
zgc:77002 (zgc:77002) NM_212910 2.65 
claudin e (cldne) NM_131765 2.64 
serum/glucocorticoid regulated kinase (sgk) NM_199212 2.62 
cDNA clone IMAGE:7225372 CN017556 2.62 
hypothetical protein LOC553515 (LOC553515) BC081659 2.61 
cDNA clone IMAGE:7923762 BC122366 2.60 
protein phosphatase 1, regulatory (inhibitor) subunit 3B (ppp1r3b) NM_212709 2.59 
zgc:92069 (zgc:92069) NM_001002376 2.58 
Unknown A_15_P113862 2.58 
Ictalurus punctatus 18S small subunit ribosomal RNA gene TC331454 2.57 
myeloid cell leukemia sequence 1b (mcl1b) NM_194394 2.57 
growth arrest and DNA-damage-inducible, alpha like (gadd45al) NM_200576 2.54 
PDZ and LIM domain 7 (pdlim7) NM_200840 2.53 
claudin 7 (cldn7) NM_131637 2.53 
growth arrest and DNA-damage-inducible, beta a (gadd45ba) NM_213031 2.52 
cDNA clone IMAGE:7235342 CN014934 2.51 
zgc:100868 (zgc:100868) NM_001003526 2.51 
claudin i (cldni) XM_692448 2.49 
zgc:92252 (zgc:92252) NM_001002622 2.48 
zgc:153827 (zgc:153827) NM_001030120 2.47 
Unknown A_15_P116930 2.47 
cDNA clone IMAGE:7247997 BC122137 2.47 
pim-1 oncogene (pim1) NM_131539 2.45 
Q4S8G5_TETNG (Q4S8G5) Chromosome 2 SCAF14705, whole genome 
shotgun sequence 
TC342277 2.45 
zgc:136830 (zgc:136830) NM_001040243 2.45 
prostaglandin-endoperoxide synthase 1 (ptgs1) NM_153656 2.43 
stanniocalcin 1 (stc1) NM_200539 2.43 
cDNA clone IMAGE:7228979 BC086730 2.43 
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Gene Name (gene symbol) GenBank accession number M-value 
prostaglandin I2 (prostacyclin) synthase like (ptgisl) BC124454 2.43 
hypothetical protein LOC792442 (LOC792442) XM_001331916 2.42 
transaldolase 1 (taldo1) NM_199687 2.42 
zgc:56136 (zgc:56136) NM_200198 2.41 
stathmin-like 4, like (stmn4l) TC327874 2.40 
Cd63 antigen (cd63) NM_199543 2.36 
cDNA clone IMAGE:7049914 BC117642 2.36 
zgc:56585 (zgc:56585) BC066622 2.35 
zgc:56706 (zgc:56706) NM_200274 2.35 
aldehyde dehydrogenase 3 family, member D1 (aldh3d1) NM_173221 2.35 
fatty acid binding protein 3, muscle and heart (fabp3) TC336225 2.33 
retinol dehydrogenase 12, like (rdh12l) NM_001009912 2.33 
zgc:136956 (zgc:136956) NM_001080029 2.32 
Q4S373_TETNG (Q4S373) Chromosome 4 SCAF14752, whole genome shotgun 
sequence 
TC305067 2.31 
zgc:110304 (zgc:110304) NM_001017593 2.31 
Unknown TC325806 2.31 
zgc:63514 (zgc:63514) NM_200013 2.31 
hypothetical LOC559958 (LOC559958) XM_683353 2.31 
smoothelin, like (smtnl) NM_212805 2.29 
im:7144703 (im:7144703) XM_686956 2.29 
thiazide sensitine NaCl cotransporter (ncct) NM_001045080 2.29 
pyrophosphatase (inorganic) (pp) NM_200733 2.29 
cDNA clone IMAGE:7120309 CK400158 2.28 
CT669859 ZF_mu Danio rerio cDNA clone ZF_mu_177e08 CT669859 2.28 
tumor-associated calcium signal transducer (tacstd) NM_213175 2.26 
Q4SMY3_TETNG (Q4SMY3) Chromosome 6 SCAF14544, whole genome 
shotgun sequence 
TC355382 2.25 
zgc:112009 (zgc:112009) NM_001017683 2.25 
zgc:91909 (zgc:91909) NM_001002178 2.25 
basic leucine zipper and W2 domains 1, like (bzw1l) NM_213092 2.25 
Unknown A_15_P116719 2.25 
chromosome 20 open reading frame 149, like (c20orf149l) NM_200008 2.23 
legumain (lgmn) NM_214759 2.23 
zgc:100900 (zgc:100900) NM_001003521 2.23 
Unknown A_15_P100589 2.22 
Unknown TC341137 2.21 
claudin i (cldni) NM_131768 2.21 
H1 histone family, member X (h1fx) NM_199276 2.20 
zgc:158528 (zgc:158528) BC095757 2.20 
chloride intracellular channel a (clica) NM_199524 2.20 
Unknown A_15_P113957 2.19 
cDNA clone IMAGE:7425015 CO926454 2.19 
Janus kinase 1 (jak1) NM_131073 2.18 
pleckstrin homology-like domain, family A, member 3 (phlda3) NM_001002455 2.18 
zgc:77882 (zgc:77882) NM_199649 2.17 
LIM domain kinase 2 (limk2) NM_001002651 2.16 
cfb protein, like (cfb) XR_028904 2.15 
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Gene Name (gene symbol) GenBank accession number M-value 
solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 
(slc1a4) 
BC076285 2.14 
ubquitin-like protein 1 (ubqlp1) XM_682249 2.13 
noggin 2 (nog2) BC067541 2.11 
Unknown A_15_P118821 2.11 
zgc:56330 (zgc:56330) NM_199683 2.10 
cDNA clone IMAGE:8744566 EE322470 2.08 
hypothetical LOC560869 (LOC560869) XM_684268 2.07 
cDNA clone IMAGE:7401354 CO796229 2.07 
zgc:100859 (zgc:100859) NM_001003533 2.06 
testis derived transcript (3 LIM domains) (tes) NM_205720 2.06 
Unknown A_15_P110843 2.06 
sphingolipid delta 4 desaturase/C-4 hydroxylase 2 (des2) BC045962 2.06 
Unknown TC351463 2.05 
dual specificity phosphatase 1 (dusp1) NM_213067 2.05 
transketolase (tkt) NM_198070 2.05 
fibrinogen, B beta polypeptide (fgb) NM_212774 2.04 
solute carrier family 16 (monocarboxylic acid transporters), member 3 (slc16a3) NM_212708 2.04 
fibrinogen, gamma polypeptide (fgg) NM_213054 2.03 
zgc:110267 (zgc:110267) NM_001017613 2.03 
spleen focus forming virus (SFFV) proviral integration oncogene (spi1) AY293624 2.02 
early growth response 2a (egr2a) NM_183341 2.02 
zgc:91870 (zgc:91870) NM_001002190 2.00 
cDNA clone IMAGE:8729487 EE310093 1.99 
si:dkey-193b15.6 (si:dkey-193b15.6) XM_689000 1.99 
Unknown TC319678 1.99 
influenza virus NS1A binding protein b (ivns1abpb) NM_201483 1.99 
zgc:56011 (zgc:56011) NM_212726 1.99 
Unknown A_15_P120377 1.98 
coagulation factor V (f5) NM_001007208 1.98 
cathepsin L1, a (ctsl1a) NM_212584 1.98 
DnaJ (Hsp40) homolog, subfamily B, member 1 (dnajb1) TC339980 1.97 
zgc:101811 (zgc:101811) NM_001006049 1.97 
eukaryotic translation initiation factor 4E binding protein 3, like (elf4ebp3l) CF269291 1.96 
complement component 9 (c9) TC320619 1.96 
chemokine (C-X-C motif) ligand 12a (stromal cell-derived factor 1) (cxcl12a) NM_178307 1.95 
zgc:91976 (zgc:91976) NM_001007325 1.95 
empty spiracles homeobox 3 (emx3) NM_131279 1.94 
zgc:103456 (zgc:103456) NM_001006032 1.93 
zgc:66409 (zgc:66409) NM_212737 1.93 
bicaudal-C (LOC402785) NM_203420 1.93 
Unknown TC343234 1.92 
phosphogluconate hydrogenase (pgd) NM_213453 1.92 
prostaglandin E synthase (ptges) NM_001014828 1.92 
hypothetical protein LOC100002476 (LOC100002476) XM_001337565 1.91 
carbonyl reductase 1-like (cbr1l) NM_194379 1.91 
CD9 antigen, like (cd9l) NM_213428 1.91 
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Gene Name (gene symbol) GenBank accession number M-value 
Unknown A_15_P116010 1.90 
cDNA clone IMAGE:7434007 BC133168 1.90 
zgc:110443 (zgc:110443) BC066727 1.90 
zgc:103604 (zgc:103604) NM_001005973 1.89 
caspase a (caspa) TC306290 1.89 
phosphoinositide-3-kinase, regulatory subunit, polypeptide 3 (p55, gamma) 
(pik3r3) 
NM_201143 1.89 
zgc:110340 (zgc:110340) BC091458 1.89 
Unknown A_15_P100772 1.89 
B-cell translocation gene 2 (btg2) NM_130922 1.89 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog f (avian) (maff) NM_200336 1.88 
Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and 
dihydroorotase 
TC308952 1.88 
zgc:112315 (zgc:112315) NM_001020678 1.88 
Unknown A_15_P102259 1.88 
Unknown A_15_P114954 1.88 
cytochrome b-245, alpha polypeptide (cyba) NM_200579 1.87 
PR domain containing 1, with ZNF domain (prdm1) NM_199515 1.86 
annexin A1a (anxa1a) NM_181758 1.86 
zgc:77868 (zgc:77868) NM_199999 1.84 
plexin D1 (plxnd1) NM_205697 1.84 
uncoupling protein 2 (ucp2) NM_131176 1.84 
retinal homeobox gene 1 (rx1) NM_131225 1.83 
transgelin 2 (tagln2) NM_201576 1.83 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) 
(mafb) 
NM_131015 1.82 
arrestin domain containing 1 (arrdc1) NM_001004561 1.82 
zgc:152839 (zgc:152839) BC124148 1.82 
zgc:92762 (zgc:92762) NM_001002561 1.81 
Unknown A_15_P119382 1.81 
MGC84748 protein TC335803 1.80 
O55566_NPVLS (O55566) P12 TC327743 1.79 
novel protein containing a ChaC-like protein domain (LOC563855) NM_001045032 1.79 
somatostatin 1 (sst1) NM_183070 1.79 
kelch-like ECH-associated protein 1 (keap1) NM_182864 1.78 
cDNA clone IMAGE:7998528 BC124510 1.78 
zgc:91992 (zgc:91992) NM_001002650 1.78 
zgc:101791 (zgc:101791) NM_001008623 1.78 
tissue inhibitor of metalloproteinase 2 (timp2) NM_182874 1.78 
helicase MOV-10-like (mov10l) TC345203 1.77 
zgc:91905 (zgc:91905) NM_001003459 1.77 
Unknown A_15_P114743 1.77 
dual specificity phosphatase 6 (dusp6) NM_194380 1.77 
coronin, actin binding protein, 1A (coro1a) NM_201114 1.77 
zgc:77286 (zgc:77286) NM_207062 1.76 
prosaposin (psap) NM_131883 1.76 
zgc:55423 (zgc:55423) NM_201171 1.76 
zgc:158387 (zgc:158387) NM_001080034 1.76 
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zgc:92266 (zgc:92266) NM_001002617 1.73 
ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast) (ube2h) NM_201489 1.73 
Unknown A_15_P109596 1.72 
bcl2-like (bcl2l) NM_131807 1.72 
zgc:92198 (zgc:92198) NM_001002642 1.71 
tight junction protein 3 (tjp3) NM_201494 1.71 
popeye domain containing 3 (popdc3) NM_001001848 1.71 
retinol binding protein 4, like (rbp4l) NM_199965 1.70 
Unknown TC348736 1.70 
coxsackie virus and adenovirus receptor (cxadr) BC045286 1.70 
SAM domain, SH3 domain and nuclear localisation signals, 1 (samsn1) BC083438 1.70 
wu:fc21h08 (wu:fc21h08) NM_001001815 1.70 
vascular endothelial growth factor A (vegfa) NM_131408 1.69 
cDNA clone 2690585 EB788158 1.69 
cytochrome c oxidase subunit III (cox3) TC322630 1.69 
glucosaminyl (N-acetyl) transferase 4, core 2 (gcnt4) NM_201583 1.69 
hypothetical LOC562892 (LOC562892) XM_701076 1.69 
methyl-CpG binding domain protein 2 (mbd2) NM_212768 1.68 
mitogen-activated protein kinase 3 (mapk3) NM_201507 1.68 
nephrosin (npsn) NM_205756 1.68 
potassium channel tetramerisation domain containing 12.2 (kctd12.2) NM_001034019 1.68 
Wiskott-Aldrich syndrome (eczema-thrombocytopenia) (was) NM_199938 1.67 
zgc:63645 (zgc:63645) BC056794 1.67 
serine protease inhibitor, Kunitz type 1-like (spint1l) NM_213152 1.67 
Unknown A_15_P116135 1.67 
MGC81751 protein TC313771 1.67 
Anguilla rostrata 28S ribosomal RNA gene TC319492 1.66 
retinol dehydrogenase 10 (rdh10) NM_201331 1.66 
Hydrolagus colliei internal transcribed spacer 1; 5.8S ribosomal RNA gene and 
internal transcribed spacer 2; and 28S ribosomal RNA gene 
TC357777 1.66 
sprouty (Drosophila) homolog 4 (spry4) NM_131826 1.66 
ral guanine nucleotide dissociation stimulator-like 1 (rgl1) NM_205637 1.65 
Unknown A_15_P113515 1.65 
Unknown TC341913 1.64 
Unknown A_15_P100273 1.64 
fibrinogen alpha chain (fga) NM_001002039 1.64 
hypothetical LOC554458 (LOC554458) XM_696332 1.64 
zinc finger, AN1-type domain 5a (zfand5a) NM_213039 1.63 
cathepsin D (ctsd) NM_131710 1.63 
sperm associated antigen 6 (spag6) NM_001002210 1.63 
zgc:112054 (zgc:112054) NM_001017664 1.63 
v-jun sarcoma virus 17 oncogene homolog (avian) (jun) NM_199987 1.63 
cDNA clone IMAGE:5072672 BI839216 1.62 
cadherin 17, LI cadherin (liver-intestine) (cdh17) NM_194422 1.62 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 25 
(slc25a25) 
NM_213257 1.61 
Pax-family transcription factor 6.2 (pax6.2) TC308490 1.61 
zgc:77455 (zgc:77455) NM_199754 1.61 
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Unknown A_15_P104204 1.61 
enhancer of polycomb homolog 2 (Drosophila) (epc2) NM_201075 1.61 
zgc:65794 (zgc:65794) NM_213349 1.61 
bridging integrator 2, like (bin2l) NM_199796 1.60 
zgc:76933 (zgc:76933) NM_207081 1.60 
vang-like 2 (van gogh, Drosophila) (vangl2) BC065983 1.60 
B lymphoma Mo-MLV insertion region 1 (bmi1) NM_194366 1.60 
LOC495986 protein, like (LOC558475) XM_681691 1.60 
hypothetical LOC563193 (LOC563193) XM_686554 1.59 
caspase 8 (casp8) NM_131510 1.59 
nuclear lamin A (lmna) TC304394 1.59 
homogentisate 1,2-dioxygenase (hgd) NM_152966 1.59 
cDNA clone IMAGE:3717298 AI545183 1.59 
adenosine deaminase (ada) NM_001002646 1.58 
zgc:103463 (zgc:103463) NM_001007351 1.58 
glutamate-cysteine ligase, catalytic subunit (gclc) NM_199277 1.58 
zgc:110333 (zgc:110333) NM_001017799 1.57 
cDNA clone IMAGE:7418695 CO927351 1.57 
zgc:101776 (zgc:101776) NM_001007404 1.57 
zgc:92505 (zgc:92505) NM_001004550 1.57 
Unknown A_15_P100047 1.56 
zgc:63593 (zgc:63593) BC058869 1.56 
hematopoietically expressed homeobox (hhex) NM_130934 1.56 
gonadotropin-releasing hormone 2 (gnrh2) NM_181439 1.56 
HIV-1 Tat interactive protein 2 (htatip2) NM_131681 1.56 
ft64a05.y1 Gong zebrafish ovary Danio rerio cDNA clone IMAGE:5157801 BI867800 1.56 
zgc:77123 (zgc:77123) NM_001001825 1.56 
Thy-1 cell surface antigen (thy1) NM_198065 1.56 
zgc:91996 (zgc:91996) TC343798 1.56 
zgc:77358 (zgc:77358) NM_205632 1.56 
zgc:92476 (zgc:92476) NM_001002643 1.55 
glutamate-ammonia ligase (glutamine synthase) b (glulb) NM_182866 1.54 
parathyroid hormone 1 (pth1) NM_212950 1.53 
zgc:103407 (zgc:103407) NM_001004014 1.52 
cDNA clone IMAGE:7116694 CK399020 1.52 
zgc:153291 (zgc:153291) NM_001045360 1.52 
cathepsin B, a (ctsba) NM_213336 1.52 
notch-regulated ankyrin repeat protein a (nrarpa) NM_181495 1.52 
orthodenticle homolog 1 (otx1) NM_131250 1.52 
Unknown CV113602 1.52 
glutamate-ammonia ligase (glutamine synthase) a (glula) NM_181559 1.52 
zgc:101676 (zgc:101676) NM_001004635 1.52 
potassium channel, subfamily K, member 5 (kcnk5) NM_200633 1.52 
peptide YY (pyy) NM_131016 1.52 
cDNA clone IMAGE:7140684 BC090456 1.52 
zic family member 2 (odd-paired homolog, Drosophila) b (zic2b) NM_001001820 1.51 
14781156 ZF35 Danio rerio cDNA clone 3426448sequence EB959676 1.51 
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activating transcription factor 4, like (atf4l) XM_701690 1.51 
pleckstrin homology domain containing, family F (with FYVE domain) member 2 
(plekhf2) 
NM_200244 1.51 
Unknown TC340992 1.50 
Tax1 (human T-cell leukemia virus type I) binding protein 3 (tax1bp3) NM_213470 1.50 
zgc:64085 (zgc:64085) NM_200408 1.50 
zgc:153034 (zgc:153034) NM_001076637 1.50 
cDNA clone IMAGE:7012610 BC085676 1.49 
zgc:153860 (zgc:153860) NM_001077248 1.49 
zgc:85680 (zgc:85680) NM_212929 1.48 
zgc:92897 (zgc:92897) NM_001003430 1.48 
myeloid cell leukemia sequence 1a (mcl1a) NM_131599 1.48 
zgc:56116 (zgc:56116) NM_200196 1.48 
zgc:123105 (zgc:123105) NM_001039994 1.48 
spermine oxidase (smox) BC066413 1.48 
cDNA clone IMAGE:7053031 BC075971 1.48 
cDNA clone IMAGE:7012947 CF550131 1.47 
zgc:63950 (zgc:63950) NM_200111 1.47 
LIM domain only 4 (lmo4) NM_177984 1.47 
cDNA clone IMAGE:6795541 CA474484 1.47 
core promoter element binding protein (copeb) NM_201461 1.47 
ornithine decarboxylase 1 (odc1) NM_131801 1.47 
Unknown A_15_P119625 1.46 
zgc:111821 (zgc:111821) NM_001002308 1.46 
zgc:110779 (zgc:110779) NM_001013318 1.46 
Unknown A_15_P114228 1.46 
cDNA clone IMAGE:8109385 BC122381 1.46 
PR domain containing 8 (prdm8) NM_213410 1.46 
renin binding protein (renbp) NM_001008610 1.46 
aminolevulinate, delta-, synthetase 1 (alas1) NM_201287 1.45 
Q4SC04_TETNG (Q4SC04) Chromosome 14 SCAF14660, whole genome 
shotgun sequence 
TC357468 1.45 
zgc:73201 (zgc:73201) NM_199668 1.45 
leucine rich repeat containing 6 (lrrc6) TC349542 1.45 
Q4SU80_TETNG (Q4SU80) Chromosome 5 SCAF13976, whole genome 
shotgun sequence 
TC315445 1.45 
connector enhancer of kinase suppressor of Ras 1 (cnksr1) NM_205659 1.44 
zgc:55316 (zgc:55316) NM_199601 1.44 
zgc:101711 (zgc:101711) NM_001007426 1.44 
zgc:64161 (zgc:64161) NM_213126 1.44 
zgc:113058 (zgc:113058) NM_001014320 1.43 
forkhead box B1.2 (foxb1.2) NM_131285 1.43 
zgc:153258 (zgc:153258) NM_001076579 1.43 
Unknown TC323161 1.43 
zgc:92512 (zgc:92512) NM_001002364 1.42 
Sp8 transcription factor a (sp8a) TC324262 1.42 
CCAAT/enhancer binding protein (C/EBP), gamma (cebpg) NM_131886 1.42 
zgc:100897 (zgc:100897) NM_001003753 1.42 
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nudix (nucleoside diphosphate linked moiety X)-type motif 4 (nudt4) NM_200110 1.42 
cDNA clone IMAGE:8154077 DV586283 1.41 
zgc:123339 (zgc:123339) NM_001037695 1.41 
nocA related zinc finger 1 (nlz1) NM_131822 1.40 
bromodomain-containing 2, transcript variant 8 (brd2) XM_704349 1.40 
catenin (cadherin-associated protein) NM_131456 1.40 
ETS-related factor1 (ef1) NM_131159 1.40 
TC338066 TC338066 1.39 
zgc:153437 (zgc:153437) NM_001045127 1.39 
Unknown A_15_P112857 1.39 
FDR103-P00038-DEPE-F_J23 FDR103 Danio rerio cDNA clone FDR103-
P00038-BR_J23 5' 
EH445291 1.39 
Hspa8 protein (Heat shock protein 8) TC308414 1.38 
ft22a01.y1 Zebrafish neuronal Danio rerio cDNA clone IMAGE:5082121 5' BI865577 1.38 
zgc:77112 (zgc:77112) NM_213180 1.38 
Unknown A_15_P106131 1.38 
prostaglandin-endoperoxide synthase 2b (ptgs2b) NM_001025504 1.38 
zgc:55456 (zgc:55456) NM_197942 1.38 
trh3 protein (trh3) NM_153671 1.38 
cDNA clone IMAGE:7086778 BC083533 1.37 
mitogen-activated protein kinase kinase 1 (map2k1) NM_213419 1.37 
zgc:114089 (zgc:114089) NM_001025472 1.37 
ADP-ribosylation factor-like 4, like (arl4l) NM_200318 1.37 
zgc:77836 (zgc:77836) NM_213196 1.37 
zgc:85866 (zgc:85866) NM_001001826 1.36 
hypothetical protein LOC407664 (LOC407664) BC066705 1.36 
purkinje cell protein 4-like 1 (pcp4l1) TC341327 1.36 
zgc:92339 (zgc:92339) NM_001002452 1.36 
zgc:77671 (zgc:77671) NM_200063 1.36 
mitogen-activated protein kinase-activated protein kinase 2 (mapkapk2) NM_201303 1.35 
zgc:101788 (zgc:101788) NM_001013535 1.35 
sp8 transcription factor (sp8) NM_213241 1.34 
zgc:85790 (zgc:85790) NM_213299 1.34 
zgc:112165 (zgc:112165) NM_001020656 1.34 
geranylgeranyl diphosphate synthase 1 (ggps1) NM_200035 1.33 
tumor protein p53 (tp53) NM_131327 1.33 
dynein, axonemal, light intermediate polypeptide 1 (dnali1) XM_001333070 1.33 
myelocytomatosis oncogene a (myca) NM_131412 1.33 
hypothetical protein LOC798347 (LOC798347) XM_001335762 1.32 
syndecan binding protein (syntenin) (sdcbp) NM_212691 1.32 
zgc:92926 (zgc:92926) NM_001002524 1.32 
homeo box D13a (hoxd13a) NM_131169 1.32 
hydroxyacylglutathione hydrolase (hagh) NM_200043 1.32 
insulin-like growth factor 1b receptor (igf1rb) NM_152969 1.32 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 
(nfkb2) 
NM_001001840 1.32 
cDNA clone IMAGE:8779532 EE719009 1.32 
zgc:101688 (zgc:101688) NM_001008652 1.32 
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ER degradation enhancer, mannosidase alpha-like 1 (edem1) NM_201189 1.32 
Unknown A_15_P108457 1.31 
sine oculis homeobox homolog 3b (six3b) NM_131363 1.31 
sine oculis homeobox homolog 3a (six3a) NM_131362 1.31 
wu:fc23f06 (wu:fc23f06) NM_194372 1.31 
heterogeneous nuclear ribonucleoprotein K (hnrpk) NM_212994 1.31 
zgc:92465 (zgc:92465) NM_001003496 1.31 
hypothetical protein LOC798783 (LOC798783) XM_001339180 1.30 
sp9 transcription factor (sp9) NM_212960 1.30 
zgc:100997 (zgc:100997) NM_001003605 1.30 
ephrin A1 (efna1) NM_200783 1.30 
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Tab. A3 MeHg-down-regulated genes determined by DNA-microarray with M < -1.30 and p < 0.05. 
Gene Name (gene symbol) GenBank accession number M-value 
cDNA clone IMAGE:8008341 BC124740 -5.62 
zgc:136930 (zgc:136930)  NM_001039819 -3.72 
glutathione peroxidase 1 (gpx1)  NM_001007281 -3.54 
cDNA clone IMAGE:7075880 BC076207 -18 
FabG (beta-ketoacyl-acyl-carrier-protein] reductase, E. coli) like (fabgl) NM_001005292 -3.38 
selenoprotein P, plasma, 1a (sepp1a) TC356400 -3.20 
cDNA clone IMAGE:6525439 BC067158 -3.13 
zgc:92263 (zgc:92263)  NM_001002618 -3.05 
zgc:109898 (zgc:109898)  NM_001020726 -3.02 
zgc:73311 (zgc:73311)  NM_200036 -2.90 
Unknown  A_15_P105535 -2.83 
zinc finger, CCHC domain containing 17 (zcchc17)  NM_200544 -2.71 
si:ch211-240l14.3 (si:ch211-240l14.3)  NM_001020525 -2.69 
lactate dehydrogenase D (ldhd)  NM_199873 -2.64 
zgc:112527 (zgc:112527)  NM_001017751 -2.63 
secernin 3 (scrn3)  NM_199738 -2.62 
hypothetical protein LOC553371 (LOC553371) BC116529 -2.61 
deiodinase, iodothyronine, type I (dio1)  NM_001007283 -2.60 
Unknown  CO804345 -2.58 
zgc:92643 (zgc:92643)  NM_001002436 -2.51 
zgc:101035 (zgc:101035)  TC327561 -2.49 
amyloid beta precursor protein binding protein 1 (appbp1)  NM_200499 -2.46 
NudC domain containing 2 (nudcd2) NM_001003539 -2.45 
zehn2354.seq.F Zebrafish Embryonic Heart cDNA Library Danio rerio cDNA AI618852 -2.42 
zgc:85626 (zgc:85626)  NM_213321 -2.42 
acyl-Coenzyme A dehydrogenase family, member 8 (acad8)  NM_201155 -2.42 
zgc:77065 (zgc:77065)  NM_212884 -2.39 
pyridoxine 5'-phosphate oxidase (pnpo) BC057246 -2.39 
Unknown  A_15_P104050 -2.38 
Unknown  A_15_P115112 -2.38 
Chromosome 18 SCAF14712, whole genome shotgun sequence TC342108 -2.37 
zgc:110030 (zgc:110030)  NM_001029968 -2.36 
cDNA clone IMAGE:7143041 BC090532 -2.33 
CHMP (charged multivesicular body) family, member 7 (chmp7)  NM_200781 -2.33 
zgc:85611 (zgc:85611)  NM_213095 -2.31 
Unknown  A_15_P109775 -2.30 
 152 
Gene Name (gene symbol) GenBank accession number M-value 
zgc:91969 (zgc:91969)  NM_001002661 -2.30 
zgc:77144 (zgc:77144)  NM_205656 -2.30 
zgc:92496 (zgc:92496)  TC338522 -2.28 
SEC22 vesicle trafficking protein homolog A (S. cerevisiae) (sec22a)  NM_199698 -2.27 
zgc:103574 (zgc:103574)  NM_001005980 -2.26 
zgc:63986 (zgc:63986)  NM_213332 -2.25 
zgc:56429 (zgc:56429)  NM_200277 -2.24 
zgc:85882 (zgc:85882)  NM_212942 -2.21 
ARP6 actin-related protein 6 homolog (yeast) (actr6)  NM_199696 -2.18 
zinc finger protein zfp113 (zfp113)  TC323584 -2.16 
zgc:103490 (zgc:103490)  NM_001004613 -2.15 
cDNA clone IMAGE:7259207 CN320754 -2.14 
zgc:55652 (zgc:55652)  NM_199775 -2.13 
zgc:92822 (zgc:92822)  NM_001004567 -2.12 
zinc finger protein zfp108 (zfp108)  TC316500 -2.12 
si:dkey-218n20.4 (si:dkey-218n20.4)  NM_001080803 -2.11 
zgc:136363 (zgc:136363)  NM_001045267 -2.10 
zinc finger protein zfp235 (zfp235)  TC352505 -2.07 
zgc:56466 (zgc:56466)  NM_200264 -2.07 
zgc:91853 (zgc:91853)  NM_001002196 -2.06 
selenoprotein M (sepm)  NM_178286 -2.06 
kaptin (actin binding protein) (kptn)  NM_001003642 -2.05 
cDNA clone IMAGE:8105683 BC122256 -2.04 
meiotic recombination 11 homolog A (S. cerevisiae) (mre11a)  NM_001001407 -2.04 
zgc:112000 (zgc:112000)  NM_001017690 -2.03 
zgc:109720 (zgc:109720)  NM_205611 -2.02 
zgc:63468 (zgc:63468)  NM_199785 -2.01 
RNA (guanine-9-) methyltransferase domain containing 2, like (rg9mtd2l)  XM_683615 -2.01 
FDR202-P00033-DEPE-F_K16 FDR202 Danio rerio cDNA clone FDR202-
P00033-BR_K16 
EH548059 -2.01 
zgc:101710 (zgc:101710)  NM_001006068 -2.01 
zgc:56476 (zgc:56476)  NM_199930 -2.01 
zgc:101627 (zgc:101627)  NM_001007447 -2.01 
zgc:110366 (zgc:110366)  NM_001017779 -2.01 
zgc:56388 (zgc:56388)  NM_200262 -2.00 
coenzyme Q3 homolog, methyltransferase (yeast) (coq3)  NM_001002620 -1.99 
zgc:92067 (zgc:92067)  NM_001002377 -1.99 
hypothetical protein LOC402865 (LOC402865) BC056692 -1.97 
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hypothetical protein MGC10433-like (H. sapiens) (mgc10433l)  NM_001003850 -1.96 
zgc:91813 (zgc:91813)  NM_001002209 -1.96 
zgc:101066 (zgc:101066)  NM_001003572 -1.96 
polyglutamine binding protein 1-like (pqbp1l)  NM_001002435 -1.95 
zgc:136869 (zgc:136869)  NM_001040304 -1.95 
hypothetical protein LOC553323 (LOC553323) BC090516 -1.95 
zgc:112432 (zgc:112432)  NM_001017780 -1.94 
hypothetical protein LOC100003154 (LOC100003154)  XM_001342741 -1.94 
DNA-binding protein (dbp) TC317091 -1.94 
Unknown  TC351278 -1.93 
WW domain containing oxidoreductase (wwox)  NM_200913 -1.93 
zgc:92656 (zgc:92656)  NM_001002427 -1.93 
acyl-Coenzyme A dehydrogenase, long chain (acadl)  NM_201181 -1.93 
zgc:55781 (zgc:55781)  NM_214694 -1.92 
zgc:92633 (zgc:92633)  NM_001002442 -1.91 
hypothetical LOC568461 (LOC568461)  XM_691792 -1.91 
zgc:110741 (zgc:110741)  TC336566 -1.89 
macrophage migration inhibitory factor (mif)  NM_001043321 -1.89 
zgc:136330 (zgc:136330)  NM_001045327 -1.89 
hydroxysteroid (17-beta) dehydrogenase 4 (hsd17b4)  NM_200136 -1.89 
parkinson disease (autosomal recessive, early onset) 7 (park7)  NM_001005938 -1.88 
OTU domain, ubiquitin aldehyde binding 1 (otub1)  NM_001002500 -1.88 
reticulocalbin 3, EF-hand calcium binding domain (rcn3)  NM_001002158 -1.88 
zgc:153376 (zgc:153376)  NM_001076739 -1.86 
Unknown  A_15_P116555 -1.86 
zgc:92030 (zgc:92030)  NM_001002645 -1.85 
traf and tnf receptor associated protein, like (ttrapl)  NM_001079703 -1.85 
zgc:77071 (zgc:77071)  NM_212685 -1.85 
cDNA clone IMAGE:7435998 BC122194 -1.84 
zgc:158612 (zgc:158612)  BC133134 -1.84 
zgc:101720 (zgc:101720)  NM_001006065 -1.83 
keratin 5 (krt5) BC063955 -1.82 
zgc:111984 (zgc:111984)  NM_001017796 -1.82 
zgc:153031 (zgc:153031)  NM_001044830 -1.82 
zgc:92915 (zgc:92915)  NM_001007052 -1.82 
SUMO1 activating enzyme subunit 1 (sae1)  NM_001002058 -1.82 
3-hydroxyisobutyryl-Coenzyme A hydrolase (hibch)  NM_001014316 -1.81 
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Gene Name (gene symbol) GenBank accession number M-value 
SUB1 homolog (S. cerevisiae) (sub1)  NM_001002505 -1.81 
zgc:101723 (zgc:101723)  NM_001005600 -1.81 
Bardet-Biedl syndrome 2 (bbs2)  NM_152887 -1.81 
zgc:110008 (zgc:110008)  NM_001020553 -1.81 
zgc:56036 (zgc:56036)  NM_213052 -1.81 
cDNA clone IMAGE:7214146 CK871898 -1.80 
Unknown  A_15_P120745 -1.80 
heterogeneous nuclear ribonucleoprotein D-like (hnrpdl)  NM_213392 -1.80 
serine hydrolase-like (serhl)  NM_199615 -1.80 
l(3)mbt-like 2 (Drosophila) (l3mbtl2)  NM_200032 -1.79 
zgc:101896 (zgc:101896)  NM_001007373 -1.79 
zgc:77531 (zgc:77531)  NM_212607 -1.79 
Unknown  A_15_P102844 -1.78 
mesoderm specific transcript (mest)  NM_131043 -1.78 
SET domain containing 6 (setd6)  NM_199600 -1.78 
zgc:55479 (zgc:55479)  NM_200158 -1.78 
zeh0124.seq.F Zebrafish Embryonic Heart cDNA Library Danio rerio cDNA AI353170 -1.78 
zgc:63568 (zgc:63568)  NM_200455 -1.78 
RAB28, member RAS oncogene family (rab28)  NM_199752 -1.78 
Unknown  A_15_P120334 -1.78 
zgc:100998 (zgc:100998)  NM_001003604 -1.77 
novel IBR domain containing protein (LOC573901)  NM_001045231 -1.77 
acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain (acadm)  NM_213010 -1.76 
Homo sapiens chromosome 6 open reading frame 203, like (HSPC230l) XM_688914 -1.75 
zgc:63722 (zgc:63722)  NM_201300 -1.75 
zgc:76871 (zgc:76871)  NM_213103 -1.75 
Meiotic recombination 11 homolog A (mre11a)  TC339226 -1.75 
tubulin, beta 5 (tubb5)  NM_198818 -1.74 
type I cytokeratin (cyt1) AI958753 -1.74 
COX15 homolog, cytochrome c oxidase assembly protein (yeast) (cox15)  BC066452 -1.74 
zgc:55317 (zgc:55317)  NM_200126 -1.74 
ubiquitin-activating enzyme E1-domain containing 1 (ube1dc1) BC046031 -1.73 
LOC496071 protein (LOC496071)  TC324268 -1.73 
si:busm1-265n4.4 (si:busm1-265n4.4)  NM_001030184 -1.73 
Unknown  A_15_P118106 -1.72 
peroxisomal biogenesis factor 3 (pex3)  NM_200228 -1.71 
zgc:112518 (zgc:112518)  NM_001017758 -1.71 
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Gene Name (gene symbol) GenBank accession number M-value 
zgc:77366 (zgc:77366)  NM_212645 -1.71 
neural precursor cell expressed, developmentally down-regulated 8 (nedd8)  NM_201321 -1.71 
MGC83215 protein, like (LOC100000478)  XM_001335434 -1.71 
dipeptidylpeptidase 3 (dpp3)  NM_001002683 -1.71 
zgc:85777 (zgc:85777)  NM_212935 -1.71 
zgc:63632 (zgc:63632)  NM_200469 -1.70 
v-ral simian leukemia viral oncogene homolog A (ras related) (rala)  NM_201018 -1.70 
swelling dependent chloride channel (icln)  NM_131424 -1.70 
AB002389 Start codon is not identified (Homo sapiens) (AB002389) TC336593 -1.69 
anaphase promoting complex subunit 5 (anapc5)  NM_199622 -1.69 
keratin 4 (krt4)  BC066728 -1.69 
catenin, beta like 1 (ctnnbl1)  NM_200866 -1.69 
zgc:100795 (zgc:100795)  NM_001004011 -1.68 
zgc:77346 (zgc:77346)  NM_212901 -1.68 
NADPH dependent diflavin oxidoreductase 1 (ndor1)  NM_200648 -1.68 
zgc:112404 (zgc:112404)  NM_001017609 -1.68 
cDNA clone IMAGE:8756495 EG572643 -1.68 
zgc:111967 (zgc:111967)  NM_001020758 -1.67 
hypothetical LOC558108 (LOC558108)  XM_679819 -1.67 
zgc:92496 (zgc:92496)  NM_001002375 -1.67 
si:rp71-1o1.6 (si:rp71-1o1.6)  NM_001030131 -1.67 
MAK10 homolog, amino-acid N-acetyltransferase subunit (S. cerevisiae) 
(mak10)  
NM_199550 -1.67 
FDR103-P00027-DEPE-F_B20 FDR103 Danio rerio cDNA clone FDR103-
P00027-BR_B20 
EH441106 -1.66 
si:ch211-20b12.1 (si:ch211-20b12.1)  NM_001001836 -1.65 
cDNA clone IMAGE:8132070 BC122393 -1.65 
zgc:92773 (zgc:92773)  NM_001002554 -1.65 
peptidylprolyl isomerase (cyclophilin)-like 4 (ppil4)  NM_199890 -1.65 
zgc:100930 (zgc:100930)  NM_001003630 -1.65 
Unknown  CN327020 -1.64 
coiled-coil domain containing 124 (ccdc124)  NM_200565 -1.64 
zgc:109897 (zgc:109897)  NM_001020523 -1.64 
zgc:123194 (zgc:123194)  NM_001037410 -1.64 
PRP31 pre-mRNA processing factor 31 homolog (yeast) (prpf31)  NM_200504 -1.64 
tubulin, alpha 8 like 3 (tuba8l3)  NM_001003558 -1.63 
zgc:92784 (zgc:92784)  NM_001002548 -1.63 
zgc:92033 (zgc:92033)  NM_001003490 -1.63 
thioredoxin domain containing 5 (txndc5)  NM_213016 -1.63 
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Gene Name (gene symbol) GenBank accession number M-value 
zgc:110332 (zgc:110332)  NM_001013473 -1.63 
excision repair protein/xeroderma pigmentosum D (errc2/xpd) TC326821 -1.63 
retinoblastoma binding protein 5 (rbbp5)  NM_200245 -1.62 
mitochondrial trans-2-enoyl-CoA reductase (mecr)  NM_001017852 -1.62 
hypothetical LOC563453 (LOC563453)  XM_686813 -1.62 
cDNA clone IMAGE:7054660 CK026881 -1.62 
thyroid autoantigen (Ku antigen) (g22p1)  NM_199904 -1.62 
kinesin family member 5B, like (kif5bl)  XM_680141 -1.61 
zgc:110323 (zgc:110323)  NM_001017809 -1.61 
Q4RTY0_TETNG (Q4RTY0) Chromosome 12 SCAF14996, whole genome 
shotgun sequence 
TC350990 -1.61 
zgc:103522 (zgc:103522)  NM_001005993 -1.61 
methylcrotonoyl-Coenzyme A carboxylase 1 (alpha), like (mccc1l)  NM_001044915 -1.61 
zgc:136962 (zgc:136962)  NM_001040051 -1.60 
cDNA clone IMAGE:8810392 EE710623 -1.60 
yippee-like 5 (ypel5)  NM_200477 -1.60 
mitochondrial ribosome recycling factor (mrrf)  NM_001002174 -1.59 
zgc:77526 (zgc:77526)  NM_207068 -1.59 
zgc:136566 (zgc:136566)  NM_001045240 -1.58 
processing of precursor 7, ribonuclease P family (pop7)  NM_001006004 -1.58 
zgc:66371 (zgc:66371)  NM_200689 -1.58 
zgc:103591 (zgc:103591)  NM_001004681 -1.58 
zgc:55794 (zgc:55794)  NM_199834 -1.58 
zgc:63674 (zgc:63674)  NM_200616 -1.58 
hypothetical protein LOC100002391 (LOC100002391)  XM_001337620 -1.58 
zgc:77093 (zgc:77093)  NM_212780 -1.58 
RAB interacting factor (rabif)  NM_001002511 -1.57 
intraflagellar transport protein 52 (ift52)  NM_001001834 -1.57 
zgc:65774 (zgc:65774)  NM_199924 -1.56 
zgc:101792 (zgc:101792)  NM_001008622 -1.56 
polymerase (RNA) II (DNA directed) polypeptide G-like (polr2gl)  NM_199669 -1.56 
NIMA (never in mitosis gene a)-related kinase 4 (nek4)  NM_201012 -1.56 
zgc:77852 (zgc:77852)  NM_205658 -1.55 
zgc:66396 (zgc:66396)  NM_200057 -1.55 
zgc:91935 (zgc:91935)  NM_001003511 -1.55 
O-sialoglycoprotein endopeptidase-like 1 (osgepl1)  NM_001005301 -1.55 
cDNA clone IMAGE:7267460 CN513453 -1.54 
zgc:153434 (zgc:153434)  BC122292 -1.54 
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Gene Name (gene symbol) GenBank accession number M-value 
zgc:92356 (zgc:92356)  NM_001002444 -1.53 
zgc:153243 (zgc:153243)  NM_001080753 -1.53 
hypothetical protein LOC794682 (LOC794682)  XM_001332661 -1.53 
l-isoaspartyl protein carboxyl methyltransferase, like (pcmtl)  NM_200768 -1.53 
cDNA clone IMAGE:8808742 EE698006 -1.53 
Chromosome 7 SCAF14601, whole genome shotgun sequence TC325349 -1.53 
zgc:77056 (zgc:77056)  NM_212698 -1.53 
zgc:91944 (zgc:91944)  NM_001002668 -1.53 
zgc:91844 (zgc:91844)  NM_001003473 -1.52 
Unknown  A_15_P112500 -1.52 
zgc:65873 (zgc:65873)  NM_200542 -1.51 
zgc:103767 (zgc:103767)  NM_001006006 -1.51 
reticulon 4 interacting protein 1 (rtn4ip1)  NM_200352 -1.51 
zgc:77086 (zgc:77086)  NM_212905 -1.51 
ring finger protein 13 (rnf13)  NM_201044 -1.51 
COP9 constitutive photomorphogenic homolog subunit 5 (cops5)  NM_200725 -1.5 
zgc:91931 (zgc:91931)  NM_001002672 -1.5 
zgc:153240 (zgc:153240)  NM_001045389 -1.5 
upstream transcription factor 2, c-fos interacting (usf2)  NM_213194 -1.5 
tenascin-W (tnw) AJ001423 -1.5 
acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain (acads) TC337290 -1.5 
2-hydroxyacyl-CoA lyase 1 (hacl1)  NM_213085 -1.5 
si:ch211-153c20.2 (si:ch211-153c20.2)  NM_001030218 -1.5 
zgc:55392 (zgc:55392)  NM_199849 -1.5 
fatty acid desaturase 2 (fads2)  NM_131645 -1.49 
zgc:101649 (zgc:101649)  NM_001013537 -1.49 
cDNA clone IMAGE:7159603 BC096816 -1.49 
ATP-binding cassette, sub-family G (WHITE), member 2c (abcg2c)  NM_001039639 -1.49 
cDNA clone IMAGE:4468666 BG799470 -1.49 
hypothetical LOC567256 (LOC567256)  XM_690548 -1.49 
hypothetical LOC570857 (LOC570857)  XM_694382 -1.49 
protein C14orf159, mitochondrial precursor, like, transcript variant 1 
(C14orf159l)  
XM_678640 -1.49 
zinc finger, CCCH-type with G patch domain (zgpat) TC305183 -1.48 
inositol(myo)-1(or 4)-monophosphatase 1 (impa1)  NM_001002745 -1.48 
si:dkey-110c1.6 (si:dkey-110c1.6) NM_001020551 -1.48 
O-6-methylguanine-DNA methyltransferase, like (mgmtl) XM_691575 -1.48 
mitochondrial ribosomal protein S33 (mrps33)  NM_001002306 -1.48 
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Gene Name (gene symbol) GenBank accession number M-value 
hypothetical protein LOC553234 (LOC553234) BC077125 -1.47 
zgc:101581 (zgc:101581)  NM_001007777 -1.47 
zgc:101872 (zgc:101872)  NM_001008589 -1.47 
Unknown  A_15_P105168 -1.47 
zgc:92714 (zgc:92714)  NM_001002393 -1.47 
RNA polymerase II transcriptional coactivator (tcp4) TC311082 -1.47 
zgc:103539 (zgc:103539)  NM_001005988 -1.47 
WD repeat domain 24 (wdr24)  NM_213063 -1.47 
zgc:66327 (zgc:66327)  NM_200663 -1.47 
zgc:56106 (zgc:56106)  NM_200194 -1.46 
zgc:92683 (zgc:92683)  NM_001002412 -1.46 
general transcription factor IIH, polypeptide 4 (gtf2h4)  NM_199927 -1.46 
zgc:92863 (zgc:92863)  NM_001002484 -1.46 
cDNA clone IMAGE:7243331 CN172869 -1.46 
pyrophosphatase (ppa) TC306400 -1.46 
glycine receptor, alpha 4a (glra4a)  NM_131782 -1.45 
Q6AZ98_BRARE (Q6AZ98) SEC23B TC339823 -1.45 
zgc:101826 (zgc:101826)  NM_001004677 -1.45 
zgc:92052 (zgc:92052)  NM_001002385 -1.45 
zgc:91802 (zgc:91802)  NM_001005584 -1.45 
intraflagellar transport 172 (ift172)  NM_001002312 -1.44 
general transcription factor IIF, polypeptide 1 (gtf2f1)  NM_199729 -1.44 
zgc:101658 (zgc:101658)  NM_001006085 -1.44 
zgc:153348 (zgc:153348)  NM_001077575 -1.44 
serum amyloid A-like 1 (saal1)  NM_200135 -1.43 
choroideremia (chm)  NM_203461 -1.43 
zgc:64174 (zgc:64174)  NM_200389 -1.43 
FDR107-P00032-DEPE-F_N07 FDR107 Danio rerio cDNA clone FDR107-
P00032-BR_N07 
EH495195 -1.43 
zgc:100927 (zgc:100927)  NM_001003633 -1.41 
solute carrier family 30 (zinc transporter), member 9 (slc30a9)  NM_001008575 -1.41 
zgc:63563 (zgc:63563)  NM_200044 -1.41 
zgc:56702 (zgc:56702)  NM_201103 -1.41 
Unknown  A_15_P103095 -1.41 
phosphatidylinositol glycan, class F (pigf)  NM_205645 -1.41 
peroxisomal biogenesis factor 19 (pex19) BC056815 -1.41 
debranching enzyme homolog 1 (S. cerevisiae) (dbr1)  NM_199653 -1.41 
mediator of RNA polymerase II transcription, subunit 18 homolog (yeast) 
(med18)  
NM_200335 -1.41 
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Gene Name (gene symbol) GenBank accession number M-value 
catalase (cat)  NM_130912 -1.4 
tetratricopeptide repeat domain 35 (ttc35)  NM_213544 -1.4 
zgc:153530 (zgc:153530) NM_001045394  -1.40 
zgc:110776 (zgc:110776) NM_001024375  -1.40 
dynein light chain 2, like (dnl2l) NM_001030000  -1.40 
zgc:103414 (zgc:103414) NM_001007394  -1.39 
zgc:114128 (zgc:114128) NM_001030103  -1.39 
steroid 5 alpha-reductase 2-like (srd5a2l) NM_001044939  -1.39 
zgc:63669 (zgc:63669) NM_201162  -1.39 
cDNA clone IMAGE:7922729 BC124310 -1.39 
synembryn-like (synbl) NM_001005293  -1.39 
zgc:55944 (zgc:55944) NM_200153  -1.39 
zgc:154012 (zgc:154012) NM_001077270  -1.39 
Unknown  ENSDART000000913
24 
-1.39 
zgc:77713 (zgc:77713) NM_205602  -1.39 
cDNA clone IMAGE:7001673 CF347661 -1.39 
selenoprotein T, 1b (selt1b) NM_178292  -1.38 
zgc:77617 (zgc:77617) NM_213253  -1.38 
hypothetical LOC569291 (LOC569291) XM_692669 -1.38 
zgc:112378 (zgc:112378) NM_001029953  -1.38 
zgc:91896 (zgc:91896) NM_001003460  -1.38 
zgc:85676 (zgc:85676) NM_212919  -1.38 
ceroid-lipofuscinosis, neuronal 6 (cln6) NM_001005982  -1.38 
FDR103-P00004-DEPE-F_F22 FDR103 Danio rerio cDNA clone FDR103-
P00004-BR_F22 5'  
EH432967 -1.38 
intraflagellar transport 88 homolog (ift88) NM_001001725  -1.38 
cleavage and polyadenylation specific factor 2 (cpsf2) NM_001002384  -1.38 
zgc:109963 (zgc:109963) NM_001024405  -1.37 
G elongation factor, mitochondrial 2 (gfm2) NM_001077545  -1.37 
zgc:91951 (zgc:91951) NM_001007764  -1.37 
si:ch211-258l4.3 (si:ch211-258l4.3) NM_001080197  -1.37 
CDKN1A interacting zinc finger protein 1 (ciz1) NM_213525  -1.37 
bisphosphate nucleotidase 1 (bpnt1) NM_001002354  -1.36 
zgc:92286 (zgc:92286) NM_001002607  -1.36 
coiled-coil domain containing 12 (ccdc12) NM_001003589  -1.36 
zgc:66407 (zgc:66407) NM_200430  -1.36 
aldehyde dehydrogenase 9 family, member A1 (aldh9a1) NM_201508  -1.36 
 A_15_P107865  -1.36 
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Gene Name (gene symbol) GenBank accession number M-value 
hypothetical protein LOC100005714 (LOC100005714) XM_001342210  -1.36 
leucine zipper transcription factor-like 1 (lztfl1) NM_199587  -1.36 
solute carrier family 39 (zinc transporter), member 7 (slc39a7) NM_130931  -1.36 
zgc:103579 (zgc:103579) NM_001007391  -1.36 
zgc:64138 (zgc:64138) NM_213129  -1.36 
zgc:92785 (zgc:92785) NM_001002547  -1.35 
zgc:92702 (zgc:92702) NM_001002401  -1.35 
FDR103-P00052-DEPE-F_N17 FDR103 Danio rerio cDNA clone FDR103-
P00052-BR_N17 5' 
EH450455 -1.35 
zgc:153688 (zgc:153688) NM_001076561  -1.35 
selenophosphate synthetase 1 (sephs1) NM_199701  -1.35 
si:dkey-72l14.8 (si:dkey-72l14.8) NM_001044811  -1.34 
zgc:109972 (zgc:109972) NM_001020499  -1.34 
delta-5/delta-6 fatty acid desaturase (fads) CN171115 -1.34 
zgc:86602 (zgc:86602) NM_001002161  -1.34 
family with sequence similarity 86, member A (fam86a) NM_001006058  -1.34 
hypothetical LOC568246 (LOC568246) XM_691567  -1.34 
zinc finger protein 330 (znf330) NM_213373  -1.34 
nuclear distribution gene C homolog (nudc) NM_200919  -1.34 
IK cytokine (ik) NM_199589  -1.34 
WD repeat domain 48 (wdr48) NM_214709  -1.33 
zinc finger protein ZFP235 (zfp235) TC337765 -1.33 
capsid protein VP2 (vp2)  TC324106 -1.33 
Q4SNU0_TETNG (Q4SNU0) Chromosome 15 SCAF14542, whole genome 
shotgun sequence  
TC319378 -1.33 
Unknown  A_15_P103019  -1.33 
hypothetical LOC566872, transcript variant 1 (LOC566872) XM_685201 -1.33 
zgc:103741 (zgc:103741) NM_001007458  -1.33 
heat shock factor binding protein 1, transcript variant 1 (hsbp1) XM_679029  -1.33 
zgc:110684 (zgc:110684) NM_001020623  -1.33 
zgc:100909 (zgc:100909) NM_001003752  -1.33 
zgc:136926 (zgc:136926) NM_001039932  -1.32 
zgc:92802 (zgc:92802) NM_001002523  -1.32 
SEC22 vesicle trafficking protein homolog B (S. cerevisiae), b (sec22bb) NM_201302  -1.32 
zgc:103655 (zgc:103655) NM_001005949  -1.32 
breast cancer metastasis-suppressor 1 (brms1) NM_200097  -1.32 
zgc:103632 (zgc:103632) NM_001005953  -1.32 
zgc:110219 (zgc:110219) NM_001017645  -1.32 
similar to DEAD box (84.8 kD) (3G940) (LOC562123) NM_001044978  -1.32 
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nucleoside diphosphate kinase-Z4 (ndpkz4) NM_130929  -1.32 
hypothetical LOC558808 (LOC558808) XM_682074  -1.32 
zgc:153664 (zgc:153664) NM_001045358  -1.32 
zgc:110742 (zgc:110742) NM_001013344  -1.31 
type I cytokeratin, enveloping layer (cyt1)  TC346768 -1.31 
zgc:86807 (zgc:86807) NM_001002120  -1.31 
zgc:103525 (zgc:103525) NM_001007338  -1.31 
zgc:77396 (zgc:77396) NM_205665  -1.30 
zgc:86625 (zgc:86625) NM_001002054  -1.30 
intraflagellar transport 80 homolog (Chlamydomonas) (ift80) NM_001008625  -1.30 
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Tab. A4 Gene ontology of MeHg-responsive genes selected for in situ hybridisation analysis. 
Gene name (gene symbol) GenBack 
accession 
number 
Molecular function, biological process and cellular component 
a disintegrin and metalloproteinase domain 
8 (adam8) 
NM_200637 Metalloendopeptidase activity; zinc ion binding; integrin-mediated signaling pathway; proteolysis 
activating transcription factor 3 (atf3) NM_200964 DNA binding; protein dimerisation activity; sequence-specific DNA binding; sequence-specific DNA binding transcription factor 
activity; response to virus; regulation of transcription, DNA-dependent; protein dimerisation activity; nucleus; nucleolus; 
intracellular 
ADP-ribosylation factor-like (arfl); 
Zgc:112199 
AI477644 GTP binding, nucleotide binding, small GTPase mediated signal transduction; intracellular 
angiotensinogen (agt) BG727310 Regulation of gene expression; ranscription factor activity; regulation of NAD(P)H oxidase activity; serine-type endopeptidase 
inhibitor activity; response to cold; cytokine production; positive regulation of muscle hypertrophy; type 2 angiotensin receptor 
binding; acetyltransferase activator activity; soluble fraction; cell fraction; intracellular 
apolipoprotein eb (apoeb) NM_131098  Lipid binding; Lipid transport; lipoprotein metabolic process; transport; extracellular region 
CCAAT/enhancer binding protein (C/EBP), 
gamma (cebpg) 
NM_131886 DNA binding; protein dimerisation activity; sequence-specific DNA binding; sequence-specific DNA binding transcription factor 
activity; regulation of transcription, DNA-dependent; natural killer cell mediated cytotoxicity; cytokine metabolic process; protein 
heterodimerisation activity; protein dimerisation activity; nucleus; nucleolus; intracellular 
chromobox protein homolog 7-like (cbx7l); 
zgc:110152 
NM_001017853 Chromatin binding; chromatin assembly or disassembly; chromatin; nucleus; intracellular 
cocaine and amphetamine regulated 
transcript protein type I-like (cartIl) 
DN857240 Brain development; regulated by testosterone; response to stress 
complement component 3-like (c3l); si:dkey-
76b14.4 
AF047413  Endopeptidase inhibitor activity; extracellular region; extracellular space 
complement component 4-2-like (c4-2l) BI672168  Complement activation; component of the classical pathway 
complement component 6 (c6) BI474371 Complement activation; complement cascade for immune response; component of the membrane attack complex of complement 
complement component 7 (c7) BC100054 Complement activation; component of the membrane attack complex of complement; induction of apoptosis  
complement factor b (cfb) AW019018 Catalytic activity; serine-type endopeptidase activity; response to bacterium; complement activation; proteolysis; extracellular 
region 
core promoter element binding protein 
(copeb) 
NM_201461 Nucleic acid binding; zinc ion binding; digestive tract development; liver development; organ growth; pancreas development; 
intracellular 
CXC chemokine 46-like (cxc46l) BI845861 Inducing directed chemotaxis 
ubiquitin carboxyl-terminal hydrolase CYLD-
like (cyldl)  
BE016427 Unknown 
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Gene name (gene symbol) GenBack 
accession 
number 
Molecular function, biological process and cellular component 
E74-like factor 3 (ets domain transcription 
factor, epithelial-specific ) (elf3) 
AI385059 DNA binding 
fibronectin 1b (fn1b) NM_001013261 Somitogenesis; Cell adhesion and migration processes including embryogenesis, wound healing, blood coagulation, host 
defense, and metastasis; extracellular region 
forkhead box B1.2 (foxb1.2) NM_131285 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; regulation of 
transcription; regulation of transcription, DNA-dependent; transcription; nucleus 
glutamate-cysteine ligase modifier subunit 
(gclm) 
BG304082 Ligase activity; oxidoreductase activity; oxidation-reduction process; response to nitrosative stress; glutamate-cysteine ligase 
catalytic subunit binding; protein heterodimerisation activity; protein dimerisation activity; glutamate-cysteine ligase activity; 
glutamate-cysteine ligase complex; soluble fraction; cell fraction; intracellular 
glutathione peroxidase 1a (gpx1a) AW232474 Glutathione peroxidase activity; oxidoreductase activity; peroxidase activity; oxidation-reduction process; response to oxidative 
stress 
glutathione peroxidase 4a (gpx4a) BI896246 Glutathione peroxidase activity; oxidoreductase activity; peroxidase activity; oxidation-reduction process; response to oxidative 
stress 
glycine dehydrogenase (decarboxylating) 
(gldc) 
BM777961 Glycine dehydrogenase (decarboxylating) activity, glycine metabolic process; oxidation-reduction process 
hematopoietically expressed homeobox 
(hhex) 
NM_130934 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; transcription regulator 
activity; multicellular organismal development; regulation of transcription; regulation of transcription, DNA-dependent; 
transcription; heart development; positive regulation of endothelial cell differentiation; regulation of organ growth; thyroid gland 
development; nucleus 
homeodomain leucine zipper gene (homez) NM_001007120 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; regulation of 
transcription; regulation of transcription, DNA-dependent; nucleus; intracellular 
interferon regulatory factor (irf9) NM_205710 Sequence-specific DNA binding transcription factor activity; regulation of transcription; regulation of transcription, DNA-
dependent; transcription; cytokine metabolic process; nucleus; intracellular 
jun B proto-oncogene (junb) NM_213556 DNA binding; protein dimerisation activity; sequence-specific DNA binding; sequence-specific DNA binding transcription factor 
activity; regulation of transcription; regulation of transcription, DNA-dependent; heart contraction; nucleus 
kruppel-like factor 10-like (klf10l) AI641738  DNA binding; TGFbeta-mediated signaling cascades; regulation of pancreatic epithelial cell growth  
kruppel-like factor 11b (klf11b) NM_001077604 Zinc ion binding; intracellular 
lysosome-associated membrane 
glycoprotein 1l (lamp1l); zgc:64072 
AI793516 Membrane 
matrix metalloproteinase 9 (mmp9) AW174507 Hydrolase activity; metal ion binding; metalloendopeptidase activity; metallopeptidase activity; peptidase activity; zinc ion binding; 
response to bacterium; metabolic process; proteolysis; positive regulation of granuloma formation; extracellular matrix 
matrix metalloproteinase 13a (mmp13a) AW305943 Calcium ion binding; hydrolase activity; metal ion binding; metalloendopeptidase activity; metallopeptidase activity; peptidase 
activity; zinc ion binding; metabolic process; proteolysis; embryo development; macrophage chemotaxis; extracellular matrix 
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Gene name (gene symbol) GenBack 
accession 
number 
Molecular function, biological process and cellular component 
matrix metalloproteinase 14a (mmp14a) NM_194416 Calcium ion binding; hydrolase activity; metal ion binding; metalloendopeptidase activity; metallopeptidase activity; peptidase 
activity; zinc ion binding;response to hypoxia; metabolic process; proteolysis; cell migration involved in gastrulation; convergent 
extension; convergent extension involved in gastrulation; establishment of cell polarity; anterior/posterior axis specification; 
cartilage development; embryonic cranial skeleton morphogenesis; extracellular matrix 
NADPH oxidase organizer 1 (noxo1) BI878214 Hosphoinositide binding; cell communication 
opsin 1 (cone pigments), long-wave-
sensitive, 1 (opn1lw1) 
AF109371 G-protein coupled receptor activity; photoreceptor activity; receptor activity; signal transducer activity; red or far-red light 
photoreceptor activity; photoperiodism; response to light stimulus; G-protein coupled receptor protein signaling pathway; 
phototransduction; protein-chromophore linkage; response to stimulus; signal transduction; visual perception; integral to 
membrane; membrane 
opsin 1 (cone pigments), medium-wave-
sensitive, 1 (opn1mw1) 
AF109369 G-protein coupled receptor activity; photoreceptor activity; receptor activity; signal transducer activity; photoreceptor activity; G-
protein coupled receptor protein signaling pathway; phototransduction; protein-chromophore linkage; response to stimulus; signal 
transduction; visual perception; photoreceptor outer segment; integral to membrane; membrane 
opsin 1 (cone pigments), short-wave-
sensitive 1 (opn1sw1) 
AF109373 G-protein coupled receptor activity; photoreceptor activity; receptor activity; signal transducer activity; G-protein coupled receptor 
protein signaling pathway; phototransduction; protein-chromophore linkage; response to stimulus; signal transduction; visual 
perception; integral to membrane; membrane 
paired box gene 2a (pax2a) NM_131184 DNA binding; cell differentiation; multicellular organismal development; nervous system development; regulation of transcription; 
transcription; anterior/posterior pattern formation; cell fate specification; embryonic camera-type eye morphogenesis; midbrain 
development; otic placode formation; cerebellum development; embryonic pattern specification; hindbrain development; kidney 
development; midbrain-hindbrain boundary development; peripheral nervous system development; pronephros development; 
thyroid gland development; nucleus 
paired box gene 6a (pax6a) NM_131304 Transcription activator activity; DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor 
activity; transcription regulator activity; multicellular organismal development; regulation of transcription;regulation of transcription, 
DNA-dependent; transcription; forebrain development; anterior/posterior pattern formation; hindbrain development; nucleus 
peroxiredoxin1 (prdx1); zgc:110343 BI980610 Antioxidant activity; oxidoreductase activity; peroxiredoxin activity; cell redox homeostasis; natural killer cell mediated cytotoxicity; 
cellular response to oxidative stress; pigment granule; nucleus; melanosome; intracellular 
phosphoenolpyruvate carboxykinase 1 
(pck1) 
BG727092 GTP binding; kinase activity; phosphoenolpyruvate carboxykinase activity; purine nucleotide binding; response to glucose 
stimulus; gluconeogenesis 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4-like (pfkfb4l) 
BI888564 6-phosphofructo-2-kinase activity; ATP binding; catalytic activity; kinase activity; fructose 2,6-bisphosphate metabolic process; 
fructose metabolic process; metabolic process; intracellular 
PLAC8-like protein 1-like (plac8l1l) BE557057  Unknown 
POU domain, class 5, transcription factor 1 
(pou5f1) 
NM_131112 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; transcription regulator 
activity; multicellular organismal development; regulation of transcription; regulation of transcription, DNA-dependent; 
transcription; positive regulation of transcription, DNA-dependent; anatomical structure morphogenesis; brain development; brain 
segmentation; dorsal/ventral pattern formation; ectoderm development; embryonic pattern specification; endoderm formation; 
epiboly involved in gastrulation with mouth forming second; hindbrain development; mesoderm development; morphogenesis of 
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Gene name (gene symbol) GenBack 
accession 
number 
Molecular function, biological process and cellular component 
embryonic epithelium; nucleus 
PR domain containing 1a, with ZNF domain 
(prdm1a) 
NM_199515 Transcription repressor activity; nucleic acid binding; zinc ion binding; embryonic axis specification; embryonic pectoral fin 
morphogenesis; fin development; muscle cell fate determination; pectoral fin morphogenesis; positive regulation of neuron 
differentiation; intracellular 
protein phosphatase 1 regulatory subunit 
15A (ppp1r15a) 
BI889255 regulation of gene expression; intracellular 
Ras-related associated with diabetes (rrad) NM_199798  GTP-binding; GTPase activity; nucleotide binding; signal transduction; small GTPase mediated signal transduction; membrane 
retinal homeobox gene 1 (rx1) NM_131225 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; transcription regulator 
activity; multicellular organismal development; regulation of transcription; regulation of transcription, DNA-dependent; 
transcription; camera-type eye photoreceptor cell differentiation; neural retina development; retina layer formation; nucleus 
S100 calcium binding protein Z (s100z) BC095285 Calcium ion binding 
secretion-associated and Ras-related gene 
homolog 2 (sar2) 
BM102635 GTP binding; intracellular 
selenoprotein W, 1 (sepw1) AW128247 Selenium binding, cell redox homeostasis; cytoplasm 
sequestosome 1 (sqstm1) AW343560 Zinc ion binding  
serum/glucocorticoid regulated kinase 1 
(sgk1) 
BI673466 ATP-binding; kinase activity; nucleotide binding; protein kinase activity; protein serine/threonine kinase activity; transferase 
activity; apoptosis; protein phosphorylation; response to stress, cytoplasm, endoplasmic reticulum, nucleus 
si:ch211-106h4.4 BG302634 Membrane 
si:ch1073-126c3.2 AI974163 Unknown 
sine oculis homeobox homolog 3a (six3a) NM_131362 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; regulation of 
transcription; regulation of transcription, DNA-dependent; brain development; nucleus 
sine oculis homeobox homolog 3b (six3b) NM_131363 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; regulation of 
transcription; regulation of transcription, DNA-dependent; embryonic camera-type eye morphogenesis; brain development; 
nucleus 
solute carrier family 16 (monocarboxylic 
acid transporters), member 9a (slc16a9a) 
AW421040 Transmembrane transport 
solute carrier family 16 (monocarboxylic 
acid transporters), member 9b (slc16a9b) 
BE016639 Transmembrane transport 
sp9 transcription factor (sp9) NM_212960 DNA binding; metal ion binding; nucleic acid binding; zinc ion binding; regulation of transcription; transcription; embryonic pectoral 
fin morphogenesis; positive regulation of fibroblast growth factor receptor signaling pathway; intracellular; nucleus 
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spleen focus forming virus (SFFV) proviral 
integration oncogene spi1 (spi1) 
AY293624 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; regulation of 
transcription, DNA-dependent; regulation of myeloid leukocyte differentiation; nucleus 
SRY-box containing gene 7 (sox7) NM_001080750 DNA binding; vasculogenesis; nucleus 
Sulfide quinone reductase-like (sqrdl) BI882244 Oxidoreductase activity; oxidation-reduction process 
suppressor of cytokine signaling 3a 
(sosc3a) 
BI878700 Intracellular signal transduction 
suppressor of cytokine signaling 3b 
(sosc3b) 
BG727181 Intracellular signaling pathway 
thioredoxin-like (txnl); zgc:92903 BI864190 Cell redox homeostasis 
thioredoxin-like 4A (txnl4a) BI886657 Mitosis ; spliceosomal complex 
tumor protein p53 (p53) NM_131327 Transcription activator activity; DNA binding; metal ion binding; sequence-specific DNA binding transcription factor activity; zinc 
ion binding; transcription regulator activity; protein binding; positive regulation of transcription, DNA-dependent; response to 
methylmercury; apoptosis; cell cycle; negative regulation of cell growth; regulation of transcription; regulation of transcription, 
DNA-dependent; response to tumor cell; transcription; DNA damage response, signal transduction by p53 class mediator 
resulting in induction of apoptosis; positive regulation of apoptosis; positive regulation of neuron apoptosis; DNA damage 
checkpoint; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; 
induction of apoptosis; negative regulation of cell cycle; negative regulation of cell division; positive regulation of apoptosis; 
positive regulation of caspase activity; positive regulation of cell cycle; response to UV; response to X-ray; cytoplasm; nucleus 
UDP glucuronosyltransferase 5 family, 
polypeptide A2 (ugt5a2) 
AW127886 Transferase activity; transferase activity, transferring glycosyl groups; transferase activity, transferring hexosyl groups; metabolic 
process 
uncoupling protein 1 (ucp1) AW420321 Binding; response to chemical stimulus; mitochondrial transport; transmembrane transport; transport; integral to membrane; 
membrane; mitochondrion 
urate oxidase (uox) AW019321 Oxidoreductase activity; urate oxidase activity; oxidation-reduction process; purine base metabolic process 
v-fos FBJ murine osteosarcoma viral 
oncogene homolog (fos) 
NM_205569 Double-stranded DNA binding; DNA binding; protein dimerisation activity; sequence-specific DNA binding; sequence-specific 
DNA binding transcription factor activity; regulation of transcription; regulation of transcription, DNA-dependent; cellular response 
to oxidative stress; protein heterodimerisation activity; protein dimerisation activity; nucleus; synaptosome; cell fraction; 
intracellular 
v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein B (avian) (mafba) 
NM_131015 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; regulation of 
transcription; regulation of transcription, DNA-dependent; transcription; anterior/posterior pattern formation; embryonic pattern 
specification; nucleus 
v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog f (avian) (maff) 
NM_200336 DNA binding; sequence-specific DNA binding; sequence-specific DNA binding transcription factor activity; protein 
heterodimerisation activity; regulation of transcription; regulation of transcription, DNA-dependent; positive regulation of 
transcription, DNA-dependent; transcription factor complex; nucleus 
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zgc:56382 BM101640 Unknown 
zgc:92254 AW019036 Glutathione transferase activity; cytoplasm 
zgc:101661 AI657551 Unknown 
AI397362 AI397362 Unknown 
AI544649  AI544649  Unknown 
AI793818 AI793818 Unknown 
AW115990  AW115990  Unknown 
BE016163  BE016163  Unknown 
BG727211  BG727211  Unknown 
BG891932  BG891932  Unknown 
BI474700 BI474700 Unknown 
BI883993  BI883993  Unknown 
BI892110  BI892110  Unknown 
BI983579  BI983579  Unknown 
BM036361  BM036361  Unknown 
BM101698 BM101698 Unknown 
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